Molecules and methods of use thereof

Abstract

The present invention provides novel molecules, compositions comprising such molecules, and methods of use of such molecules for the treatment of various conditions.

Description

[0001]MOLECULES AND METHODS OF USE THEREOF CROSS-REFERENCE TO RELATED APPLICATIONS This application claims the benefit of priority of U.S. Provisional patent application no. 63 / 498,511 filed on April 26, 2023, the content of which is hereby incorporated by reference in its entirety. SEQUENCE LISTING The instant application contains a sequence listing which has been submitted electronically in XML format and is hereby incorporated by reference in its entirety. Said XML copy, created on April 19, 2024, is named Woolwich_001_WO1_SL, and is 2,453,732 bytes in size. INCORPORATION-BY-REFERENCE For the purposes of only those jurisdictions that permit incorporation by reference, the content of all documents cited herein is hereby incorporated by reference in its entirety. BACKGROUND OF THE INVENTION Opioid receptors are 7-transmembrane G-protein coupled receptors. The four types of opioid receptors are termed mu, delta, kappa, and nociceptin receptors. Endogenous opioids and opioid drugs activate these opioid receptors and can produce analgesic effects as well as other biological effects. Studies suggest that delta opioid receptor agonists may have a role in a variety of therapeutic areas including but not limited to chronic and acute pain management1–25. However, although several delta opioid agonists have been identified, none have yet been approved by a regulatory body for the treatment of pain or any other condition. For at least the following reasons, there is a need in the art for new agonists of delta opioid receptors: • First, there is a need for chemically novel delta opioid agonists to facilitate the mechanistic understanding of the delta opioid receptor’s role in human pathophysiology. • Second, there is a need for chemically novel delta opioid agonists that are safe and avoid some of the adverse events (such as convulsions) that have been observed with prior delta opioid agonists. • Third, there is a need for chemically novel molecules including chemically novel delta opioid agonists that exhibit clinical analgesic efficacy. • Fourth, there is a need for chemically novel molecules including chemically novel delta opioid agonists that have a sufficiently long duration of action to make them clinically useful (such as for the treatment of pain). • Fifth, there is a need for chemically novel molecules including chemically novel delta opioid agonists that are effective (such as for the treatment of pain) when delivered orally. • Sixth, there is a need for chemically novel molecules including chemically novel delta opioid agonists that exhibit analgesic efficacy in a range of animal species including in non-human primates. • Seventh, there is a need for chemically novel molecules including chemically novel delta opioid agonists that exhibit analgesic efficacy in a range of animal models such as acute mechanical pain, acute thermal pain, inflammatory pain, visceral pain, and / or neuropathic pain. • Eighth, there is a need for chemically novel analgesic molecules including chemically novel delta opioid agonists that have a site of action not in the central nervous system. • Ninth, there is a need for chemically novel analgesic molecules including chemically novel delta opioid agonists that do not exhibit any undesirable neurological effects such as narcotic effects. • Tenth, there is a need for chemically novel analgesic molecules including chemically novel delta opioid agonists that do not induce tolerance upon repeated administration and can maintain clinical efficacy over repeated administrations. • Eleventh, there is a need for chemically novel delta opioid agonists that have analgesic efficacy predominantly mediated by the delta opioid receptor and not the mu opioid receptor (for example as demonstrated through use of antagonists and / or genetic knock-out models). • Twelfth, there is a need for chemically novel delta opioid agonists that are stable for extended periods of time as a solid and / or in solution at room temperature and / or at elevated temperatures. • Thirteenth, there is a need for chemically novel delta opioid agonists that are stable in acidic and / or peroxidic solutions, and / or under ultraviolet light. • Fourteenth, there is a need for chemically novel delta opioid agonists that are biased DOR agonists, for example having a higher potency (lower EC50) and / or activity (higher maximal effect) for one downstream effect of DOR agonism (such as cAMP production or calcium flux) over another (such as beta arrestin recruitment or receptor internalization). The present invention aims to address these needs. SUMMARY OF THE INVENTION The present invention is based, in part, on a series of important developments and discoveries relating to delta opioid receptor agonists, further details of which are provided in the “Examples” and “Detailed Description of the Invention” sections of this patent disclosure. In brief, a panel of novel peptides have been developed that have delta opioid receptor agonist activity and that are chemically novel, do not demonstrate convulsions in animals, exhibit analgesic efficacy in animal models, maintain analgesic efficacy for clinically useful durations in animal models, and / or are effective at exhibiting analgesic efficacy when administered orally. Building on these developments, the present invention provides a variety of new peptide agonists of delta opioid receptors, compositions comprising such peptides, and methods of use of such peptides. Several of the peptides of the present invention are identified herein using sequence identification number (SEQ ID NO:) and / or a peptide number (PEP NO:). Peptides that meet the requirements for inclusion in a sequence listing are assigned both a PEP NO: and a SEQ ID NO: of the same number. Peptides that have amino acid sequences that do not meet the requirements for inclusion in a sequence listing (i.e., peptides having fewer than 4 defined amino acids) are assigned only a PEP NO:), as further described in the “Definitions & Abbreviations” section of this patent disclosure. The phrase “SEQ ID NO: and / or PEP NO:” (or the plural form “SEQ ID NOs: and / or PEP NOs:”) and “PEP NO: and / or SEQ ID NO:” (or the plural form “PEP NOs: and / or SEQ ID NOs:”) may be used to refer to a peptide or group of peptides that may include some with or without a SEQ ID NO:. For a peptide that has a SEQ ID NO: the phrase should be understood to refer to that peptide’s SEQ ID NO: and for a peptide that does not have a SEQ ID NO: (and only has a PEP NO:) that phrase should be understood to refer to that peptide’s PEP NO:. In the sequence listing a placeholder is inserted to ensure all peptides that have both a SEQ ID NO: and a PEP NO: have the same number assigned to both the SEQ ID NO: and the PEP NO:. For additional clarity PEP NOs: 199, 207, 636, 644, 756, 762, 766, 769, 771, 773, 782, 797, 811, 854, 860, 865, 869, 872, 874, 875 as well as 316 and 318-437 do not meet the criteria for sequence listing and where a SEQ ID NO: may appear to refer to one of these numbers the PEP NO: of the same number should be considered instead. All other PEP NOs: and / or SEQ ID NOs: may be referred to by either their PEP NO: and / or SEQ ID NO: and are included in the sequence listing. Accordingly, in some embodiments, the present invention provides peptides that comprise the amino acid sequence of any one of PEP NO: and / or SEQ ID NO: 1-315. Each of these peptides was demonstrated to exhibit activity as a delta opioid receptor agonist in vitro. Interestingly, it was discovered that retro-inverso variants of our delta opioid agonist peptides also exhibit delta opioid receptor agonist activity in vitro, since PEP NOs: and / or SEQ ID NOs: 305-315 are retro-inverso variants of the reference alignment provided by PEP NOs: and / or SEQ ID NOs: 1-304, and each of PEP NOs: and / or SEQ ID NOs: 305-315 exhibits delta opioid receptor agonist activity. Accordingly, in some embodiments, the present invention provides peptides that comprise the amino acid sequence of any one of PEP NOs: and / or SEQ ID NOs: 438-752 – which are retro-inverso forms of PEP NOs: and / or SEQ ID NOs: 1-315. In some embodiments, the present invention provides peptides that comprise the amino acid sequence of any one of PEP NOs: and / or SEQ ID NOs: 16, 17, 24, 86, 87, 157, 162, 163, 164, 165, 166, 167, 170, 171, 173, 175, 177, 178, 179, 182, 183, 185, 186, or 187. This group of 24 peptides was studied in an animal model of analgesia, and all 24 peptides were found exhibit analgesic efficacy in vivo (none of the peptides tested in vivo failed to have an analgesic effect) - providing evidence that the in vitro delta opioid receptor agonist activity of the peptides of the present invention correlates with their in vivo analgesic activity. Furthermore, and importantly, the 24 peptides tested differed substantially from one another in their structure, size, length, and sequence - confirming that the ability to elicit in vivo analgesia is not unique to one peptide, or one narrow group of peptides, but rather appears to be a general property of the peptides invented. Analysis of the amino acid sequences of the peptides described above revealed certain common sequence motifs that could be described using consensus amino sequences. Accordingly, in some embodiments, the present invention provides peptides that comprise the amino acid sequence of any one of PEP NOs: and / or SEQ ID NOs: 316-437, each of which consensus sequences has at least one variable amino acid position. Similarly, in some embodiments, the present invention provides peptides that comprise the amino acid sequence of any one of PEP NOs: and / or SEQ ID NOs: 747-875, each of which consensus sequences represents a sequence motif that is shared by numerous of the peptides described herein. The present invention also provides variants of the peptides described above. For example, in some embodiments, the present invention provides peptides comprising an amino acid sequence that is at least 90% identical to any one of PEP NOs: and / or SEQ ID NOs: 1-315, 438-752, or 747-875, provided that the variant peptides have delta opioid agonist activity. Numerous other types of variant peptide are also provided by the present invention, as described in other sections of this patent disclosure. The present invention also provides compositions comprising the peptides described herein. For example, in some embodiments, the present invention provides pharmaceutical compositions comprising a peptide as described herein and at least one pharmaceutically acceptable carrier or excipient. The present invention also provides various methods of using the peptides of the present invention. For example, in some embodiments, the present invention provides methods of activating a delta opioid receptor, such methods comprising contacting a delta opioid receptor, or a cell comprising a delta opioid receptor, in vitro or in vivo, with a peptide as described herein. Similarly, in some embodiments, the present invention provides methods of treating pain in subjects in need thereof, such methods comprising administering to such a subject an effective amount of a peptide as described herein. For ease of reading the present specification, the following summary table of PEP NOs: and / or SEQ ID NOs: is provided: Table 1. Summary table of PEP NOs and / or SEQ ID NOs: These and other embodiments of the present invention are further described below. BRIEF DESCRIPTION OF THE FIGURES Fig.1A-F. Amino acid sequences of 304 delta opioid receptor agonist peptides shown in Table 3 (PEP NOs: and / or SEQ ID NOs: 1-304) aligned according to sequence identity and numbered according to the aligned position. Positions are numbered from 1 through 20 (X1 through X20). Positions may contain one or more amino acids as well as other molecular elements. Fig.1G. Amino acid sequences of 11 delta opioid receptor agonist peptides shown in Table 3 (PEP NOs: and / or SEQ ID NOs: 305-315) aligned according to sequence identity and numbered according to the aligned position. Positions are numbered from 20 through 1 (X20 through X1) to demonstrate positional alignment with the reference alignment of PEP NOs: and / or SEQ ID NOs: 1-304, of which the reference alignment of PEP NOs: and / or SEQ ID NOs: 305-315 is a retro-inverso. Positions may contain one or more amino acids as well as other molecular elements. Fig.2A. An in vitro agonist response curve for a peptide having the amino acid sequence of PEP NO: and / or SEQ ID NO: 157 in a fluorescent cAMP assay, as detailed in Example 1. Fig.2B. An in vitro agonist response curve for a peptide having the amino acid sequence of PEP NO: and / or SEQ ID NO: 24 in a calcium flux assay, as detailed in Example 2. Fig.2C. An in vitro binding curve for a peptide having the amino acid sequence of PEP NO: and / or SEQ ID NO: 157 in a competitive radioligand assay, as detailed in Example 3. Fig.3. An example of a predicted or modeled chemical structure of a peptide having the amino acid sequence of DSYGEVGVRQAPFPLSISCN (PEP NO: and / or SEQ ID NO: 1). Fig.4. An example of a predicted or modeled chemical structure of a peptide having the amino acid sequence of DSYGEVGVRQAPFPSRASCN (PEP NO: and / or SEQ ID NO: 2). Fig.5. An example of a predicted or modeled chemical structure of a peptide having the amino acid sequence of DSYGEVGVRQAPFPSRASC (PEP NO: and / or SEQ ID NO: 3). Fig.6. An example of a predicted or modeled chemical structure of a peptide having the amino acid sequence of RGDGEVGVRQAPFPLSISCN (PEP NO: and / or SEQ ID NO: 4). Fig.7. An example of a predicted or modeled chemical structure of a peptide having the amino acid sequence of RGDGEVGVRQAPFPLSISC (PEP NO: and / or SEQ ID NO: 5). Fig.8. An example of a predicted or modeled chemical structure of a peptide having the amino acid sequence of RGDGEVGVRQAPFPSRASC (PEP NO: and / or SEQ ID NO: 6). Fig.9. An example of a predicted or modeled chemical structure of a peptide having the amino acid sequence of RGDGEVGVRQAPYPSRASC (PEP NO: and / or SEQ ID NO: 7). Fig.10. An example of a predicted or modeled chemical structure of a peptide having the amino acid sequence of RGDGEVGVRQAPYLSRAFC (PEP NO: and / or SEQ ID NO: 8). Fig.11. An example of a predicted or modeled chemical structure of a peptide having the amino acid sequence of DGDGEVGVRQAPFPSRASC (PEP NO: and / or SEQ ID NO: 9). Fig.12. An example of a predicted or modeled chemical structure of a peptide having the amino acid sequence of RGDSYGEVGVRQAPFPSRASC (PEP NO: and / or SEQ ID NO: 10). Fig.13. An example of a predicted or modeled chemical structure of a peptide having the amino acid sequence of DSYGEVGVRQAPFPSRAS{c-amid-C} (PEP NO: and / or SEQ ID NO: 11). Fig.14. An example of a predicted or modeled chemical structure of a peptide having the amino acid sequence of DSYGEVGVRQAPFPSRAS{c-amid-{dC}} (PEP NO: and / or SEQ ID NO: 12). Fig.15. An example of a predicted or modeled chemical structure of a peptide having the amino acid sequence of {dβD}SYGEVGVRQAPFPSRASC (PEP NO: and / or SEQ ID NO: 13). Fig.16. An example of a predicted or modeled chemical structure of a peptide having the amino acid sequence of DSYGEVGVRQAPFPSRAS{dC} (PEP NO: and / or SEQ ID NO: 14). Fig.17. An example of a predicted or modeled chemical structure of a peptide having the amino acid sequence of {dD}SYGEVGVRQAPFPSRASC (PEP NO: and / or SEQ ID NO: 15). Fig.18. An example of a predicted or modeled chemical structure of a peptide having the amino acid sequence of {n-acet-D}SYGEVGVRQAPFPSRAS{c-amid-C} (PEP NO: and / or SEQ ID NO: 16). Fig.19. An example of a predicted or modeled chemical structure of a peptide having the amino acid sequence of {n-acet-{dβD}}{dS}{dY}GEVGVRQAPF{dP}{dS}{dR}{dA}{dS}{c-amid- {dC}} (PEP NO: and / or SEQ ID NO: 17). Fig.20. An example of a predicted or modeled chemical structure of a peptide having the amino acid sequence of {dD}SYGEVGVRQAPF{dP}SRASC (PEP NO: and / or SEQ ID NO: 18). Fig.21. An example of a predicted or modeled chemical structure of a peptide having the amino acid sequence of {htt-cyclic-D}SYGEVGVRQAPFPSRASC (PEP NO: and / or SEQ ID NO: 19). Fig.22. An example of a predicted or modeled chemical structure of a peptide having the amino acid sequence of {n-peg12-{dβD}}{dS}{dY}GEVGVRQAPF{dP}{dS}{dR}{dA}{dS}{c- amid-{dC}} (PEP NO: and / or SEQ ID NO: 20). Fig.23. An example of a predicted or modeled chemical structure of a peptide having the amino acid sequence of {n-acet-{dβD}}{dS}{dY}GEVGVRQAPF{dP}{dS}{r-pal-K}{dA}{dS}{c- amid-{dC}} (PEP NO: and / or SEQ ID NO: 24). Fig.24. An example of a predicted or modeled chemical structure of a peptide having the amino acid sequence of {n-acet-D}SYGEVGVRQAPFPS{r-pal-K}AS{c-amid-C} (PEP NO: and / or SEQ ID NO: 86). Fig.25. An example of a predicted or modeled chemical structure of a peptide having the amino acid sequence of {n-acet-{dβD}}{dS}{dY}GEVGVRQAPF{dP}{dS}{r-ste-K}{dA}{dS}{c- amid-{dC}} (PEP NO: and / or SEQ ID NO: 87). Fig.26. An example of a predicted or modeled chemical structure of a peptide having the amino acid sequence of {n-acet-{dβD}}{dS}{dY}GEVGVRQAPF{dP}{dS}{r-pal-K}{dA}{c-amid- {dS}} (PEP NO: and / or SEQ ID NO: 157). Fig.27. An example of a predicted or modeled chemical structure of a peptide having the amino acid sequence of {n-acet-D}SYGEVGVRQAPFPSRA{c-amid-S} (PEP NO: and / or SEQ ID NO: 162). Fig.28. An example of a predicted or modeled chemical structure of a peptide having the amino acid sequence of {n-acet-Y}GEVGVRQAPF{c-amid-P} (PEP NO: and / or SEQ ID NO: 163). Fig.29. An example of a predicted or modeled chemical structure of a peptide having the amino acid sequence of {n-acet-Y}GEVGVRQAPFPSRA{c-amid-S} (PEP NO: and / or SEQ ID NO: 164). Fig.30. An example of a predicted or modeled chemical structure of a peptide having the amino acid sequence of {n-acet-D}SYGEVGVRQAPF{c-amid-P} (PEP NO: and / or SEQ ID NO: 165). Fig.31. An example of a predicted or modeled chemical structure of a peptide having the amino acid sequence of {n-acet-Y}GEVGVRQAPFPS{c-amid-R} (PEP NO: and / or SEQ ID NO: 166). Fig.32. An example of a predicted or modeled chemical structure of a peptide having the amino acid sequence of {n-acet-Y}GEVGVRQA{c-amid-P} (PEP NO: and / or SEQ ID NO: 167). Fig.33. An example of a predicted or modeled chemical structure of a peptide having the amino acid sequence of {n-pal-E}VGVRQA{c-amid-P} (PEP NO: and / or SEQ ID NO: 170). Fig.34. An example of a predicted or modeled chemical structure of a peptide having the amino acid sequence of {n-pal-V}GVRQA{c-amid-P} (PEP NO: and / or SEQ ID NO: 171). Fig.35. An example of a predicted or modeled chemical structure of a peptide having the amino acid sequence of {n-pal-Y}GEVGVRQA{c-amid-P} (PEP NO: and / or SEQ ID NO: 173). Fig.36. An example of a predicted or modeled chemical structure of a peptide having the amino acid sequence of {n-pal-Y}GEVGV{hR}QA{c-amid-P} (PEP NO: and / or SEQ ID NO: 175). Fig.37. An example of a predicted or modeled chemical structure of a peptide having the amino acid sequence of {n-pal-{dY}}GEVGV{hR}QA{c-amid-P} (PEP NO: and / or SEQ ID NO: 177). Fig.38. An example of a predicted or modeled chemical structure of a peptide having the amino acid sequence of {n-pal-{dY}}GEVGVRHA{c-amid-P} (PEP NO: and / or SEQ ID NO: 178). Fig.39. An example of a predicted or modeled chemical structure of a peptide having the amino acid sequence of {n-pal-Y}GEVGV{hR}HA{c-amid-P} (PEP NO: and / or SEQ ID NO: 179). Fig.40. An example of a predicted or modeled chemical structure of a peptide having the amino acid sequence of {n-pal-G}LMGVRQA{c-amid-P} (PEP NO: and / or SEQ ID NO: 182). Fig.41. An example of a predicted or modeled chemical structure of a peptide having the amino acid sequence of {n-acet-{dD}}{dS}{dY}GEVGVRQAPF{dP}{dS}{r-pal-K}{c-amid-{dA}} (PEP NO: and / or SEQ ID NO: 183). Fig.42. An example of a predicted or modeled chemical structure of a peptide having the amino acid sequence of {n-acet-Y}GEVGVRQAPFPS{c-amid-{r-pal-K}} (PEP NO: and / or SEQ ID NO: 185). Fig.43. An example of a predicted or modeled chemical structure of a peptide having the amino acid sequence of {n-pal-D}SYGEVGVRQAPFPSRA{c-amid-S} (PEP NO: and / or SEQ ID NO: 186). Fig.44. An example of a predicted or modeled chemical structure of a peptide having the amino acid sequence of {n-acet-D}SYGEVGVRQAPFPS{r-pal-K}A{c-amid-S} (PEP NO: and / or SEQ ID NO: 187). DETAILED DESCRIPTION OF THE INVENTION Some embodiments of the present invention are described in the “Summary of the Invention”, “Brief Description of the Figures”, “Examples”, “Claims,” and “Figures” sections of this patent disclosure. This “Detailed Description of the Invention” section provides certain additional embodiments, and certain additional description and details relating to embodiments described throughout the present patent disclosure and is intended to be read in conjunction with all other sections of the present patent disclosure. For ease of reference, this Detailed Description of the Invention section is arranged using the following headings and subheadings: Table 2. Headings and subheadings of the Detailed Description of the Invention The headings and subheadings used herein are not intended to limit the scope of the invention in any way. All sections of this patent disclosure should be read in conjunction with all other sections of the patent disclosure. Similarly, one of ordinary skill in the art will understand that the various embodiments of the present invention can be combined in various different ways. All such combinations of embodiments fall within the scope of the present invention. 1. Definitions & Abbreviations In order that the present invention can be more readily understood, certain terms are defined below. Additional definitions are set forth throughout the disclosure where the terms are used. Unless defined otherwise, or a specific meaning is clear from the context of use, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention is related. The Dictionary of Cell and Molecular Biology (5th ed. J.M. Lackie ed., 2013), the Oxford Dictionary of Biochemistry and Molecular Biology (2d ed. R. Cammack et al. eds., 2008), and The Concise Dictionary of Biomedicine and Molecular Biology (2d ed. P-S. Juo, 2002) can provide one of skill with general definitions of some of the terms used herein. Units, prefixes, and symbols as used herein are denoted in their Système International de Unites (SI) accepted form. Numeric ranges provided herein are inclusive of the numbers defining the range. As used herein, the singular forms “a,” “an,” and “the” include plural referents, unless the context clearly dictates otherwise. The terms “a” (or “an”) as well as the terms “one or more” and “at least one” can be used interchangeably. As used herein, “and / or” is to be taken as specific disclosure of each of the two specified features or components with or without the other. Thus, the term “and / or” as used in a phrase such as “A and / or B” is intended to include A and B, A or B, A (alone), and B (alone). Likewise, the term “and / or” as used in a phrase such as “A, B, and / or C” is intended to include A, B, and C; A, B, or C; A or B; A or C; B or C; A and B; A and C; B and C; A (alone); B (alone); and C (alone). As used herein the terms “about” and “approximately,” when used in relation to numerical values, mean within + or – 10% of the stated value. As used herein, the terms “affinity” and “binding affinity” refer to the strength of the sum-total of non-covalent interactions between a binding site on a first molecule (e.g., a peptide as described herein) and a second molecule (e.g., a delta opioid receptor). Unless indicated otherwise, as used herein, “binding affinity” refers to intrinsic binding affinity which reflects a 1:1 interaction between members of a binding pair (e.g., a peptide and a delta opioid receptor). The affinity of a molecule for another molecule can be represented by the dissociation constant (KD). Affinity can be measured by common methods known in the art (such as radiolabeled assays) or as described herein. As used herein, the term “agonist” refers to a molecule (e.g., a peptide) with the ability to produce a detectable, measurable, or observable activation of a specified receptor (e.g., a delta opioid receptor), for example in an in vitro or in vivo assay. As used herein, the term “amino acid” includes all canonical and non-canonical amino acids known in the art, and includes both naturally occurring and non-naturally occurring amino acids known in the art. As used herein, the term “naturally occurring” as it refers to an amino acid refers to the twenty canonical amino acids encoded by the human genetic code (i.e., Alanine (Ala, A), arginine (Arg, R), asparagine (Asn, N), aspartic acid (Asp, D), cysteine (Cys, C), glutamine (Gln, Q), glutamic acid (Glu, E), glycine (Gly, G), histidine (His, H), isoleucine (Ile, I), leucine (Leu, L), lysine (Lys, K), methionine (Met, M), phenylalanine (Phe, F), proline (Pro, P), serine (Ser, S), threonine (Thr, T), tryptophan (Trp, W), tyrosine (Tyr, Y), and valine (Val, V)). Examples of non-naturally occurring and / or non-canonical amino acids include but are not limited to citrulline (Cit), hydroxyproline (Hyp), norleucine (Nle), 3-nitrotyrosine, nitroarginine, ornithine (Orn), naphtylalanine (Nal), Abu, DAB, methionine sulfoxide or methionine sulfone. In some embodiments, the peptides of the present invention may contain one or more “modified amino acids.” As used herein the term “modified” when used in relation to amino acids refers to an amino acid that differs chemically from the form of that amino acid that is encoded by the genetic code or that typically exists in nature. Examples of modified amino acids include but are not limited to amino acids having D chirality as opposed to L chirality, amino acids in their beta form as opposed to alpha form, homo amino acids (e.g., homoalanine), gamma amino acids, beta homo amino acids, N-methyl amino acids, alpha-methyl amino acids, beta-methyl amino acids, fluoro-amino acids, amino acids that are acetylated, amino acids that are acylated, amino acids that are fatty acylated, amino acids that are amidated, amino acids that are methylated, amino acids that are phosphorylated, amino acids that are palmitoylated, amino acids that are glycosylated, amino acids that have undergone stearic acid conjugation, amino acids that are pegylated, amino acids conjugated to deoxyribonucleic acids or ribonucleic acids or oligonucleotides or polynucleotides, amino acids that have been labelled or tagged (e.g. using a fluorescent or isotopic label or tag), amino acids that have an added protecting group, and amino acids altered using other manipulations or modifications known in the art. Further information regarding “modified amino acids” that may be used in the peptides of the present invention is provided elsewhere in this patent disclosure (see, e.g., the description under the subheading “Peptides” regarding “modified” amino acids). Other modified, non-naturally occurring, and non-canonical amino acids are known in the art, for example as described in Sandberg et al., “New Chemical Descriptors Relevant for the Design of Biologically Active Peptides. A Multivariate Characterization of 87 Amino Acids;” J. Med. Chem.; 1998; 41(14); pp.2481-91). Amino acids are typically referred to using either their accepted three-letter or one-letter symbols as recommended by the IUPAC-IUB Biochemical Nomenclature Commission. Amino acids are referred to herein using their one-letter symbols recommended by the IUPAC-IUB Biochemical Nomenclature Commission. Modified amino acids are referred to herein using their one-letter symbol in conjunction with one or more prefixes, as described further in the “Detailed Description of the Invention” section of this patent disclosure. The terms “comprising,” “consisting of”, and / or “consisting essentially of” are used herein consistently with their accepted meanings according to U.S. patent law. Wherever embodiments are described with the language “comprising,” otherwise analogous embodiments described in terms of “consisting of”, and / or “consisting essentially of” are also intended and included within the scope of the invention. The terms “consensus” or “consensus sequence” or “consensus amino acid sequence,” as used herein, refer to an amino acid sequence obtained by comparing multiple aligned amino acid sequences to identify shared sequence motifs. For example, the present invention provides various consensus amino acid sequences obtained by aligning and comparing the amino acid sequences of peptides having the sequences of PEP NOs: and / or SEQ ID NOs: 1-315, or by comparing subgroups of peptides from among PEP NOs: and / or SEQ ID NOs: 1-315, and identifying shared sequence motifs. In some cases, consensus sequences are identified in which the amino acid occurring at each aligned position is the same, in which case the amino acid at each position of the consensus sequence is specified (such as, for example, the consensus amino acid sequences PEP NOs: and / or SEQ ID NOs: 747-875 as provided herein). In some cases, consensus sequences are identified in which one or more positions can vary in terms of the amino acid occurring at that position, in which case one or more of the positions in the consensus sequence is identified as a variable “X” amino acid residue, with the possible amino acids that can occur at the variable “X” position being specified (such as, for example, PEP NOs: and / or SEQ ID NOs: 316-437 as provided herein). Amino acid consensus sequences are useful because they provide a method of correlating the structure of a group of proteins or peptides to their biological function. For example, the consensus amino acid sequences provided herein represent common structural motifs that are believed to be correlated to the DOR agonist activity of the peptides that contain them. As used herein, the abbreviation “DOR” refers to a delta opioid receptor. In some embodiments of the present invention, the DOR is a mammalian DOR. In some embodiments of the present invention, the DOR is a rodent DOR. In some embodiments, of the present invention, the DOR is a non-human primate DOR. In some embodiments of the present invention, the DOR is a human DOR. As used herein, the term “delta opioid agonist” or “DOR agonist” refers to a molecule that has agonist activity at the delta opioid receptor that is detectable in any suitable assay for delta opioid agonism known in the art, such as, for example, detection of a variety of downstream effects including but not limited to: effects on cyclic adenosine monophosphate (“cAMP”) (e.g., cAMP production),which can be detected using methods known in the art such as the assay in Example 1, effects on beta-arrestin (e.g., beta-arrestin recruitment), which can be detected using methods known in the art such as the assay in Example 4, effects on calcium (e.g., calcium flux), which can be detected using methods known in the art such as the assay in Example 2, or effects on receptor conformational changes and / or receptor internalization, which can be detected using methods known in the art such as the assay in Example 4. As used herein, the term “biased DOR agonist” refers to a molecule (such as a peptide) that preferentially activates (as measured by lower EC50 and / or greater maximal effect) one or more effects downstream of DOR agonism (as are known in the art (e.g. cAMP production, beta arrestin recruitment, receptor internalization, calcium flux, and / or others)) relative to one or more other effects downstream of DOR agonism. As used herein when referring to a peptide, the terms “stable” or “exhibiting stability” and the like refer to the peptide exhibiting less than 10% degradation or a less than 10% decrease in biological activity under the stated conditions (e.g., in a stated composition, and / or for a stated time, and / or at a stated temperature) unless another specific stability level is stated. In some embodiments the level of stability is assessed using one or more of the stability assays described in Examples section of this patent disclosure, which include stability assays based on assessing peptide degradation by HPLC, and stability assays based on assessing biological activity in vivo or in vitro. As used herein, the term “effective amount,” when used in relation to the DOR agonist peptides of the present invention, refers to an amount of a DOR agonist peptide that is sufficient to have activity as an agonist of a DOR Example 1, or to achieve detectable, measurable, or observable agonism of a DOR, or to achieve a detectable, measurable, or observable biological effect or treatment effect (see definition of “treatment” below defined below), in the stated situation. The amount of a given peptide, or composition comprising such a peptide, that is an “effective amount” may depend on variety of factors including, but not limited to, the species of the subject (e.g., whether a human or some other animal species), the age of the subject, the sex of the subject, the weight of the subject, the formulation of the peptide, the route of administration of the peptide, the planned dosing regimen, etc. The effective amount (which may be a range of effective amounts) can be determined by standard techniques, for example using in vitro assays and / or in vivo assays in the intended subject species or any suitable animal model species. Suitable methods for determining an effective amount include, but are not limited to, dose- escalation studies, extrapolation from dose-response curves, and / or extrapolation from other data derived from in vitro and / or in vivo model systems. In some embodiments, the effective amount may be determined according to the judgment of a medical or veterinary practitioner based on the specific circumstances. The term “selective agonists of the delta opioid receptor” or “selective delta opioid receptor agonists” as used herein denotes any compound which has a higher binding affinity for (or a higher agonist activity at) the delta-opioid receptor than for / at any other opioid receptor (such as at the mu opioid receptor). Preferably the compounds have a binding affinity or an agonist activity that is at least 2, or more preferably at least 5, or more preferably at least 10, or more preferably at least 20, or more preferably at least 50, or more preferably at least 100 or more preferably at least 200, or more preferably at least 500, or more preferably at least 1000 times higher for the delta-opioid receptor than for any other opioid receptor (such as the mu opioid receptor). Such binding affinity levels and agonist activity levels can be determined by methods known in the art including by the assay described in Example 3 (in the case of binding activity) or Example 1, or Example 2, or Example 4 (in the case of agonist activity). Similarly, in vivo selectivity for the delta opioid receptor can be determined using any suitable methods known in the art, for example using genetic knockout animals that lack expression of an opioid receptor (e.g., DOR knockouts and / or knockouts of other opioid receptors (such as at the mu opioid receptor)), or using antagonists or competitive agonists having known specificity for a given opioid receptor (such as the DOR or mu opioid receptor). As used herein, the terms “exemplary” or “e.g.” or “for example” or “such as” mean serving as an example, instance, or illustration. These terms are non-limiting and are not intended to denote preferred embodiments. As used herein, the terms “gastrointestinal site of action” or “GI site of action” mean, when referring to an orally administered DOR agonist peptide as described herein, having activity primarily at DORs within or in the vicinity of to the gastrointestinal (GI) tract rather than at DORs systemically or elsewhere in the body (such as in the brain). A GI site of action can be demonstrated using any suitable method known in the art, or any method as described herein. For example, a GI site of action of a peptide of the present invention is demonstrated when the therapeutic efficacy of the peptide is proportional to the dose of that peptide that is administered orally, but not proportional to and independent of the level of that peptide in blood circulation following oral administration (i.e., independent of systemic exposure). As used herein, the terms “identical” and “percent identity” when used to refer to a comparison between two peptides, refer, respectively, to two peptides that have the same amino acid sequence and the same amino acid modifications (i.e. they are “identical”) or that have a specified percentage of amino acid residues that have the same amino acid sequence and the same amino acid modifications (i.e. they have the stated “percent identity”) when the two peptides are compared and aligned (introducing gaps or insertions, if necessary) for maximum correspondence. For example, if two 10 amino acid peptides have the same amino acid sequence but in one peptide, and not the other, one amino acid is acetylated or one amino acids has D chirality instead of L chirality, the two peptides are considered to be 90% identical or to have 90% identity. Percent identity can be determined or measured using sequence comparison software or algorithms or by visual inspection. Various algorithms and software are known in the art that can be used to obtain alignments of amino acid sequences and to calculate percent identity. As used herein, the term “isolated” refers to molecules (e.g., peptides) that are not within a living subject or cell and are typically in a form not found in nature. In some embodiments, an isolated molecule may have been purified to a degree that it is not in a form in which it is found in nature. In some embodiments, a molecule that is isolated is “substantially pure.” In some embodiments, the peptides described herein are isolated peptides. As used herein, the term “peptide” refers to a polymer of amino acids linked via peptide bond(s) regardless of conformation or internal linkages. Thus, the term “peptide” includes linear, branched, disulfide bridged, and cyclized peptides, as well as peptides having any other topology known in the art. The peptides of the present invention can be modified and / or can include modified amino acids and / or can be interrupted by and / or conjugated with non-amino acids. Peptides may be represented herein using strings of amino acid abbreviations (i.e., amino acid sequences). Such amino acid sequences may be referred to using a sequence identification number (SEQ ID NO:) as per the sequence listing associated with this application) or a corresponding peptide number (PEP NO:), wherein the terms SEQ ID NO: 1 and PEP NO:1 refer to the same peptide having the same amino acid sequence, and the terms SEQ ID NO: 2 and PEP NO:2 refer to the same peptide having the same amino acid sequence, and so on for all SEQ ID NOs: and PEP NOs:. The two terms may thus be used interchangeably. Unless stated otherwise, peptides represented by their amino acid sequence are presented with the N-terminus on the left and the sequence is written from the N-terminus to the C-terminus. Peptides may also be represented herein by their chemical structure. A peptide may be comprised of any number of amino acids but preferably less than 200 amino acids such as fewer than 200 amino acids, fewer than 100 amino acids, fewer than 50 amino acids, fewer than 40 amino acids, fewer than 30 amino acids, fewer than 20 amino acids, fewer than 15 amino acids, fewer than 10 amino acids, 3-20 amino acids, 4-20 amino acids, 5-20 amino acids, 6-20 amino acids, 7-20 amino acids, 8-20 amino acids, 9-20 amino acids, or 10-20 amino acids. As used herein, the term “pharmaceutical composition” refers to a composition that is in such form as to permit the biological activity of the active agent(s) contained therein (e.g., peptide(s)), and that contain no additional components that are unacceptably toxic to a subject to which the composition may be administered. In some embodiments, such compositions may be sterile. As used herein, the term “potency” is used consistent with its accepted meaning in the art and is a measure of the activity of a given agent (e.g., a peptide as described herein) expressed in terms of the amount required to produce a stated effect (e.g., detectable activation of the DOR). A highly potent agent produces the stated effect at a low concentration, while an agent having lower potency produces the stated effect only at higher concentrations. The “potency” of the peptides described herein may be expressed using any suitable measure known in the art. For example, the potency of the peptides may be referred to in terms of their “EC50” values or “IC50” values. For example, in a functional assay, the EC50may be the concentration of the peptide that induces a biological response that is 50% of the peptide’s maximum biological response in the stated functional assay. For example, in the case of the present invention, the EC50 of a peptide described herein is the concentration of the peptide that induces 50% of that peptide’s maximal DOR agonism. As an alternative to expressing potency using EC50values, the potency of the peptides of the present invention may also be described herein in terms of the % of DOR agonism relative to a known standard (e.g., D-Pen2,5 -Enkephalin (“DPDPE”)) observed at a given concentration of the peptide or at or below a given concentration of the peptide. For example, a peptide of the present invention may be described as having DOR agonist activity of at least 50% at a concentration at or below 10 µM, or may be described as having DOR agonist activity of at least 90% at a concentration at or below 10 µM. As used herein, the term “primate” refers to any mammal of the group that includes the lemurs, lorises, tarsiers, monkeys, apes, and humans. As used herein, the term “retro-inverso” refers to a peptide that has amino acids in the reverse order and where each amino acid has changed chirality (i.e., from L to D or from D to L) relative to a stated reference amino acid sequence, disregarding N-terminal and C-terminal modifications of the reference amino acid sequence. The stated reference amino acid sequence may specify all amino acid residues or it may be a consensus amino acid sequence in which some of the amino acid residues can vary in a specified manner. As used herein, the term “subject” refers to an individual for whom prophylaxis or treatment using a peptide, composition, or method as described herein is desired, needed or performed. As used herein, a subject “in need thereof” is a subject who could reasonably be expected to benefit from prophylaxis or treatment using a peptide, composition, or method as described – for example as determined by a medical professional. In some embodiments, the subject is any mammalian subject, including, but not limited to, humans (male and / or female), non-human primates, dogs, cats, rodents (such as rats, mice and guinea pigs), cows, pigs, sheep, goats, horses, and the like – including all mammalian animal species used in animal husbandry, as well as animals kept as pets and in zoos, and animals used in preclinical testing. In some embodiments, the subject may be a juvenile. In some embodiments, the subject may be an adult. In some embodiments, the subject may be an elderly adult. As used herein, the term “substantially pure” when used in reference to a peptide refers to at least about 70%, preferably at least about 80%, more preferably at least about 90%, and most preferably at least about 95%, 98%, 99%, or 99.9% purity of the peptide. As used herein, the terms “treat,” “treating,” and “treatment” refer to achieving, and / or performing a method that achieves, a detectable, measurable, or observable improvement in one or more clinical parameters or symptoms. For example, in the case of pain, “treatment” refers to achieving, and / or performing a method that achieves, a detectable, measurable, or observable analgesic effect (e.g., comprising an improvement in pain, a reduction in pain, an elimination of pain, a prevention of pain, a lessened duration of pain, etc.). Thus, the phrases “method of treating pain” and “method of inducing analgesia” (and grammatical variations of these phrases) may be used interchangeably herein. The term “means” is used herein consistently with its usage in U.S. patent law, and shall be given its broadest possible interpretation in accordance with 35 U.S.C. section 112(f). Accordingly, a claim incorporating the term “means” shall cover all structures, materials, or acts described herein, and all equivalents thereof. Further, the structures, materials, or acts shall include all of those described in the Summary of the Invention, Brief Description of the Figures, Figures, Detailed Description of the Invention, Examples, Claims, Abstract, and Sequence Listing. It is intended that the peptides of the present invention may also be referred to as a means for achieving a function or effect as described herein. Thus, whenever an embodiment of the present invention is described without using “means” language, it is to be understood that an analogous embodiment, described as a “means” for achieving a certain function or effect, is also contemplated and falls within the scope of the present invention. Other terms are defined elsewhere in this patent disclosure, or else are used in accordance with their accepted meaning in the art. 2. Peptides The present invention provides a number of novel peptides. In some embodiments, the present invention provides peptides that comprise the amino acid sequence of any one of PEP NOs: and / or SEQ ID NOs: 1-315 (as described in more detail in section 2.1 below and elsewhere herein). In some embodiments, the present invention provides peptides that can be described using the consensus amino acid sequence of any of PEP NO: and / or SEQ ID NO: 316-437 (as described in more detail in section 2.7 below and elsewhere herein). In some embodiments, the present invention provides peptides that comprise the amino acid sequence of any one of PEP NOs: and / or SEQ ID NOs: 438-752 (as described in more detail in section 2.8 below and elsewhere herein). In some embodiments, the present invention provides peptides that comprise the amino acid sequence of any one of PEP NOs: and / or SEQ ID NOs: 747-875 (as described in more detail in section 2.4 below and elsewhere herein). Whenever a peptide is referred to herein in terms of its PEP NO: and / or SEQ ID NO:, without further qualification, the peptide has the amino acid residues, amino acid modifications, and other peptide attributes (such as cyclization) specified in the description of that PEP NO: and / or SEQ ID NO: that is provided herein (such as in Table 3, below). In some embodiments, the present invention provides peptides having the chemical structures provided in Figs.3-44. In some embodiments, the present invention provides “variant” peptides that differ from, or that comprise a peptide that differs from, any of the amino acid sequences provided herein. The differences between the variant peptides and peptides that comprise each PEP NO: and / or SEQ ID NO: can occur at various levels, including at the level of the amino acid residues (e.g., variant peptides may comprise amino acid substitutions, deletions, or additions as compared to that of any specified PEP NO: and / or SEQ ID NO:), at the level of amino acid modifications (e.g., variant peptides may have modifications added or removed as compared to any specified PEP NO: and / or SEQ ID NO:, or may include different modifications from those in any specified any specified PEP NO: and / or SEQ ID NO:), and at the level of other peptide attributes (such as cyclization, dimerization, multimerization, and the like). Examples of such variant peptides are described in more detail in section 2.9 below and elsewhere herein. In some embodiments, the peptides of the present invention have a maximum length of 3 amino acids, or 4 amino acids, or 5 amino acids, or 6 amino acids, or 7 amino acids, or 8 amino acids, or 9 amino acids, or 10 amino acids, or 11 amino acids, or 12 amino acids, or 13 amino acids, or 14 amino acids, or 15 amino acids, or 16 amino acids, or 17 amino acids, or 18 amino acids, or 19 amino acids, or 20 amino acids, or 21 amino acids, or 22 amino acids, or 23 amino acids, or 24 amino acids, or 25 amino acids, or 26 amino acids, or 27 amino acids, or 28 amino acids, or 29 amino acids, or 30 amino acids. In some embodiments, the peptides of the present invention provide novel tools for studying the delta opioid receptor’s role in human pathophysiology. In some embodiments, the peptides of the present invention have delta opioid agonist activity. In some embodiments, the peptides of the present invention have delta opioid agonist activity in animal models. In some embodiments, the peptides of the present invention have delta opioid agonist activity in primates. In some embodiments, the peptides of the present invention have delta opioid agonist activity in non-human primates. In some embodiments, the peptides of the present invention have delta opioid agonist activity in human subjects. In some embodiments, the peptides of the present invention act predominantly through agonism of the delta opioid receptor and not through agonism of the mu opioid receptor. In some embodiments, the peptides of the present invention act predominantly through agonism of the delta opioid receptor and not through agonism of the mu opioid receptor in animal models. In some embodiments, the peptides of the present invention act predominantly through agonism of the delta opioid receptor and not through agonism of the mu opioid receptor in primates. In some embodiments, the peptides of the present invention act predominantly through agonism of the delta opioid receptor and not through agonism of the mu opioid receptor in non-human primates. In some embodiments, the peptides of the present invention act predominantly through agonism of the delta opioid receptor and not through agonism of the mu opioid receptor in human subjects. In some embodiments, the peptides of the present invention are selective delta opioid receptor agonists. In some embodiments, the peptides of the present invention are selective delta opioid receptor agonists in animal models. In some embodiments, the peptides of the present invention are selective delta opioid receptor agonists in primates. In some embodiments, the peptides of the present invention are selective delta opioid receptor agonists in non-human primates. In some embodiments, the peptides of the present invention are selective delta opioid receptor agonists in human subjects. In some embodiments, the peptides of the present invention are specific delta opioid receptor agonists. In some embodiments, the peptides of the present invention are specific delta opioid receptor agonists in animal models. In some embodiments, the peptides of the present invention are specific delta opioid receptor agonists in primates. In some embodiments, the peptides of the present invention are specific delta opioid receptor agonists in non-human primates. In some embodiments, the peptides of the present invention are specific delta opioid receptor agonists in human subjects. In some embodiments, the peptides of the present invention exhibit analgesic efficacy in animal models. In some embodiments, the peptides of the present invention exhibit analgesic efficacy in a rodent model of pain such as that described in Example 5. In some embodiments, the peptides of the present invention exhibit analgesic efficacy in primates. In some embodiments, the peptides of the present invention exhibit analgesic efficacy in non-human primates. In some embodiments, the peptides of the present invention exhibit analgesic efficacy in human subjects. In some embodiments, the peptides of the present invention exhibit analgesic efficacy in animal models mediated by DOR agonism. In some embodiments, the peptides of the present invention exhibit analgesic efficacy in rodent models mediated by DOR agonism. In some embodiments, the peptides of the present invention exhibit analgesic efficacy in primates mediated by DOR agonism. In some embodiments, the peptides of the present invention exhibit analgesic efficacy in non- human primates mediated by DOR agonism. In some embodiments, the peptides of the present invention exhibit analgesic efficacy in human subjects mediated by DOR agonism. In some embodiments, mediation by DOR agonism is determined through use of genetic knockout animals (e.g., DOR knockouts) and / or other methods known in the art. In some embodiments, mediation by DOR agonism is determined through use of known DOR specific antagonists and methods known in the art. In some embodiments, the peptides of the present invention exhibit analgesic efficacy in a range of animal models such as animal models of acute mechanical pain, acute thermal pain, inflammatory pain, visceral pain, and / or neuropathic pain. In some embodiments, the peptides of the present invention exhibit oral efficacy in animal models. In some embodiments, the peptides of the present invention exhibit oral efficacy in primates. In some embodiments, the peptides of the present invention exhibit oral efficacy in non-human primates. In some embodiments, the peptides of the present invention exhibit oral efficacy in human subjects. In some embodiments, the peptides of the present invention exhibit oral bioavailability in animal models. In some embodiments, the peptides of the present invention exhibit oral bioavailability in primates. In some embodiments, the peptides of the present invention exhibit oral bioavailability in non-human primates. In some embodiments, the peptides of the present invention exhibit oral bioavailability in human subjects. In some embodiments, the peptides of the present invention have a site of action that is not in the central nervous system. This is demonstrated by any methods known in the art including by use of conditional knockouts such as those utilizing Cre recombinase as is known in the art. In some embodiments, the peptides of the present invention have a GI site of action. This is demonstrated by any methods known in the art including by demonstration of effect (such as analgesic efficacy) proportional to oral dose but not proportional to systemic exposure. In some embodiments, the peptides of the present invention provide analgesic efficacy lasting a clinically useful time. In some embodiments, the peptides of the present invention provide analgesic efficacy lasting a clinically useful time when administered orally. In some embodiments, the peptides of the present invention provide analgesic efficacy lasting about 2-6 hours. In some embodiments, the peptides of the present invention provide analgesic efficacy lasting about 2- 12 hours. In some embodiments, the peptides of the present invention provide analgesic efficacy lasting about 2-18 hours. In some embodiments, the peptides of the present invention provide analgesic efficacy lasting about 2-24 hours. In some embodiments, the peptides of the present invention provide analgesic efficacy lasting about 6-12 hours. In some embodiments, the peptides of the present invention provide analgesic efficacy lasting about 6-18 hours. In some embodiments, the peptides of the present invention provide analgesic efficacy lasting about 6- 24 hours. In some embodiments, the peptides of the present invention provide analgesic efficacy lasting about 12-18 hours. In some embodiments, the peptides of the present invention provide analgesic efficacy lasting about 12-24 hours. In some embodiments, the peptides of the present invention provide analgesic efficacy lasting about 18-24 hours. In some embodiments, the peptides of the present invention are safe for administration to living subjects. In some embodiments, the peptides of the present invention are safe for administration to primates. In some embodiments, the peptides of the present invention are safe for administration to non-human primates. In some embodiments, the peptides of the present invention are safe for administration to human subjects. In some embodiments, the peptides of the present invention do not cause convulsions in living subjects. In some embodiments, the peptides of the present invention do not cause convulsions in primates. In some embodiments, the peptides of the present invention do not cause convulsions in non-human primates. In some embodiments, the peptides of the present invention do not cause convulsions in human subjects. In some embodiments, the peptides of the present invention do not cause undesirable neurological effects such as narcotic effects in living subjects. In some embodiments, the peptides of the present invention do not cause undesirable neurological effects such as narcotic effects in primates. In some embodiments, the peptides of the present invention do not cause undesirable neurological effects such as narcotic effects in non-human primates. In some embodiments, the peptides of the present invention do not cause undesirable neurological effects such as narcotic effects in human subjects. In some embodiments, the peptides of the present invention do not induce tolerance following repeated administration and / or maintain clinical efficacy following repeated administration in living subjects. In some embodiments, the peptides of the present invention do not induce tolerance following repeated administration and / or maintain clinical efficacy following repeated administration in primates. In some embodiments, the peptides of the present invention do not induce tolerance following repeated administration and / or maintain clinical efficacy following repeated administration in non-human primates. In some embodiments, the peptides of the present invention do not induce tolerance following repeated administration and / or maintain clinical efficacy following repeated administration in human subjects. In some embodiments, the peptides of the present invention are not addictive in living subjects. In some embodiments, the peptides of the present invention are not addictive in primates. In some embodiments, the peptides of the present invention are not addictive in non-human primates. In some embodiments, the peptides of the present invention are not addictive in human subjects. In some embodiments, the peptides of the present invention are stable as a solid (e.g. a lyophilized powder) for up to 1 hour at less than -15°C, or at 0 to 4°C, or at 4 to 25°C, or at 25 to 40°C, or at 40 to 70°C, or at 70 to 90°C, or at 90 to 100°C, or at 100 to 110°C, or at -20 to 25°C, or at -20 to 4°C, or at -20 to 40°C. In some embodiments, the peptides of the present invention are stable as a solid (e.g. a lyophilized powder) for up to 24 hours at less than -15°C, or at 0 to 4°C, or at 4 to 25°C, or at 25 to 40°C, or at 40 to 70°C, or at 70 to 90°C, or at 90 to 100°C, or at 100 to 110°C, or at -20 to 25°C, or at -20 to 4°C, or at -20 to 40°C. In some embodiments, the peptides of the present invention are stable as a solid (e.g. a lyophilized powder) for up to 1 week at less than - 15°C, or at 0 to 4°C, or at 4 to 25°C, or at 25 to 40°C, or at 40 to 70°C, or at 70 to 90°C, or at 90 to 100°C, or at 100 to 110°C, or at -20 to 25°C, or at -20 to 4°C, or at -20 to 40°C. In some embodiments, the peptides of the present invention are stable as a solid (e.g. a lyophilized powder) for up to 1 month at less than -15°C, or at 0 to 4°C, or at 4 to 25°C, or at 25 to 40°C, or at 40 to 70°C, or at 70 to 90°C, or at 90 to 100°C, or at 100 to 110°C, or at -20 to 25°C, or at -20 to 4°C, or at -20 to 40°C. In some embodiments, the peptides of the present invention are stable as a solid (e.g. a lyophilized powder) for up to 6 months at less than -15°C, or at 0 to 4°C, or at 4 to 25°C, or at 25 to 40°C, or at 40 to 70°C, or at 70 to 90°C, or at 90 to 100°C, or at 100 to 110°C, or at - 20 to 25°C, or at -20 to 4°C, or at -20 to 40°C. In some embodiments, the peptides of the present invention are stable as a solid (e.g. a lyophilized powder) as described in Example 7. In some embodiments, the peptides of the present invention are stable in an aqueous solution (e.g. in solution with water) for up to 1 hour at less than -15°C, or at 0 to 4°C, or at 4 to 25°C, or at 25 to 40°C, or at 40 to 70°C, or at 70 to 90°C, or at 90 to 100°C, or at 100 to 110°C, or at -20 to 25°C, or at -20 to 4°C, or at -20 to 40°C. In some embodiments, the peptides of the present invention are stable in an aqueous solution (e.g. in solution with water) for up to 24 hours at less than -15°C, or at 0 to 4°C, or at 4 to 25°C, or at 25 to 40°C, or at 40 to 70°C, or at 70 to 90°C, or at 90 to 100°C, or at 100 to 110°C, or at -20 to 25°C, or at -20 to 4°C, or at -20 to 40°C. In some embodiments, the peptides of the present invention are stable in an aqueous solution (e.g. in solution with water) for up to 1 week at less than -15°C, or at 0 to 4°C, or at 4 to 25°C, or at 25 to 40°C, or at 40 to 70°C, or at 70 to 90°C, or at 90 to 100°C, or at 100 to 110°C, or at -20 to 25°C, or at -20 to 4°C, or at -20 to 40°C. In some embodiments, the peptides of the present invention are stable in an aqueous solution (e.g. in solution with water) for up to 1 month at less than -15°C, or at 0 to 4°C, or at 4 to 25°C, or at 25 to 40°C, or at 40 to 70°C, or at 70 to 90°C, or at 90 to 100°C, or at 100 to 110°C, or at -20 to 25°C, or at -20 to 4°C, or at -20 to 40°C. In some embodiments, the peptides of the present invention are stable in an aqueous solution (e.g. in solution with water) for up to 6 months at less than -15°C, or at 0 to 4°C, or at 4 to 25°C, or at 25 to 40°C, or at 40 to 70°C, or at 70 to 90°C, or at 90 to 100°C, or at 100 to 110°C, or at -20 to 25°C, or at -20 to 4°C, or at -20 to 40°C. In some embodiments, the peptides of the present invention are stable in a non-aqueous solution for up to 1 hour at less than -15°C, or at 0 to 4°C, or at 4 to 25°C, or at 25 to 40°C, or at 40 to 70°C, or at 70 to 90°C, or at 90 to 100°C, or at 100 to 110°C, or at -20 to 25°C, or at -20 to 4°C, or at -20 to 40°C. In some embodiments, the peptides of the present invention are stable in a non- aqueous solution for up to 24 hours at less than -15°C, or at 0 to 4°C, or at 4 to 25°C, or at 25 to 40°C, or at 40 to 70°C, or at 70 to 90°C, or at 90 to 100°C, or at 100 to 110°C, or at -20 to 25°C, or at -20 to 4°C, or at -20 to 40°C. In some embodiments, the peptides of the present invention are stable in a non-aqueous solution for up to 1 week at less than -15°C, or at 0 to 4°C, or at 4 to 25°C, or at 25 to 40°C, or at 40 to 70°C, or at 70 to 90°C, or at 90 to 100°C, or at 100 to 110°C, or at - 20 to 25°C, or at -20 to 4°C, or at -20 to 40°C. In some embodiments, the peptides of the present invention are stable in a non-aqueous solution for up to 1 month at less than -15°C, or at 0 to 4°C, or at 4 to 25°C, or at 25 to 40°C, or at 40 to 70°C, or at 70 to 90°C, or at 90 to 100°C, or at 100 to 110°C, or at -20 to 25°C, or at -20 to 4°C, or at -20 to 40°C. In some embodiments, the peptides of the present invention are stable in a non-aqueous solution for up to 6 months at less than -15°C, or at 0 to 4°C, or at 4 to 25°C, or at 25 to 40°C, or at 40 to 70°C, or at 70 to 90°C, or at 90 to 100°C, or at 100 to 110°C, or at -20 to 25°C, or at -20 to 4°C, or at -20 to 40°C. In some embodiments, the peptides of the present invention are stable under acidic conditions such as described in Example 7. In some embodiments, the peptides of the present invention are stable in a peroxide solution as described in Example 7. In some embodiments, the peptides of the present invention are stable under ultraviolet light as described in Example 7. In the embodiments described above, the peptides exhibit less than 10% degradation or a less than 10% decrease in biological activity under the stated conditions - as described in the Definitions & Abbreviations section of this patent disclosure relating to stability. However, in some embodiments, the peptides of the present invention exhibit even higher levels of stability under the conditions stated above. For example, in some embodiments the peptides of the invention exhibit less than 5% degradation or a less than 5% decrease in biological activity under the conditions stated above. In some embodiments the peptides of the invention exhibit less than 4% degradation or a less than 4% decrease in biological activity under the conditions stated above. In some embodiments the peptides of the invention exhibit less than 3% degradation or a less than 3% decrease in biological activity under the conditions stated above. In some embodiments the peptides of the invention exhibit less than 2% degradation or a less than 2% decrease in biological activity under the conditions stated above. In some embodiments the peptides of the invention exhibit less than 1% degradation or a less than 1% decrease in biological activity under the conditions stated above. Additionally, in some embodiments, the peptides of the present invention exhibit lower levels of stability under the conditions stated above. In the embodiments described above, the peptides exhibit less than 90% degradation or a less than 90% decrease in biological activity under the stated conditions. In the embodiments described above, the peptides exhibit less than 80% degradation or a less than 80% decrease in biological activity under the stated conditions. In the embodiments described above, the peptides exhibit less than 70% degradation or a less than 70% decrease in biological activity under the stated conditions. In the embodiments described above, the peptides exhibit less than 60% degradation or a less than 60% decrease in biological activity under the stated conditions. In the embodiments described above, the peptides exhibit less than 50% degradation or a less than 50% decrease in biological activity under the stated conditions. In the embodiments described above, the peptides exhibit less than 40% degradation or a less than 40% decrease in biological activity under the stated conditions. In the embodiments described above, the peptides exhibit less than 30% degradation or a less than 30% decrease in biological activity under the stated conditions. In the embodiments described above, the peptides exhibit less than 20% degradation or a less than 20% decrease in biological activity under the stated conditions. In some embodiments, the peptides of the present invention are biased DOR agonists. In some embodiments, the peptides of the present invention exhibit preferential activation of one effect downstream of DOR activation as compared to another effect downstream of DOR activation. In some embodiments the peptides of the present invention are biased DOR agonists and have higher potency and / or activity at the DOR in a cAMP assay than in a beta arrestin assay. In some embodiments, the EC50 of the peptide at the DOR in a beta arrestin assay is 1-1.2x, or 1.2-1.5x, or 1.5-1.75x, or 1.75-2x, or 2-5x, or 5-10x, or 10-50x, or 50-100x, or 100-1000x, or 1000-10000x that in a cAMP assay. In some embodiments, the maximal effect of the peptide at the DOR in a cAMP assay is 1-1.2x, or 1.2-1.5x, or 1.5-1.75x, or 1.75-2x, or 2-5x, or 5-10x, or 10-50x, or 50- 100x, or 100-300x, or 300-1000x, or 1000-10000x that in a beta arrestin assay. In some embodiments, the peptides of the present invention are biased DOR agonists and have higher potency and / or activity at the DOR in a calcium flux assay than in a beta arrestin assay. In some embodiments, the EC50 of the peptide at the DOR in a beta arrestin assay is 1-1.2x, or 1.2- 1.5x, or 1.5-1.75x, or 1.75-2x, or 2-5x, or 5-10x, or 10-50x, or 50-100x, or 100-300x, or 300- 1000x, or 1000-10000x that in a calcium flux assay. In some embodiments, the maximal effect of the peptide at the DOR in a calcium flux assay is 1-1.2x, or 1.2-1.5x, or 1.5-1.75x, or 1.75-2x, or 2-5x, or 5-10x, or 10-50x, or 50-100x, or 100-300x, or 300-1000x, or 1000-10000x that in a beta arrestin assay. In some embodiments, the peptides of the present invention are biased DOR agonists and have higher potency and / or activity at the DOR in a cAMP assay than in a receptor internalization assay. In some embodiments, the EC50 of the peptide at the DOR in a receptor internalization assay is 1- 1.2x, or 1.2-1.5x, or 1.5-1.75x, or 1.75-2x, or 2-5x, or 5-10x, or 10-50x, or 50-100x, or 100-300x, or 300-1000x, or 1000-10000x that in a cAMP assay. In some embodiments, the maximal effect of the peptide at the DOR in a receptor cAMP assay is 1-1.2x, or 1.2-1.5x, or 1.5-1.75x, or 1.75- 2x, or 2-5x, or 5-10x, or 10-50x, or 50-100x, or 100-300x, or 300-1000x, or 1000-10000x that in a internalization assay. In some embodiments, the peptides of the present invention are biased DOR agonists and have higher potency and / or activity at the DOR in a calcium flux assay than in a receptor internalization assay. In some embodiments, the EC50 of the peptide at the DOR in a receptor internalization assay is 1-1.2x, or 1.2-1.5x, or 1.5-1.75x, or 1.75-2x, or 2-5x, or 5-10x, or 10-50x, or 50-100x, or 100-300x, or 300-1000x, or 1000-10000x that in a calcium flux assay. In some embodiments, the maximal effect of the peptide at the DOR in a calcium flux assay is 1-1.2x, or 1.2-1.5x, or 1.5- 1.75x, or 1.75-2x, or 2-5x, or 5-10x, or 10-50x, or 50-100x, or 100-300x, or 300-1000x, or 1000- 10000x that in a receptor internalization assay. Further details of the peptides of the present invention are provided below. 2.1. PEP NOs: and / or SEQ ID NOs: 1-315 Table 3 provides the amino acid sequences of 315 peptides (PEP NOs: and / or SEQ ID NOs: 1- 315). Each of these peptides was synthesized and demonstrated to have delta opioid receptor agonist activity of at least 50% at or below 100 µM, as described in Example 1. Table 3. Amino acid sequences of PEP NOs: and / or SEQ ID NOs: 1-315 Several of the peptides in Table 3, and described elsewhere in this patent disclosure, contain chemical modifications and / or contain “modified” amino acids. In Table 3, and elsewhere in this patent disclosure, amino acids and amino acid modifications are represented as follows. Amino acids are represented using their single-letter amino acid code using capital letters. Amino acids illustrated using capital letters unadorned with prefixes or surrounding braces are naturally occurring amino acids. Modified amino acids are illustrated by enclosure with braces (“{” and “}”) which enclose the modification(s) to the amino acid residue. For example, {mod-A} or {modA} denotes a modified version of the naturally occurring alanine (A) amino acid residue according to an example modification (mod or mod-). Specific modifications are represented using prefixes. For example, the amino acid modifications present in the peptides shown in Table 3 are represented using the following prefixes: • D chirality of an amino acid is represented by the prefix “d”, e.g., {dD} denotes D- aspartic acid. • Beta amino acids are represented by the prefix “β”, e.g., {βD} denotes beta aspartic acid. • Homo amino acids are represented by the prefix “h”, e.g., {hD} denotes homo aspartic acid. • Acetylation is represented by the prefix “acet-”. • Amidation is represented by the prefix “amid-”. • Palmitoylation is represented by the prefix “pal-”. • Stearic acid conjugation is represented by the prefix “ste-”. • Polyethylene glycol (PEG) conjugation is represented by the prefix “peg-”. The number (#) of repeating ethylene glycol units in a conjugated PEG moiety may be represented using the prefix “peg#-” e.g., the prefix “peg12-” represents conjugation of a polyethylene glycol moiety consisting of 12 ethylene glycol units. The molecular weight of a PEG moiety may also be represented, e.g., the prefix “peg40k-” represents conjugation of a PEG moiety having a molecular weight of 40 kDa. Several of the peptides in Table 3, and described elsewhere in this patent disclosure, are cyclized. In Table 3, and elsewhere in this patent disclosure, cyclization of a peptide is represented by the prefix “cyclic-”. “Head-to-tail” cyclization of a peptide (i.e., N-terminal cyclization of a peptide to its C-terminus) is represented by the prefix “htt-cyclic-”. Several of the peptides in Table 3, and described elsewhere in this patent disclosure, include the amino acid surrogate N,N-Dimethyltryptamine. In Table 3, and elsewhere in this patent disclosure, the abbreviation “DMT” refers to N,N-Dimethyltryptamine. In Table 3, and elsewhere in this patent disclosure, the locations of amino acid modifications may also be represented. For example, modifications to an N-terminus, R side chain, or C- terminus may be presented with “n-”, “r-”, or “c-” prefixes, respectively, for example, N- terminal acetylation is represented by the prefix “n-acet-”, N-terminal palmitoylation is represented by the prefix “n-pal-”, side chain palmitoylation is represented by the prefix “r-pal- ”(for example palmitoylation of a lysine side chain is represented as {r-pal-K}), N-terminal conjugation of polyethylene glycol (PEG) is represented by the prefix “n-peg-” (for example N- terminal conjugation of polyethylene glycol to D-cysteine is represented as {n-peg-{dC}} and N- terminal conjugation of a polyethylene glycol (PEG) moiety having 12 ethylene glycol monomers to D-beta aspartic acid is represented as {n-peg12-{dβD}}, and N-terminal conjugation of a 40 kDa average molecular weight PEG moiety is represented as “n-peg40k-”), side chain conjugation of stearic acid is represented by the prefix “r-ste-” (for example conjugation of stearic acid to a lysine side chain is represented as{r-ste-K}), side chain conjugation of polyethylene glycol (PEG) is represented by the prefix “r-peg-” (for example side chain conjugation of polyethylene glycol to D-cysteine is represented as {r-peg-{dC}} and, side chain conjugation of a polyethylene glycol (PEG) moiety having 12 ethylene glycol monomers to D-cysteine is represented as{r-peg12-{dC}}, and side chain conjugation of a 40 kDa average molecular weight PEG moiety is represented as“r-peg40k-”), and C-terminal amidation is represented by the prefix “c-amid-”. In Table 3, and elsewhere in this patent disclosure, combinations of any of the prefixes described above are used where necessary to appropriately represent amino acid modifications or other peptide attributes. For example, the combination of prefixes {n-acet-{dβD}} represents an N-terminal D-beta aspartic acid amino acid residue that has an acetyl group attached to its free N-terminal amino group. In Table 3, and elsewhere in this patent disclosure, the conjugation of PEG40k with lysine using the reaction of PEG40k-DBCO with lysine-azide is represented as {{r-peg40k-dbco}-{azide-K}}. In Table 3, and elsewhere in this patent disclosure, the conjugation of PEG40k with cysteine using the reaction of PEG40k- Maleimide with cysteine is represented as {r-peg40k-C}. In Table 3, and elsewhere in this patent disclosure, the conjugation of PEG40k with D-cysteine using the reaction of PEG40k-Maleimide with cysteine is represented as {r-peg40k-{dC}}. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 1. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 2. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 3. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 4. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 5. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 6. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 7. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 8. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 9. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 10. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 11. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 12. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 13. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 14. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 15. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 16. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 17. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 18. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 19. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 20. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 21. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 22. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 23. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 24. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 25. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 26. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 27. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 28. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 29. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 30. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 31. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 32. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 33. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 34. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 35. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 36. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 37. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 38. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 39. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 40. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 41. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 42. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 43. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 44. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 45. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 46. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 47. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 48. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 49. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 50. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 51. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 52. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 53. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 54. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 55. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 56. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 57. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 58. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 59. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 60. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 61. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 62. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 63. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 64. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 65. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 66. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 67. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 68. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 69. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 70. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 71. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 72. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 73. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 74. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 75. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 76. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 77. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 78. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 79. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 80. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 81. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 82. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 83. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 84. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 85. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 86. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 87. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 88. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 89. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 90. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 91. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 92. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 93. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 94. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 95. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 96. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 97. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 98. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 99. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 100. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 101. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 102. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 103. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 104. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 105. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 106. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 107. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 108. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 109. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 110. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 111. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 112. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 113. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 114. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 115. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 116. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 117. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 118. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 119. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 120. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 121. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 122. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 123. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 124. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 125. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 126. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 127. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 128. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 129. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 130. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 131. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 132. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 133. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 134. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 135. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 136. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 137. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 138. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 139. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 140. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 141. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 142. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 143. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 144. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 145. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 146. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 147. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 148. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 149. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 150. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 151. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 152. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 153. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 154. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 155. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 156. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 157. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 158. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 159. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 160. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 161. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 162. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 163. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 164. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 165. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 166. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 167. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 168. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 169. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 170. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 171. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 172. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 173. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 174. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 175. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 176. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 177. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 178. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 179. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 180. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 181. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 182. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 183. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 184. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 185. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 186. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 187. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 188. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 189. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 190. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 191. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 192. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 193. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 194. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 195. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 196. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 197. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 198. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 199. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 200. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 201. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 202. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 203. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 204. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 205. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 206. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 207. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 208. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 209. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 210. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 211. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 212. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 213. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 214. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 215. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 216. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 217. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 218. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 219. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 220. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 221. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 222. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 223. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 224. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 225. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 226. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 227. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 228. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 229. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 230. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 231. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 232. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 233. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 234. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 235. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 236. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 237. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 238. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 239. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 240. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 241. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 242. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 243. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 244. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 245. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 246. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 247. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 248. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 249. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 250. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 251. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 252. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 253. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 254. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 255. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 256. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 257. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 258. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 259. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 260. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 261. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 262. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 263. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 264. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 265. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 266. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 267. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 268. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 269. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 270. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 271. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 272. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 273. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 274. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 275. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 276. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 277. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 278. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 279. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 280. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 281. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 282. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 283. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 284. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 285. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 286. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 287. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 288. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 289. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 290. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 291. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 292. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 293. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 294. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 295. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 296. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 297. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 298. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 299. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 300. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 301. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 302. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 303. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 304. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 305. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 306. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 307. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 308. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 309. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 310. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 311. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 312. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 313. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 314. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 315. In one embodiment, the present invention provides a peptide having the chemical structure shown in Fig.3. In one embodiment, the present invention provides a peptide having the chemical structure shown in Fig.4. In one embodiment, the present invention provides a peptide having the chemical structure shown in Fig.5. In one embodiment, the present invention provides a peptide having the chemical structure shown in Fig.6. In one embodiment, the present invention provides a peptide having the chemical structure shown in Fig.7. In one embodiment, the present invention provides a peptide having the chemical structure shown in Fig.8. In one embodiment, the present invention provides a peptide having the chemical structure shown in Fig.9. In one embodiment, the present invention provides a peptide having the chemical structure shown in Fig.10. In one embodiment, the present invention provides a peptide having the chemical structure shown in Fig.11. In one embodiment, the present invention provides a peptide having the chemical structure shown in Fig.12. In one embodiment, the present invention provides a peptide having the chemical structure shown in Fig.13. In one embodiment, the present invention provides a peptide having the chemical structure shown in Fig.14. In one embodiment, the present invention provides a peptide having the chemical structure shown in Fig.15. In one embodiment, the present invention provides a peptide having the chemical structure shown in Fig.16. In one embodiment, the present invention provides a peptide having the chemical structure shown in Fig.17. In one embodiment, the present invention provides a peptide having the chemical structure shown in Fig.18. In one embodiment, the present invention provides a peptide having the chemical structure shown in Fig.19. In one embodiment, the present invention provides a peptide having the chemical structure shown in Fig.20. In one embodiment, the present invention provides a peptide having the chemical structure shown in Fig.21. In one embodiment, the present invention provides a peptide having the chemical structure shown in Fig.22. In one embodiment, the present invention provides a peptide having the chemical structure shown in Fig.23. In one embodiment, the present invention provides a peptide having the chemical structure shown in Fig.24. In one embodiment, the present invention provides a peptide having the chemical structure shown in Fig.25. In one embodiment, the present invention provides a peptide having the chemical structure shown in Fig.26. In one embodiment, the present invention provides a peptide having the chemical structure shown in Fig.27. In one embodiment, the present invention provides a peptide having the chemical structure shown in Fig.28. In one embodiment, the present invention provides a peptide having the chemical structure shown in Fig.29. In one embodiment, the present invention provides a peptide having the chemical structure shown in Fig.30. In one embodiment, the present invention provides a peptide having the chemical structure shown in Fig.31. In one embodiment, the present invention provides a peptide having the chemical structure shown in Fig.32. In one embodiment, the present invention provides a peptide having the chemical structure shown in Fig.33. In one embodiment, the present invention provides a peptide having the chemical structure shown in Fig.34. In one embodiment, the present invention provides a peptide having the chemical structure shown in Fig.35. In one embodiment, the present invention provides a peptide having the chemical structure shown in Fig.36. In one embodiment, the present invention provides a peptide having the chemical structure shown in Fig.37. In one embodiment, the present invention provides a peptide having the chemical structure shown in Fig.38. In one embodiment, the present invention provides a peptide having the chemical structure shown in Fig.39. In one embodiment, the present invention provides a peptide having the chemical structure shown in Fig.40. In one embodiment, the present invention provides a peptide having the chemical structure shown in Fig.41. In one embodiment, the present invention provides a peptide having the chemical structure shown in Fig.42. In one embodiment, the present invention provides a peptide having the chemical structure shown in Fig.43. In one embodiment, the present invention provides a peptide having the chemical structure shown in Fig.44. 2.2. Activity Groups In some embodiments, the present invention provides a peptide comprising the amino acid sequence of any one of PEP NOs: and / or SEQ ID NOs: 1-315. Such peptides exhibit DOR agonist activity of at least 50% at or below 100 µM as described in Example 1. In some embodiments, the present invention provides a peptide comprising the amino acid sequence of any one of PEP NOs: and / or SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 103, 104, 105, 106, 107, 109, 111, 112, 113, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 152, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 200, 201, 202, 203, 205, 206, 207, 208, 209, 213, 214, 215, 216, 220, 221, 222, 223, 224, 228, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 248, 249, 250, 251, 252, 253, 254, 255, 257, 259, 260, 261, 263, 264, 265, 266, 267, 268, 269, 270, 271, 272, 273, 275, 276, 279, 280, 281, 282, 283, 284, 285, 286, 288, 289, 290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, or 304. Such peptides form a group of peptides (“Group 1”) and, along with PEP NOs: and / or SEQ ID NOs: 305, 309, 311, 312, 314, and 315, form a group of peptides (“Group 1A”). The peptides of both Group 1 and Group 1A exhibit DOR agonist activity of at least 75% at or below 100 µM as described in Example 1. In some embodiments, the present invention provides a peptide comprising the amino acid sequence of any one of PEP NOs: and / or SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 64, 65, 66, 67, 68, 69, 70, 71, 74, 75, 76, 77, 78, 79, 80, 82, 83, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 99, 100, 101, 103, 104, 105, 106, 107, 109, 112, 113, 115, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 137, 138, 139, 140, 141, 142, 145, 146, 147, 148, 149, 150, 152, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 200, 201, 202, 203, 208, 209, 214, 215, 220, 221, 222, 223, 224, 231, 232, 233, 234, 235, 237, 239, 240, 241, 242, 243, 244, 245, 246, 248, 249, 250, 251, 252, 253, 254, 257, 259, 260, 261, 263, 264, 265, 267, 268, 269, 270, 272, 273, 275, 276, 280, 281, 282, 283, 284, 285, 286, 290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, and 304. Such peptides form a group of peptides (“Group 2”) and, along with PEP NOs: and / or SEQ ID NOs: 305, 309, 314, and 315, form a group of peptides (“Group 2A”). The peptides of both Group 2 and Group 2A exhibit DOR agonist activity of at least 90% at or below 100 µM as described in Example 1. In some embodiments, the present invention provides a peptide comprising the amino acid sequence of any one of PEP NOs: and / or SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 64, 65, 66, 67, 68, 69, 70, 71, 74, 75, 76, 77, 78, 79, 80, 82, 83, 85, 86, 87, 88, 89, 90, 91, 92, 93, 95, 96, 97, 99, 100, 101, 103, 105, 107, 109, 112, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 137, 138, 139, 140, 141, 142, 145, 146, 147, 148, 149, 150, 152, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 200, 201, 202, 203, 205, 206, 207, 208, 209, 213, 214, 215, 216, 223, 224, 228, 230, 231, 232, 233, 234, 235, 236, 237, 239, 240, 241, 242, 243, 244, 245, 246, 248, 249, 250, 251, 252, 253, 254, 255, 257, 264, 265, 266, 267, 268, 269, 270, 271, 272, 273, 275, 276, 280, 281, 282, 283, 284, 285, 286, 288, 289, 290, 291, 292, 293, 294, 295, 296, 297, 301, 302, 303, and 304. Such peptides form a group of peptides (“Group 3”) and, along with PEP NOs: and / or SEQ ID NOs: 305, 309, 311, and 315, form a group of peptides (“Group 3A”). The peptides of both Group 3 and Group 3A exhibit DOR agonist activity of at least 50% at or below 10 µM as described in Example 1. In some embodiments, the present invention provides a peptide comprising the amino acid sequence of any one of PEP NOs: and / or SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 45, 46, 47, 48, 52, 53, 54, 55, 56, 57, 58, 59, 60, 62, 64, 65, 66, 67, 68, 69, 70, 71, 74, 75, 78, 79, 80, 82, 83, 86, 87, 88, 89, 90, 92, 96, 97, 99, 100, 105, 107, 109, 112, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 128, 129, 130, 131, 134, 135, 137, 138, 139, 140, 145, 146, 147, 148, 149, 150, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 168, 169, 170, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 200, 201, 202, 203, 205, 208, 209, 214, 215, 223, 224, 231, 232, 233, 234, 235, 237, 240, 241, 242, 243, 244, 245, 246, 248, 249, 250, 251, 252, 253, 254, 255, 257, 264, 265, 266, 268, 270, 272, 273, 281, 282, 283, 284, 286, 288, 289, 290, 291, 292, 293, 294, 295, 296, 297, and 304. Such peptides form a group of peptides (“Group 4”) and, along with PEP NOs: and / or SEQ ID NOs: 305, and 309, form a group of peptides (“Group 4A”). The peptides of both Group 4 and Group 4A exhibit DOR agonist activity of at least 75% at or below 10 µM as described in Example 1. In some embodiments, the present invention provides a peptide comprising the amino acid sequence of any one of PEP NOs: and / or SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 19, 20, 22, 23, 24, 25, 26, 27, 28, 29, 30, 33, 34, 35, 36, 37, 38, 39, 40, 42, 43, 45, 46, 52, 53, 54, 55, 56, 57, 58, 59, 60, 65, 66, 67, 68, 69, 70, 71, 75, 79, 80, 82, 83, 86, 87, 90, 92, 96, 97, 99, 109, 112, 117, 118, 119, 120, 123, 124, 125, 126, 128, 129, 130, 131, 134, 135, 138, 139, 140, 145, 147, 149, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 169, 170, 173, 174, 176, 177, 178, 179, 180, 183, 184, 185, 186, 187, 188, 189, 190, 191, 193, 194, 196, 197, 200, 201, 202, 208, 209, 214, 215, 223, 224, 231, 232, 233, 234, 235, 237, 240, 241, 242, 243, 244, 245, 246, 248, 249, 250, 251, 252, 253, 254, 257, 265, 268, 272, 282, 284, 286, 290, 291, 292, 293, 295, 296, and 297. Such peptides form a group of peptides (“Group 5”) and, along with PEP NO: and / or SEQ ID NO: 309, form a group of peptides (“Group 5A”). The peptides of both Group 5 and Group 5A exhibit DOR agonist activity of at least 90% at or below 10 µM as described in Example 1. In some embodiments, the present invention provides a peptide comprising the amino acid sequence of any one of PEP NOs: and / or SEQ ID NOs: 1, 2, 3, 4, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 19, 20, 22, 23, 24, 25, 26, 27, 28, 29, 30, 33, 34, 35, 36, 37, 38, 39, 40, 42, 43, 45, 46, 52, 53, 54, 55, 56, 57, 58, 59, 60, 62, 65, 66, 67, 68, 69, 70, 71, 74, 75, 79, 80, 82, 83, 85, 86, 87, 90, 92, 96, 97, 99, 105, 107, 109, 112, 117, 118, 119, 120, 125, 126, 128, 129, 130, 131, 134, 138, 139, 140, 147, 149, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 168, 169, 170, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 200, 201, 202, 205, 208, 209, 214, 215, 223, 224, 231, 232, 233, 234, 235, 237, 240, 241, 242, 243, 244, 245, 246, 248, 249, 250, 251, 252, 253, 254, 257, 265, 268, 270, 272, 282, 284, 285, 286, 288, 289, 290, 292, 293, 296, and 297. Such peptides form a group of peptides (“Group 6”) and, along with PEP NOs: and / or SEQ ID NOs: 305, and 309, form a group of peptides (“Group 6A”). The peptides of both Group 6 and Group 6A exhibit DOR agonist activity of at least 50% at or below 1 µM as described in Example 1. In some embodiments, the present invention provides a peptide comprising the amino acid sequence of any one of PEP NOs: and / or SEQ ID NOs: 2, 3, 7, 9, 10, 11, 12, 13, 14, 15, 16, 17, 19, 20, 22, 24, 25, 26, 27, 28, 29, 30, 33, 34, 35, 36, 37, 38, 39, 40, 42, 43, 45, 46, 52, 53, 54, 55, 56, 57, 58, 59, 60, 65, 66, 67, 68, 69, 70, 71, 75, 79, 82, 83, 86, 87, 90, 92, 96, 99, 109, 117, 118, 119, 125, 126, 129, 130, 131, 139, 140, 147, 149, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 169, 170, 173, 174, 175, 176, 177, 178, 179, 180, 183, 184, 185, 186, 187, 188, 189, 190, 191, 193, 194, 200, 201, 202, 205, 208, 209, 214, 215, 223, 224, 232, 233, 234, 235, 237, 240, 241, 242, 243, 244, 245, 246, 248, 249, 250, 252, 254, 257, 268, 272, 282, 284, and 290. Such peptides form a group of peptides (“Group 7”) and, along with PEP NOs: and / or SEQ ID NOs: 305, and 309, form a group of peptides (“Group 7A”). The peptides of both Group 7 and Group 7A exhibit DOR agonist activity of at least 75% at or below 1 µM as described in Example 1. In some embodiments, the present invention provides a peptide comprising the amino acid sequence of any one of PEP NOs: and / or SEQ ID NOs: 2, 3, 7, 10, 11, 12, 15, 16, 17, 24, 25, 26, 27, 28, 29, 33, 35, 36, 37, 38, 42, 43, 45, 46, 53, 54, 55, 56, 57, 58, 59, 60, 65, 66, 67, 68, 69, 70, 71, 79, 82, 83, 86, 87, 92, 109, 117, 119, 126, 131, 139, 140, 147, 149, 156, 157, 158, 159, 160, 161, 162, 163, 169, 170, 173, 174, 176, 178, 180, 183, 184, 185, 186, 187, 188, 189, 191, 193, 194, 200, 201, 202, 208, 209, 214, 215, 232, 233, 234, 235, 241, 242, 243, 244, 245, 246, 248, 249, 250, 252, 272, 282, and 284. Such peptides form a group of peptides (“Group 8”) and, along with PEP NO: and / or SEQ ID NO: 309, form a group of peptides (“Group 8A”). The peptides of both Group 8 and Group 8A exhibit DOR agonist activity of at least 90% at or below 1 µM as described in Example 1. In some embodiments, the present invention provides a peptide comprising the amino acid sequence of any one of PEP NOs: and / or SEQ ID NOs: 16, 17, 24, 86, 87, 157, 162, 163, 164, 165, 166, 167, 170, 171, 173, 175, 177, 178, 179, 182, 183, 185, 186, or 187. Such peptides were demonstrated to have an analgesic effect in vivo, as described in Example 5. Such peptides form a group of peptides (“Group 9”). 2.3. Modification Groups In some embodiments, the present invention provides a peptide comprising the amino acid sequence of any one of PEP NOs: and / or SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304. Such peptides contain only naturally occurring amino acids and can be produced synthetically or using non-synthetic methods (such as by expression of a nucleotide sequence that encodes the peptide in a suitable cell type). Such peptides form a group of peptides (“Group 10”). In some embodiments, the present invention provides a peptide comprising the amino acid sequence of any one of PEP NOs: and / or SEQ ID NOs: 11, 16, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 169, 170, 171, 172, 173, 176, 180, 181, 182, 186, 189, 190, 191, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 272, 273, 274, 275, 276, 277, 278, 279, 280, 281, 282, 283, 284, 285, 286, 287, 288, 289, 290, 306, 307, 308. Such peptides contain only N- terminal or C-terminal modifications and naturally occurring amino acids and can be produced synthetically or using a combination of non-synthetic methods (such as by expression of a nucleotide sequence that encodes the peptide in a suitable cell type) and chemical modification. Such peptides form a group of peptides (“Group 11”). In some embodiments, the present invention provides a peptide comprising the amino acid sequence of any one of PEP NOs: and / or SEQ ID NOs: 24, 42, 86, 87, 157, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 272, 273, 274, 275, 276, 277, 278, 279, 280, 281, 282, 283, 284, 285, 286, 287, 288, 289, 290, 305, 306, 307, 308, 309, 310, 311, 312, 313, 314, 315. Such peptides contain a fatty acid and may exhibit improved properties such as affinity, specificity, and pharmacokinetic properties. Such peptides form a group of peptides (“Group 12”). In some embodiments, the present invention provides a peptide comprising the amino acid sequence of any one of PEP NOs: and / or SEQ ID NOs: 24, 42, 86, 157, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 272, 273, 274, 275, 276, 277, 278, 279, 280, 281, 282, 283, 284, 285, 286, 287, 288, 289, 290, 305, 306, 307, 308, 309, 310, 311, 312, 313, 314, 315. Such peptides contain a palmitic acid and may exhibit improved properties such as affinity, specificity, and pharmacokinetic properties. Such peptides form a group of peptides (“Group 13”). In some embodiments, the present invention provides a peptide comprising the amino acid sequence of any one of PEP NOs: and / or SEQ ID NOs: 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 186, 188, 189, 191, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 272, 273, 274, 275, 276, 277, 278, 279, 280, 281, 282, 283, 284, 285, 286, 287, 288, 289, 290, 305, 306, 307, 308, 309, 310, 311, 312, 313, 314, 315. Such peptides contain an N-terminal palmitic acid and may exhibit improved properties such as affinity, specificity, and pharmacokinetic properties. Such peptides form a group of peptides (“Group 14”). In some embodiments, the present invention provides a peptide comprising the amino acid sequence of any one of PEP NOs: and / or SEQ ID NOs: 24, 42, 86, 157, 183, 184, 185, 187, 188, 192. Such peptides contain a palmitoylated lysine and may exhibit improved properties such as affinity, specificity, and pharmacokinetic properties. Such peptides form a group of peptides (“Group 15”). In some embodiments, the present invention provides a peptide comprising the amino acid sequence of any one of PEP NOs: and / or SEQ ID NOs: 20, 21, 22, 23. Such peptides contain a polyethylene glycol and may exhibit improved properties such as affinity, specificity, and pharmacokinetic properties. Such peptides form a group of peptides (“Group 16”). In some embodiments, the present invention provides a peptide comprising the amino acid sequence of any one of PEP NOs: and / or SEQ ID NOs: 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 86, 87, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 272, 273, 274, 275, 276, 277, 278, 279, 280, 281, 282, 283, 284, 285, 286, 287, 288, 289, 290, 305, 306, 307, 308, 309, 310, 311, 312, 313, 314, 315. Such peptides contain non-naturally occurring amino acids and may exhibit improved properties such as affinity, specificity, and pharmacokinetic properties. Such peptides form a group of peptides (“Group 17”). In some embodiments, the present invention provides a peptide comprising the amino acid sequence of any one of PEP NOs: and / or SEQ ID NOs: 12, 13, 14, 15, 17, 18, 20, 21, 22, 23, 24, 38, 39, 40, 41, 42, 87, 142, 143, 144, 157, 168, 174, 177, 178, 183, 184, 305, 309, 310, 311, 312, 313, 314, 315. Such peptides contain a D-amino acid and may exhibit improved properties such as affinity, specificity, and pharmacokinetic properties. Such peptides form a group of peptides (“Group 18”). In some embodiments, the present invention provides a peptide comprising the amino acid sequence of any one of PEP NOs: and / or SEQ ID NOs: 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 175, 177, 179. Such peptides contain a homo amino acid and may exhibit improved properties such as affinity, specificity, and pharmacokinetic properties. Such peptides form a group of peptides (“Group 19”). In some embodiments, the present invention provides a peptide comprising the amino acid sequence of any one of PEP NOs: and / or SEQ ID NOs: 13, 17, 20, 21, 22, 23, 24, 42, 87, 145, 146, 150, 151, 152, 153, 154, 155, 156, 157, 168. Such peptides contain a beta amino acid and may exhibit improved properties such as affinity, specificity, and pharmacokinetic properties. Such peptides form a group of peptides (“Group 20”). In some embodiments, the present invention provides a peptide comprising the amino acid sequence of any one of PEP NOs: and / or SEQ ID NOs: 150, 151, 152, 153, 154, 155, 156. Such peptides contain a beta homo amino acid and may exhibit improved properties such as affinity, specificity, and pharmacokinetic properties. Such peptides form a group of peptides (“Group 21”). In some embodiments, the present invention provides a peptide comprising the amino acid sequence of any one of PEP NOs: and / or SEQ ID NOs: 13, 17, 20, 21, 22, 23, 24, 42, 87, 157, 168. Such peptides contain a D-beta aspartic acid and may exhibit improved properties such as affinity, specificity, and pharmacokinetic properties. Such peptides form a group of peptides (“Group 22”). In some embodiments, the present invention provides a peptide comprising the amino acid sequence of any one of PEP NOs: and / or SEQ ID NOs: 16, 17, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 86, 87, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 183, 184, 185, 187, 190. Such peptides have N-terminal acetylation and may exhibit improved properties such as affinity, specificity, and pharmacokinetic properties. Such peptides form a group of peptides (“Group 23”). In some embodiments, the present invention provides a peptide comprising the amino acid sequence of any one of PEP NOs: and / or SEQ ID NOs: 11, 12, 16, 17, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 86, 87, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250. Such peptides have C-terminal amidation and may exhibit improved properties such as affinity, specificity, and pharmacokinetic properties. Such peptides form a group of peptides (“Group 24”). In some embodiments, the present invention provides a peptide comprising the amino acid sequence of any one of PEP NOs: and / or SEQ ID NOs: 19. Such peptides have a cyclic conformation and may exhibit improved properties such as affinity, specificity, and pharmacokinetic properties. Such peptides form a group of peptides (“Group 25”). 2.4. Sequence Groups In some embodiments, the present invention provides a peptide comprising the amino acid sequence of any one of PEP NOs: and / or SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 33, 34, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 76, 77, 78, 79, 80, 81, 82, 83, 85, 86, 87, 88, 89, 90, 91, 92, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 144, 149, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 168, 180, 183, 184, 185, 186, 187, 188, 189, 190, 191, 214, 221, 222, 231, 291, 292, 293, 294, 295, 296, 297. Such peptides contain the 9 amino acid sequence GEVGVRQAP (PEP NO: and / or SEQ ID NO: 747). Such peptides form a group of peptides (“Group 26”). In some embodiments, the present invention provides a peptide comprising the amino acid sequence of any one of PEP NOs: and / or SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 33, 34, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 76, 77, 78, 79, 80, 81, 82, 83, 85, 86, 87, 88, 89, 90, 91, 92, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 144, 148, 149, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 173, 174, 180, 183, 184, 185, 186, 187, 188, 189, 190, 191, 213, 214, 221, 222, 230, 231, 291, 292, 293, 294, 295, 296, 297. Such peptides contain the 8 amino acid sequence GEVGVRQA (PEP NO: and / or SEQ ID NO: 753). Such peptides form a group of peptides (“Group 27”). In some embodiments, the present invention provides a peptide comprising the amino acid sequence of any one of PEP NOs: and / or SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 32, 33, 34, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 76, 77, 78, 79, 80, 81, 82, 83, 85, 86, 87, 88, 89, 90, 91, 92, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 144, 146, 148, 149, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 172, 173, 174, 180, 183, 184, 185, 186, 187, 188, 189, 190, 191, 212, 213, 214, 220, 221, 222, 229, 230, 231, 291, 292, 293, 294, 295, 296, 297. Such peptides contain the 7 amino acid sequence GEVGVRQ (PEP NO: and / or SEQ ID NO: 751). Such peptides form a group of peptides (“Group 28”). In some embodiments, the present invention provides a peptide comprising the amino acid sequence of any one of PEP NOs: and / or SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 31, 32, 33, 34, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 76, 77, 78, 79, 80, 81, 82, 83, 85, 86, 87, 88, 89, 90, 91, 92, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 144, 146, 148, 149, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 172, 173, 174, 176, 178, 180, 183, 184, 185, 186, 187, 188, 189, 190, 191, 212, 213, 214, 220, 221, 222, 229, 230, 231, 291, 292, 293, 294, 295, 296, 297. Such peptides contain the 6 amino acid sequence GEVGVR (PEP NO: and / or SEQ ID NO: 752). Such peptides form a group of peptides (“Group 29”). In some embodiments, the present invention provides a peptide comprising the amino acid sequence of any one of PEP NOs: and / or SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 144, 146, 147, 148, 149, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 172, 173, 174, 175, 176, 177, 178, 179, 180, 183, 184, 185, 186, 187, 188, 189, 190, 191, 211, 212, 213, 214, 220, 221, 222, 228, 229, 230, 231, 291, 292, 293, 294, 295, 296, 297. Such peptides contain the 5 amino acid sequence GEVGV (PEP NO: and / or SEQ ID NO: 754). Such peptides form a group of peptides (“Group 30”). In some embodiments, the present invention provides a peptide comprising the amino acid sequence of any one of PEP NOs: and / or SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 143, 144, 146, 147, 148, 149, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 172, 173, 174, 175, 176, 177, 178, 179, 180, 183, 184, 185, 186, 187, 188, 189, 190, 191, 211, 212, 213, 214, 219, 220, 221, 222, 227, 228, 229, 230, 231, 291, 292, 293, 294, 295, 296, 297. Such peptides contain the 4 amino acid sequence GEVG (PEP NO: and / or SEQ ID NO: 755). Such peptides form a group of peptides (“Group 31”). In some embodiments, the present invention provides a peptide comprising the amino acid sequence of any one of PEP NOs: and / or SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 143, 144, 146, 147, 148, 149, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 172, 173, 174, 175, 176, 177, 178, 179, 180, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 211, 212, 213, 214, 217, 218, 219, 220, 221, 222, 226, 227, 228, 229, 230, 231, 291, 292, 293, 294, 295, 296, 297. Such peptides contain the 3 amino acid sequence GEV (PEP NO: 756). Such peptides form a group of peptides (“Group 32”). In some embodiments, the present invention provides a peptide comprising the amino acid sequence of any one of PEP NOs: and / or SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 33, 34, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 76, 77, 78, 79, 80, 81, 82, 83, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 144, 149, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 168, 180, 183, 184, 185, 186, 187, 188, 189, 190, 191, 193, 208, 214, 221, 222, 231, 235, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304. Such peptides contain the 8 amino acid sequence EVGVRQAP (PEP NO: and / or SEQ ID NO: 757). Such peptides form a group of peptides (“Group 33”). In some embodiments, the present invention provides a peptide comprising the amino acid sequence of any one of PEP NOs: and / or SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 33, 34, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 76, 77, 78, 79, 80, 81, 82, 83, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 144, 148, 149, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 173, 174, 180, 183, 184, 185, 186, 187, 188, 189, 190, 191, 193, 200, 208, 213, 214, 221, 222, 230, 231, 233, 235, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304. Such peptides contain the 7 amino acid sequence EVGVRQA (PEP NO: and / or SEQ ID NO: 758). Such peptides form a group of peptides (“Group 34”). In some embodiments, the present invention provides a peptide comprising the amino acid sequence of any one of PEP NOs: and / or SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 32, 33, 34, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 76, 77, 78, 79, 80, 81, 82, 83, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 144, 146, 148, 149, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 172, 173, 174, 180, 183, 184, 185, 186, 187, 188, 189, 190, 191, 193, 200, 201, 208, 212, 213, 214, 220, 221, 222, 229, 230, 231, 233, 235, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304. Such peptides contain the 6 amino acid sequence EVGVRQ (PEP NO: and / or SEQ ID NO: 759). Such peptides form a group of peptides (“Group 35”). In some embodiments, the present invention provides a peptide comprising the amino acid sequence of any one of PEP NOs: and / or SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 31, 32, 33, 34, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 76, 77, 78, 79, 80, 81, 82, 83, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 144, 146, 148, 149, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 172, 173, 174, 176, 178, 180, 183, 184, 185, 186, 187, 188, 189, 190, 191, 193, 200, 201, 202, 208, 212, 213, 214, 220, 221, 222, 229, 230, 231, 233, 235, 251, 253, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304. Such peptides contain the 5 amino acid sequence EVGVR (PEP NO: and / or SEQ ID NO: 760). Such peptides form a group of peptides (“Group 36”). In some embodiments, the present invention provides a peptide comprising the amino acid sequence of any one of PEP NOs: and / or SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 144, 146, 147, 148, 149, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 172, 173, 174, 175, 176, 177, 178, 179, 180, 183, 184, 185, 186, 187, 188, 189, 190, 191, 193, 200, 201, 202, 208, 211, 212, 213, 214, 220, 221, 222, 228, 229, 230, 231, 233, 235, 251, 253, 257, 258, 259, 260, 261, 262, 263, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304. Such peptides contain the 4 amino acid sequence EVGV (PEP NO: and / or SEQ ID NO: 761). Such peptides form a group of peptides (“Group 37”). In some embodiments, the present invention provides a peptide comprising the amino acid sequence of any one of PEP NOs: and / or SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 143, 144, 146, 147, 148, 149, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 172, 173, 174, 175, 176, 177, 178, 179, 180, 183, 184, 185, 186, 187, 188, 189, 190, 191, 193, 200, 201, 202, 208, 211, 212, 213, 214, 219, 220, 221, 222, 227, 228, 229, 230, 231, 233, 235, 251, 253, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304. Such peptides contain the 3 amino acid sequence EVG (PEP NO: 762). Such peptides form a group of peptides (“Group 38”). In some embodiments, the present invention provides a peptide comprising the amino acid sequence of any one of PEP NOs: and / or SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 33, 34, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 76, 77, 78, 79, 80, 81, 82, 83, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 144, 145, 149, 150, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 168, 180, 183, 184, 185, 186, 187, 188, 189, 190, 191, 193, 194, 208, 209, 214, 215, 221, 222, 231, 234, 235, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304. Such peptides contain the 7 amino acid sequence VGVRQAP (PEP NO: and / or SEQ ID NO: 748). Such peptides form a group of peptides (“Group 39”). In some embodiments, the present invention provides a peptide comprising the amino acid sequence of any one of PEP NOs: and / or SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 33, 34, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 76, 77, 78, 79, 80, 81, 82, 83, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 144, 145, 148, 149, 150, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 173, 174, 180, 183, 184, 185, 186, 187, 188, 189, 190, 191, 193, 194, 200, 208, 209, 213, 214, 215, 221, 222, 230, 231, 232, 233, 234, 235, 243, 250, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304. Such peptides contain the 6 amino acid sequence VGVRQA (PEP NO: and / or SEQ ID NO: 763). Such peptides form a group of peptides (“Group 40”). In some embodiments, the present invention provides a peptide comprising the amino acid sequence of any one of PEP NOs: and / or SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 32, 33, 34, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 76, 77, 78, 79, 80, 81, 82, 83, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 144, 145, 146, 148, 149, 150, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 172, 173, 174, 180, 183, 184, 185, 186, 187, 188, 189, 190, 191, 193, 194, 200, 201, 208, 209, 212, 213, 214, 215, 220, 221, 222, 229, 230, 231, 232, 233, 234, 235, 241, 242, 243, 249, 250, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304. Such peptides contain the 5 amino acid sequence VGVRQ (PEP NO: and / or SEQ ID NO: 764). Such peptides form a group of peptides (“Group 41”). In some embodiments, the present invention provides a peptide comprising the amino acid sequence of any one of PEP NOs: and / or SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 31, 32, 33, 34, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 76, 77, 78, 79, 80, 81, 82, 83, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 144, 145, 146, 148, 149, 150, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 172, 173, 174, 176, 178, 180, 183, 184, 185, 186, 187, 188, 189, 190, 191, 193, 194, 200, 201, 202, 208, 209, 212, 213, 214, 215, 220, 221, 222, 229, 230, 231, 232, 233, 234, 235, 240, 241, 242, 243, 248, 249, 250, 251, 253, 254, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304. Such peptides contain the 4 amino acid sequence VGVR (PEP NO: and / or SEQ ID NO: 765). Such peptides form a group of peptides (“Group 42”). In some embodiments, the present invention provides a peptide comprising the amino acid sequence of any one of PEP NOs: and / or SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 144, 145, 146, 147, 148, 149, 150, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 172, 173, 174, 175, 176, 177, 178, 179, 180, 183, 184, 185, 186, 187, 188, 189, 190, 191, 193, 194, 200, 201, 202, 208, 209, 211, 212, 213, 214, 215, 220, 221, 222, 228, 229, 230, 231, 232, 233, 234, 235, 239, 240, 241, 242, 243, 247, 248, 249, 250, 251, 253, 254, 257, 258, 259, 260, 261, 262, 263, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304, 306, 307, 308. Such peptides contain the 3 amino acid sequence VGV (PEP NO: 766). Such peptides form a group of peptides (“Group 43”). In some embodiments, the present invention provides a peptide comprising the amino acid sequence of any one of PEP NOs: and / or SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 33, 34, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 76, 77, 78, 79, 80, 81, 82, 83, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 144, 145, 149, 150, 151, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 168, 180, 181, 183, 184, 185, 186, 187, 188, 189, 190, 191, 193, 194, 195, 203, 208, 209, 210, 214, 215, 216, 221, 222, 223, 224, 231, 234, 235, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304. Such peptides contain the 6 amino acid sequence GVRQAP (PEP NO: and / or SEQ ID NO: 749). Such peptides form a group of peptides (“Group 44”). In some embodiments, the present invention provides a peptide comprising the amino acid sequence of any one of PEP NOs: and / or SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 33, 34, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 76, 77, 78, 79, 80, 81, 82, 83, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 144, 145, 148, 149, 150, 151, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 173, 174, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 193, 194, 195, 200, 203, 208, 209, 210, 213, 214, 215, 216, 221, 222, 223, 224, 230, 231, 232, 233, 234, 235, 236, 237, 243, 244, 250, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304. Such peptides contain the 5 amino acid sequence GVRQA (PEP NO: and / or SEQ ID NO: 767). Such peptides form a group of peptides (“Group 45”). In some embodiments, the present invention provides a peptide comprising the amino acid sequence of any one of PEP NOs: and / or SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 32, 33, 34, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 76, 77, 78, 79, 80, 81, 82, 83, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 144, 145, 146, 148, 149, 150, 151, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 193, 194, 195, 200, 201, 203, 208, 209, 210, 212, 213, 214, 215, 216, 220, 221, 222, 223, 224, 229, 230, 231, 232, 233, 234, 235, 236, 237, 241, 242, 243, 244, 249, 250, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304. Such peptides contain the 4 amino acid sequence GVRQ (PEP NO: and / or SEQ ID NO: 768). Such peptides form a group of peptides (“Group 46”). In some embodiments, the present invention provides a peptide comprising the amino acid sequence of any one of PEP NOs: and / or SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 31, 32, 33, 34, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 76, 77, 78, 79, 80, 81, 82, 83, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 144, 145, 146, 148, 149, 150, 151, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 176, 178, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 193, 194, 195, 200, 201, 202, 203, 204, 208, 209, 210, 212, 213, 214, 215, 216, 220, 221, 222, 223, 224, 229, 230, 231, 232, 233, 234, 235, 236, 237, 240, 241, 242, 243, 244, 248, 249, 250, 251, 253, 254, 255, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304. Such peptides contain the 3 amino acid sequence GVR (PEP NO: 769). Such peptides form a group of peptides (“Group 47”). In some embodiments, the present invention provides a peptide comprising the amino acid sequence of any one of PEP NOs: and / or SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 33, 34, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 76, 77, 78, 79, 80, 81, 82, 83, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 144, 145, 149, 150, 151, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 168, 180, 181, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 203, 205, 208, 209, 210, 214, 215, 216, 217, 218, 221, 222, 223, 224, 231, 234, 235, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304. Such peptides contain the 5 amino acid sequence VRQAP (PEP NO: and / or SEQ ID NO: 770). Such peptides form a group of peptides (“Group 48”). In some embodiments, the present invention provides a peptide comprising the amino acid sequence of any one of PEP NOs: and / or SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 33, 34, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 76, 77, 78, 79, 80, 81, 82, 83, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 144, 145, 148, 149, 150, 151, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 173, 174, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 200, 203, 205, 206, 208, 209, 210, 213, 214, 215, 216, 217, 218, 221, 222, 223, 224, 230, 231, 232, 233, 234, 235, 236, 237, 238, 243, 244, 245, 250, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304. Such peptides contain the 4 amino acid sequence VRQA (PEP NO: and / or SEQ ID NO: 750). Such peptides form a group of peptides (“Group 49”). In some embodiments, the present invention provides a peptide comprising the amino acid sequence of any one of PEP NOs: and / or SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 32, 33, 34, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 76, 77, 78, 79, 80, 81, 82, 83, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 144, 145, 146, 148, 149, 150, 151, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 200, 201, 203, 205, 206, 208, 209, 210, 212, 213, 214, 215, 216, 217, 218, 220, 221, 222, 223, 224, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 241, 242, 243, 244, 245, 249, 250, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304. Such peptides contain the 3 amino acid sequence VRQ (PEP NO: 771). Such peptides form a group of peptides (“Group 50”). In some embodiments, the present invention provides a peptide comprising the amino acid sequence of any one of PEP NOs: and / or SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 33, 34, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 149, 150, 151, 152, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 168, 180, 181, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 203, 205, 208, 209, 210, 214, 215, 216, 217, 218, 221, 222, 223, 224, 225, 231, 234, 235, 252, 272, 281, 282, 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304. Such peptides contain the 4 amino acid sequence RQAP (PEP NO: and / or SEQ ID NO: 772). Such peptides form a group of peptides (“Group 51”). In some embodiments, the present invention provides a peptide comprising the amino acid sequence of any one of PEP NOs: and / or SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 33, 34, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 148, 149, 150, 151, 152, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 173, 174, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 200, 203, 205, 206, 208, 209, 210, 213, 214, 215, 216, 217, 218, 221, 222, 223, 224, 225, 230, 231, 232, 233, 234, 235, 236, 237, 238, 243, 244, 245, 246, 250, 252, 272, 281, 282, 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304. Such peptides contain the 3 amino acid sequence RQA (PEP NO: 773). Such peptides form a group of peptides (“Group 52”). In some embodiments, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 747 wherein the peptide has delta opioid agonist activity. In some embodiments, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 748 wherein the peptide has delta opioid agonist activity. In some embodiments, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 749 wherein the peptide has delta opioid agonist activity. In some embodiments, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 750 wherein the peptide has delta opioid agonist activity. In some embodiments, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 751 wherein the peptide has delta opioid agonist activity. In some embodiments, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 752 wherein the peptide has delta opioid agonist activity. In some embodiments, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 753 wherein the peptide has delta opioid agonist activity. In some embodiments, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 754 wherein the peptide has delta opioid agonist activity. In some embodiments, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 755 wherein the peptide has delta opioid agonist activity. In some embodiments, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 756 wherein the peptide has delta opioid agonist activity. In some embodiments, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 757 wherein the peptide has delta opioid agonist activity. In some embodiments, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 758 wherein the peptide has delta opioid agonist activity. In some embodiments, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 759 wherein the peptide has delta opioid agonist activity. In some embodiments, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 760 wherein the peptide has delta opioid agonist activity. In some embodiments, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 761 wherein the peptide has delta opioid agonist activity. In some embodiments, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 762 wherein the peptide has delta opioid agonist activity. In some embodiments, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 763 wherein the peptide has delta opioid agonist activity. In some embodiments, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 764 wherein the peptide has delta opioid agonist activity. In some embodiments, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 765 wherein the peptide has delta opioid agonist activity. In some embodiments, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 766 wherein the peptide has delta opioid agonist activity. In some embodiments, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 767 wherein the peptide has delta opioid agonist activity. In some embodiments, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 768 wherein the peptide has delta opioid agonist activity. In some embodiments, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 769 wherein the peptide has delta opioid agonist activity. In some embodiments, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 770 wherein the peptide has delta opioid agonist activity. In some embodiments, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 771 wherein the peptide has delta opioid agonist activity. In some embodiments, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 772 wherein the peptide has delta opioid agonist activity. In some embodiments, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 773 wherein the peptide has delta opioid agonist activity. 2.5. Sequence Groups with Variants In some embodiments, the present invention provides a peptide comprising the amino acid sequence of any one of PEP NOs: and / or SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 76, 77, 78, 79, 80, 81, 82, 83, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 173, 174, 180, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 208, 209, 210, 211, 212, 213, 214, 220, 221, 222, 229, 230, 231, 235, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304. Such peptides contain a variant of the amino acid sequence that defines Group 26 in which one of the amino acids in the sequence is deleted or substituted with a different amino acid. Such peptides form a group of peptides (“Group 53”). In some embodiments, the present invention provides a peptide comprising the amino acid sequence of any one of PEP NOs: and / or SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 76, 77, 78, 79, 80, 81, 82, 83, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 172, 173, 174, 175, 176, 177, 178, 180, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 200, 208, 209, 210, 211, 212, 213, 214, 220, 221, 222, 229, 230, 231, 233, 235, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304. Such peptides contain a variant of the amino acid sequence that defines Group 27 in which one of the amino acids in the sequence is deleted or substituted with a different amino acid. Such peptides form a group of peptides (“Group 54”). In some embodiments, the present invention provides a peptide comprising the amino acid sequence of any one of PEP NOs: and / or SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 76, 77, 78, 79, 80, 81, 82, 83, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 172, 173, 174, 175, 176, 177, 178, 180, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 200, 201, 208, 209, 210, 211, 212, 213, 214, 220, 221, 222, 229, 230, 231, 233, 235, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304. Such peptides contain a variant of the amino acid sequence that defines Group 28 in which one of the amino acids in the sequence is deleted or substituted with a different amino acid. Such peptides form a group of peptides (“Group 55”). In some embodiments, the present invention provides a peptide comprising the amino acid sequence of any one of PEP NOs: and / or SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 172, 173, 174, 175, 176, 177, 178, 179, 180, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 200, 201, 202, 208, 209, 210, 211, 212, 213, 214, 219, 220, 221, 222, 227, 228, 229, 230, 231, 233, 235, 251, 253, 254, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304. Such peptides contain a variant of the amino acid sequence that defines Group 29 in which one of the amino acids in the sequence is deleted or substituted with a different amino acid. Such peptides form a group of peptides (“Group 56”). In some embodiments, the present invention provides a peptide comprising the amino acid sequence of any one of PEP NOs: and / or SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 172, 173, 174, 175, 176, 177, 178, 179, 180, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 200, 201, 202, 208, 209, 210, 211, 212, 213, 214, 219, 220, 221, 222, 227, 228, 229, 230, 231, 233, 235, 251, 253, 254, 257, 258, 259, 260, 261, 262, 263, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304. Such peptides contain a variant of the amino acid sequence that defines Group 30 in which one of the amino acids in the sequence is deleted or substituted with a different amino acid. Such peptides form a group of peptides (“Group 57”). In some embodiments, the present invention provides a peptide comprising the amino acid sequence of any one of PEP NOs: and / or SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 172, 173, 174, 175, 176, 177, 178, 179, 180, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 200, 201, 202, 208, 209, 210, 211, 212, 213, 214, 217, 218, 219, 220, 221, 222, 226, 227, 228, 229, 230, 231, 233, 235, 251, 253, 254, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304. Such peptides contain a variant of the amino acid sequence that defines Group 31 in which one of the amino acids in the sequence is deleted or substituted with a different amino acid. Such peptides form a group of peptides (“Group 58”). In some embodiments, the present invention provides a peptide comprising the amino acid sequence of any one of PEP NOs: and / or SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 239, 240, 241, 242, 243, 244, 247, 248, 249, 250, 251, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304, 305, 306, 307, 308, 309, 310, 311, 314, 315. Such peptides contain a variant of the amino acid sequence that defines Group 32 in which one of the amino acids in the sequence is deleted or substituted with a different amino acid. Such peptides form a group of peptides (“Group 59”). In some embodiments, the present invention provides a peptide comprising the amino acid sequence of any one of PEP NOs: and / or SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 76, 77, 78, 79, 80, 81, 82, 83, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 173, 174, 180, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 200, 208, 209, 210, 211, 212, 213, 214, 215, 220, 221, 222, 229, 230, 231, 233, 234, 235, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304. Such peptides contain a variant of the amino acid sequence that defines Group 33 in which one of the amino acids in the sequence is deleted or substituted with a different amino acid. Such peptides form a group of peptides (“Group 60”). In some embodiments, the present invention provides a peptide comprising the amino acid sequence of any one of PEP NOs: and / or SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 76, 77, 78, 79, 80, 81, 82, 83, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 172, 173, 174, 175, 176, 177, 178, 180, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 200, 201, 208, 209, 210, 211, 212, 213, 214, 215, 220, 221, 222, 229, 230, 231, 232, 233, 234, 235, 237, 243, 244, 250, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304. Such peptides contain a variant of the amino acid sequence that defines Group 34 in which one of the amino acids in the sequence is deleted or substituted with a different amino acid. Such peptides form a group of peptides (“Group 61”). In some embodiments, the present invention provides a peptide comprising the amino acid sequence of any one of PEP NOs: and / or SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 76, 77, 78, 79, 80, 81, 82, 83, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 172, 173, 174, 175, 176, 177, 178, 180, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 200, 201, 202, 208, 209, 210, 211, 212, 213, 214, 215, 220, 221, 222, 229, 230, 231, 232, 233, 234, 235, 237, 241, 242, 243, 244, 249, 250, 251, 253, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304. Such peptides contain a variant of the amino acid sequence that defines Group 35 in which one of the amino acids in the sequence is deleted or substituted with a different amino acid. Such peptides form a group of peptides (“Group 62”). In some embodiments, the present invention provides a peptide comprising the amino acid sequence of any one of PEP NOs: and / or SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 172, 173, 174, 175, 176, 177, 178, 179, 180, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 200, 201, 202, 208, 209, 210, 211, 212, 213, 214, 215, 219, 220, 221, 222, 227, 228, 229, 230, 231, 232, 233, 234, 235, 237, 240, 241, 242, 243, 244, 248, 249, 250, 251, 253, 254, 255, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304. Such peptides contain a variant of the amino acid sequence that defines Group 36 in which one of the amino acids in the sequence is deleted or substituted with a different amino acid. Such peptides form a group of peptides (“Group 63”). In some embodiments, the present invention provides a peptide comprising the amino acid sequence of any one of PEP NOs: and / or SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 172, 173, 174, 175, 176, 177, 178, 179, 180, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 200, 201, 202, 208, 209, 210, 211, 212, 213, 214, 215, 219, 220, 221, 222, 227, 228, 229, 230, 231, 232, 233, 234, 235, 237, 239, 240, 241, 242, 243, 244, 247, 248, 249, 250, 251, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304, 306, 307, 308. Such peptides contain a variant of the amino acid sequence that defines Group 37 in which one of the amino acids in the sequence is deleted or substituted with a different amino acid. Such peptides form a group of peptides (“Group 64”). In some embodiments, the present invention provides a peptide comprising the amino acid sequence of any one of PEP NOs: and / or SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 172, 173, 174, 175, 176, 177, 178, 179, 180, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 200, 201, 202, 208, 209, 210, 211, 212, 213, 214, 215, 217, 218, 219, 220, 221, 222, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 237, 239, 240, 241, 242, 243, 244, 246, 247, 248, 249, 250, 251, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304, 305, 306, 307, 308, 309, 310, 314, 315. Such peptides contain a variant of the amino acid sequence that defines Group 38 in which one of the amino acids in the sequence is deleted or substituted with a different amino acid. Such peptides form a group of peptides (“Group 65”). In some embodiments, the present invention provides a peptide comprising the amino acid sequence of any one of PEP NOs: and / or SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 76, 77, 78, 79, 80, 81, 82, 83, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 173, 174, 180, 181, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 200, 203, 208, 209, 210, 211, 212, 213, 214, 215, 216, 220, 221, 222, 223, 224, 229, 230, 231, 232, 233, 234, 235, 241, 243, 249, 250, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304. Such peptides contain a variant of the amino acid sequence that defines Group 39 in which one of the amino acids in the sequence is deleted or substituted with a different amino acid. Such peptides form a group of peptides (“Group 66”). In some embodiments, the present invention provides a peptide comprising the amino acid sequence of any one of PEP NOs: and / or SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 76, 77, 78, 79, 80, 81, 82, 83, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 200, 201, 203, 208, 209, 210, 211, 212, 213, 214, 215, 216, 220, 221, 222, 223, 224, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304. Such peptides contain a variant of the amino acid sequence that defines Group 40 in which one of the amino acids in the sequence is deleted or substituted with a different amino acid. Such peptides form a group of peptides (“Group 67”). In some embodiments, the present invention provides a peptide comprising the amino acid sequence of any one of PEP NOs: and / or SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 76, 77, 78, 79, 80, 81, 82, 83, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 200, 201, 202, 203, 208, 209, 210, 211, 212, 213, 214, 215, 216, 220, 221, 222, 223, 224, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 253, 254, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304. Such peptides contain a variant of the amino acid sequence that defines Group 41 in which one of the amino acids in the sequence is deleted or substituted with a different amino acid. Such peptides form a group of peptides (“Group 68”). In some embodiments, the present invention provides a peptide comprising the amino acid sequence of any one of PEP NOs: and / or SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 200, 201, 202, 203, 204, 208, 209, 210, 211, 212, 213, 214, 215, 216, 219, 220, 221, 222, 223, 224, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304, 306, 307, 308. Such peptides contain a variant of the amino acid sequence that defines Group 42 in which one of the amino acids in the sequence is deleted or substituted with a different amino acid. Such peptides form a group of peptides (“Group 69”). In some embodiments, the present invention provides a peptide comprising the amino acid sequence of any one of PEP NOs: and / or SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 200, 201, 202, 203, 204, 208, 209, 210, 211, 212, 213, 214, 215, 216, 219, 220, 221, 222, 223, 224, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304, 305, 306, 307, 308, 309, 310, 311, 314, 315. Such peptides contain a variant of the amino acid sequence that defines Group 43 in which one of the amino acids in the sequence is deleted or substituted with a different amino acid. Such peptides form a group of peptides (“Group 70”). In some embodiments, the present invention provides a peptide comprising the amino acid sequence of any one of PEP NOs: and / or SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 173, 174, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 200, 203, 205, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 220, 221, 222, 223, 224, 225, 229, 230, 231, 232, 233, 234, 235, 236, 237, 241, 243, 244, 249, 250, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304. Such peptides contain a variant of the amino acid sequence that defines Group 44 in which one of the amino acids in the sequence is deleted or substituted with a different amino acid. Such peptides form a group of peptides (“Group 71”). In some embodiments, the present invention provides a peptide comprising the amino acid sequence of any one of PEP NOs: and / or SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 200, 201, 203, 205, 206, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 220, 221, 222, 223, 224, 225, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304. Such peptides contain a variant of the amino acid sequence that defines Group 45 in which one of the amino acids in the sequence is deleted or substituted with a different amino acid. Such peptides form a group of peptides (“Group 72”). In some embodiments, the present invention provides a peptide comprising the amino acid sequence of any one of PEP NOs: and / or SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 200, 201, 202, 203, 204, 205, 206, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 220, 221, 222, 223, 224, 225, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 253, 254, 255, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304. Such peptides contain a variant of the amino acid sequence that defines Group 46 in which one of the amino acids in the sequence is deleted or substituted with a different amino acid. Such peptides form a group of peptides (“Group 73”). In some embodiments, the present invention provides a peptide comprising the amino acid sequence of any one of PEP NOs: and / or SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304, 306, 307, 308. Such peptides contain a variant of the amino acid sequence that defines Group 47 in which one of the amino acids in the sequence is deleted or substituted with a different amino acid. Such peptides form a group of peptides (“Group 74”). In some embodiments, the present invention provides a peptide comprising the amino acid sequence of any one of PEP NOs: and / or SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 173, 174, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 200, 203, 205, 206, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 241, 243, 244, 245, 249, 250, 252, 272, 273, 277, 278, 279, 280, 281, 282, 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304. Such peptides contain a variant of the amino acid sequence that defines Group 48 in which one of the amino acids in the sequence is deleted or substituted with a different amino acid. Such peptides form a group of peptides (“Group 75”). In some embodiments, the present invention provides a peptide comprising the amino acid sequence of any one of PEP NOs: and / or SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 200, 201, 203, 205, 206, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 252, 272, 273, 277, 278, 279, 280, 281, 282, 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304. Such peptides contain a variant of the amino acid sequence that defines Group 49 in which one of the amino acids in the sequence is deleted or substituted with a different amino acid. Such peptides form a group of peptides (“Group 76”). In some embodiments, the present invention provides a peptide comprising the amino acid sequence of any one of PEP NOs: and / or SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 271, 272, 273, 274, 275, 276, 277, 278, 279, 280, 281, 282, 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304. Such peptides contain a variant of the amino acid sequence that defines Group 50 in which one of the amino acids in the sequence is deleted or substituted with a different amino acid. Such peptides form a group of peptides (“Group 77”). In some embodiments, the present invention provides a peptide comprising the amino acid sequence of any one of PEP NOs: and / or SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 173, 174, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 200, 203, 205, 206, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 241, 243, 244, 245, 246, 249, 250, 252, 272, 273, 274, 276, 277, 278, 279, 280, 281, 282, 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304. Such peptides contain a variant of the amino acid sequence that defines Group 51 in which one of the amino acids in the sequence is deleted or substituted with a different amino acid. Such peptides form a group of peptides (“Group 78”). In some embodiments, the present invention provides a peptide comprising the amino acid sequence of any one of PEP NOs: and / or SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 200, 201, 203, 205, 206, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 252, 272, 273, 274, 275, 276, 277, 278, 279, 280, 281, 282, 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304, 305, 308, 309. Such peptides contain a variant of the amino acid sequence that defines Group 52 in which one of the amino acids in the sequence is deleted or substituted with a different amino acid. Such peptides form a group of peptides (“Group 79”). 2.6. Additional Sequence Groups In some embodiments, the present invention provides a peptide comprising the amino acid sequence of any one of PEP NOs: and / or SEQ ID NOs: 2, 3, 10, 11, 12, 14, 57, 70, 92, 159, 161. Such peptides contain the 18 amino acid sequence DSYGEVGVRQAPFPSRAS (PEP NO: and / or SEQ ID NO: 70). Such peptides form a group of peptides (“Group 80”). In some embodiments, the present invention provides a peptide comprising the amino acid sequence of any one of PEP NOs: and / or SEQ ID NOs: 2, 3, 10, 11, 12, 14, 56, 57, 69, 70, 82, 92, 126, 159, 161. Such peptides contain the 17 amino acid sequence DSYGEVGVRQAPFPSRA (PEP NO: and / or SEQ ID NO: 126). Such peptides form a group of peptides (“Group 81”). In some embodiments, the present invention provides a peptide comprising the amino acid sequence of any one of PEP NOs: and / or SEQ ID NOs: 2, 3, 10, 11, 12, 14, 55, 56, 57, 68, 69, 70, 82, 92, 125, 126, 131, 159, 161. Such peptides contain the 16 amino acid sequence DSYGEVGVRQAPFPSR (PEP NO: and / or SEQ ID NO: 131). Such peptides form a group of peptides (“Group 82”). In some embodiments, the present invention provides a peptide comprising the amino acid sequence of any one of PEP NOs: and / or SEQ ID NOs: 2, 3, 10, 11, 12, 14, 54, 55, 56, 57, 67, 68, 69, 70, 82, 92, 124, 125, 126, 129, 130, 131, 135, 159, 161, 291, 292, 293, 294, 295, 296, 297. Such peptides contain the 15 amino acid sequence DSYGEVGVRQAPFPS (PEP NO: and / or SEQ ID NO: 135). Such peptides form a group of peptides (“Group 83”). In some embodiments, the present invention provides a peptide comprising the amino acid sequence of any one of PEP NOs: and / or SEQ ID NOs: 1, 2, 3, 10, 11, 12, 14, 53, 54, 55, 56, 57, 66, 67, 68, 69, 70, 80, 82, 83, 92, 123, 124, 125, 126, 129, 130, 131, 134, 135, 138, 159, 161, 291, 292, 293, 294, 295, 296, 297. Such peptides contain the 14 amino acid sequence DSYGEVGVRQAPFP (PEP NO: and / or SEQ ID NO: 138). Such peptides form a group of peptides (“Group 84”). In some embodiments, the present invention provides a peptide comprising the amino acid sequence of any one of PEP NOs: and / or SEQ ID NOs: 1, 2, 3, 10, 11, 12, 14, 52, 53, 54, 55, 56, 57, 65, 66, 67, 68, 69, 70, 80, 82, 83, 92, 122, 123, 124, 125, 126, 128, 129, 130, 131, 133, 134, 135, 137, 138, 159, 161, 291, 292, 293, 294, 295, 296, 297. Such peptides contain the 13 amino acid sequence DSYGEVGVRQAPF (PEP NO: and / or SEQ ID NO: 137). Such peptides form a group of peptides (“Group 85”). In some embodiments, the present invention provides a peptide comprising the amino acid sequence of any one of PEP NOs: and / or SEQ ID NOs: 1, 2, 3, 10, 11, 12, 14, 51, 52, 53, 54, 55, 56, 57, 64, 65, 66, 67, 68, 69, 70, 79, 80, 82, 83, 92, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 141, 144, 149, 156, 159, 161, 291, 292, 293, 294, 295, 296, 297. Such peptides contain the 12 amino acid sequence DSYGEVGVRQAP (PEP NO: and / or SEQ ID NO: 141). Such peptides form a group of peptides (“Group 86”). In some embodiments, the present invention provides a peptide comprising the amino acid sequence of any one of PEP NOs: and / or SEQ ID NOs: 1, 2, 3, 10, 11, 12, 14, 50, 51, 52, 53, 54, 55, 56, 57, 63, 64, 65, 66, 67, 68, 69, 70, 79, 80, 82, 83, 92, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 141, 144, 148, 149, 155, 156, 159, 161, 291, 292, 293, 294, 295, 296, 297. Such peptides contain the 11 amino acid sequence DSYGEVGVRQA (PEP NO: and / or SEQ ID NO: 774). Such peptides form a group of peptides (“Group 87”). In some embodiments, the present invention provides a peptide comprising the amino acid sequence of any one of PEP NOs: and / or SEQ ID NOs: 1, 2, 3, 10, 11, 12, 14, 50, 51, 52, 53, 54, 55, 56, 57, 63, 64, 65, 66, 67, 68, 69, 70, 79, 80, 82, 83, 92, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 141, 144, 146, 148, 149, 154, 155, 156, 159, 161, 291, 292, 293, 294, 295, 296, 297. Such peptides contain the 10 amino acid sequence DSYGEVGVRQ (PEP NO: and / or SEQ ID NO: 775). Such peptides form a group of peptides (“Group 88”). In some embodiments, the present invention provides a peptide comprising the amino acid sequence of any one of PEP NOs: and / or SEQ ID NOs: 1, 2, 3, 10, 11, 12, 14, 50, 51, 52, 53, 54, 55, 56, 57, 63, 64, 65, 66, 67, 68, 69, 70, 79, 80, 82, 83, 92, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 141, 144, 146, 148, 149, 153, 154, 155, 156, 159, 161, 291, 292, 293, 294, 295, 296, 297. Such peptides contain the 9 amino acid sequence DSYGEVGVR (PEP NO: and / or SEQ ID NO: 776). Such peptides form a group of peptides (“Group 89”). In some embodiments, the present invention provides a peptide comprising the amino acid sequence of any one of PEP NOs: and / or SEQ ID NOs: 1, 2, 3, 10, 11, 12, 14, 50, 51, 52, 53, 54, 55, 56, 57, 63, 64, 65, 66, 67, 68, 69, 70, 79, 80, 82, 83, 84, 92, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 141, 144, 146, 147, 148, 149, 153, 154, 155, 156, 159, 161, 291, 292, 293, 294, 295, 296, 297. Such peptides contain the 8 amino acid sequence DSYGEVGV (PEP NO: and / or SEQ ID NO: 777). Such peptides form a group of peptides (“Group 90”). In some embodiments, the present invention provides a peptide comprising the amino acid sequence of any one of PEP NOs: and / or SEQ ID NOs: 1, 2, 3, 10, 11, 12, 14, 49, 50, 51, 52, 53, 54, 55, 56, 57, 63, 64, 65, 66, 67, 68, 69, 70, 79, 80, 82, 83, 84, 92, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 141, 143, 144, 146, 147, 148, 149, 152, 153, 154, 155, 156, 159, 161, 291, 292, 293, 294, 295, 296, 297. Such peptides contain the 7 amino acid sequence DSYGEVG (PEP NO: and / or SEQ ID NO: 778). Such peptides form a group of peptides (“Group 91”). In some embodiments, the present invention provides a peptide comprising the amino acid sequence of any one of PEP NOs: and / or SEQ ID NOs: 1, 2, 3, 10, 11, 12, 14, 49, 50, 51, 52, 53, 54, 55, 56, 57, 63, 64, 65, 66, 67, 68, 69, 70, 79, 80, 82, 83, 84, 92, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 141, 143, 144, 146, 147, 148, 149, 152, 153, 154, 155, 156, 159, 161, 192, 291, 292, 293, 294, 295, 296, 297. Such peptides contain the 6 amino acid sequence DSYGEV (PEP NO: and / or SEQ ID NO: 779). Such peptides form a group of peptides (“Group 92”). In some embodiments, the present invention provides a peptide comprising the amino acid sequence of any one of PEP NOs: and / or SEQ ID NOs: 1, 2, 3, 10, 11, 12, 14, 49, 50, 51, 52, 53, 54, 55, 56, 57, 63, 64, 65, 66, 67, 68, 69, 70, 79, 80, 82, 83, 84, 92, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 141, 143, 144, 146, 147, 148, 149, 151, 152, 153, 154, 155, 156, 159, 161, 192, 291, 292, 293, 294, 295, 296, 297. Such peptides contain the 5 amino acid sequence DSYGE (PEP NO: and / or SEQ ID NO: 780). Such peptides form a group of peptides (“Group 93”). In some embodiments, the present invention provides a peptide comprising the amino acid sequence of any one of PEP NOs: and / or SEQ ID NOs: 1, 2, 3, 10, 11, 12, 14, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 62, 63, 64, 65, 66, 67, 68, 69, 70, 79, 80, 82, 83, 84, 92, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 159, 161, 192, 291, 292, 293, 294, 295, 296, 297. Such peptides contain the 4 amino acid sequence DSYG (PEP NO: and / or SEQ ID NO: 781). Such peptides form a group of peptides (“Group 94”). In some embodiments, the present invention provides a peptide comprising the amino acid sequence of any one of PEP NOs: and / or SEQ ID NOs: 1, 2, 3, 10, 11, 12, 14, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 79, 80, 82, 83, 84, 85, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 159, 161, 192, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304. Such peptides contain the 3 amino acid sequence DSY (PEP NO: 782). Such peptides form a group of peptides (“Group 95”). In some embodiments, the present invention provides a peptide comprising the amino acid sequence of any one of PEP NOs: and / or SEQ ID NOs: 2, 3, 10, 11, 12, 13, 14, 15, 16, 19, 45, 57, 58, 70, 92, 158, 159, 160, 161. Such peptides contain the 17 amino acid sequence SYGEVGVRQAPFPSRAS (PEP NO: and / or SEQ ID NO: 783). Such peptides form a group of peptides (“Group 96”). In some embodiments, the present invention provides a peptide comprising the amino acid sequence of any one of PEP NOs: and / or SEQ ID NOs: 2, 3, 10, 11, 12, 13, 14, 15, 16, 19, 29, 45, 56, 57, 58, 69, 70, 82, 92, 126, 158, 159, 160, 161, 162, 180, 186. Such peptides contain the 16 amino acid sequence SYGEVGVRQAPFPSRA (PEP NO: and / or SEQ ID NO: 784). Such peptides form a group of peptides (“Group 97”). In some embodiments, the present invention provides a peptide comprising the amino acid sequence of any one of PEP NOs: and / or SEQ ID NOs: 2, 3, 10, 11, 12, 13, 14, 15, 16, 19, 28, 29, 45, 55, 56, 57, 58, 68, 69, 70, 82, 92, 125, 126, 131, 158, 159, 160, 161, 162, 180, 186. Such peptides contain the 15 amino acid sequence SYGEVGVRQAPFPSR (PEP NO: and / or SEQ ID NO: 785). Such peptides form a group of peptides (“Group 98”). In some embodiments, the present invention provides a peptide comprising the amino acid sequence of any one of PEP NOs: and / or SEQ ID NOs: 2, 3, 10, 11, 12, 13, 14, 15, 16, 19, 25, 26, 28, 29, 38, 39, 40, 45, 54, 55, 56, 57, 58, 67, 68, 69, 70, 82, 86, 92, 124, 125, 126, 129, 130, 131, 135, 158, 159, 160, 161, 162, 180, 186, 187, 188, 291, 292, 293, 294, 295, 296, 297. Such peptides contain the 14 amino acid sequence SYGEVGVRQAPFPS (PEP NO: and / or SEQ ID NO: 786). Such peptides form a group of peptides (“Group 99”). In some embodiments, the present invention provides a peptide comprising the amino acid sequence of any one of PEP NOs: and / or SEQ ID NOs: 1, 2, 3, 10, 11, 12, 13, 14, 15, 16, 19, 25, 26, 27, 28, 29, 33, 34, 38, 39, 40, 45, 53, 54, 55, 56, 57, 58, 66, 67, 68, 69, 70, 80, 82, 83, 86, 92, 123, 124, 125, 126, 129, 130, 131, 134, 135, 138, 158, 159, 160, 161, 162, 180, 186, 187, 188, 291, 292, 293, 294, 295, 296, 297. Such peptides contain the 13 amino acid sequence SYGEVGVRQAPFP (PEP NO: and / or SEQ ID NO: 787). Such peptides form a group of peptides (“Group 100”). In some embodiments, the present invention provides a peptide comprising the amino acid sequence of any one of PEP NOs: and / or SEQ ID NOs: 1, 2, 3, 10, 11, 12, 13, 14, 15, 16, 18, 19, 25, 26, 27, 28, 29, 33, 34, 38, 39, 40, 41, 45, 52, 53, 54, 55, 56, 57, 58, 65, 66, 67, 68, 69, 70, 80, 82, 83, 86, 92, 122, 123, 124, 125, 126, 128, 129, 130, 131, 133, 134, 135, 137, 138, 158, 159, 160, 161, 162, 165, 180, 186, 187, 188, 291, 292, 293, 294, 295, 296, 297. Such peptides contain the 12 amino acid sequence SYGEVGVRQAPF (PEP NO: and / or SEQ ID NO: 788). Such peptides form a group of peptides (“Group 101”). In some embodiments, the present invention provides a peptide comprising the amino acid sequence of any one of PEP NOs: and / or SEQ ID NOs: 1, 2, 3, 10, 11, 12, 13, 14, 15, 16, 18, 19, 25, 26, 27, 28, 29, 33, 34, 38, 39, 40, 41, 45, 51, 52, 53, 54, 55, 56, 57, 58, 64, 65, 66, 67, 68, 69, 70, 79, 80, 82, 83, 86, 92, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 141, 144, 149, 156, 158, 159, 160, 161, 162, 165, 180, 186, 187, 188, 214, 221, 222, 231, 291, 292, 293, 294, 295, 296, 297. Such peptides contain the 11 amino acid sequence SYGEVGVRQAP (PEP NO: and / or SEQ ID NO: 789). Such peptides form a group of peptides (“Group 102”). In some embodiments, the present invention provides a peptide comprising the amino acid sequence of any one of PEP NOs: and / or SEQ ID NOs: 1, 2, 3, 10, 11, 12, 13, 14, 15, 16, 18, 19, 25, 26, 27, 28, 29, 33, 34, 38, 39, 40, 41, 45, 50, 51, 52, 53, 54, 55, 56, 57, 58, 63, 64, 65, 66, 67, 68, 69, 70, 79, 80, 82, 83, 86, 92, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 141, 144, 148, 149, 155, 156, 158, 159, 160, 161, 162, 165, 180, 186, 187, 188, 213, 214, 221, 222, 230, 231, 291, 292, 293, 294, 295, 296, 297. Such peptides contain the 10 amino acid sequence SYGEVGVRQA (PEP NO: and / or SEQ ID NO: 790). Such peptides form a group of peptides (“Group 103”). In some embodiments, the present invention provides a peptide comprising the amino acid sequence of any one of PEP NOs: and / or SEQ ID NOs: 1, 2, 3, 10, 11, 12, 13, 14, 15, 16, 18, 19, 25, 26, 27, 28, 29, 32, 33, 34, 38, 39, 40, 41, 45, 50, 51, 52, 53, 54, 55, 56, 57, 58, 63, 64, 65, 66, 67, 68, 69, 70, 79, 80, 82, 83, 86, 92, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 141, 144, 146, 148, 149, 154, 155, 156, 158, 159, 160, 161, 162, 165, 180, 186, 187, 188, 212, 213, 214, 220, 221, 222, 229, 230, 231, 291, 292, 293, 294, 295, 296, 297. Such peptides contain the 9 amino acid sequence SYGEVGVRQ (PEP NO: and / or SEQ ID NO: 791). Such peptides form a group of peptides (“Group 104”). In some embodiments, the present invention provides a peptide comprising the amino acid sequence of any one of PEP NOs: and / or SEQ ID NOs: 1, 2, 3, 10, 11, 12, 13, 14, 15, 16, 18, 19, 25, 26, 27, 28, 29, 31, 32, 33, 34, 38, 39, 40, 41, 45, 50, 51, 52, 53, 54, 55, 56, 57, 58, 63, 64, 65, 66, 67, 68, 69, 70, 79, 80, 82, 83, 86, 92, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 141, 144, 146, 148, 149, 153, 154, 155, 156, 158, 159, 160, 161, 162, 165, 180, 186, 187, 188, 212, 213, 214, 220, 221, 222, 229, 230, 231, 291, 292, 293, 294, 295, 296, 297. Such peptides contain the 8 amino acid sequence SYGEVGVR (PEP NO: and / or SEQ ID NO: 792). Such peptides form a group of peptides (“Group 105”). In some embodiments, the present invention provides a peptide comprising the amino acid sequence of any one of PEP NOs: and / or SEQ ID NOs: 1, 2, 3, 10, 11, 12, 13, 14, 15, 16, 18, 19, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 45, 50, 51, 52, 53, 54, 55, 56, 57, 58, 63, 64, 65, 66, 67, 68, 69, 70, 79, 80, 82, 83, 84, 86, 92, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 141, 144, 146, 147, 148, 149, 153, 154, 155, 156, 158, 159, 160, 161, 162, 165, 180, 186, 187, 188, 211, 212, 213, 214, 220, 221, 222, 228, 229, 230, 231, 291, 292, 293, 294, 295, 296, 297. Such peptides contain the 7 amino acid sequence SYGEVGV (PEP NO: and / or SEQ ID NO: 793). Such peptides form a group of peptides (“Group 106”). In some embodiments, the present invention provides a peptide comprising the amino acid sequence of any one of PEP NOs: and / or SEQ ID NOs: 1, 2, 3, 10, 11, 12, 13, 14, 15, 16, 18, 19, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 45, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 63, 64, 65, 66, 67, 68, 69, 70, 79, 80, 82, 83, 84, 86, 92, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 141, 143, 144, 146, 147, 148, 149, 152, 153, 154, 155, 156, 158, 159, 160, 161, 162, 165, 180, 186, 187, 188, 211, 212, 213, 214, 219, 220, 221, 222, 227, 228, 229, 230, 231, 291, 292, 293, 294, 295, 296, 297. Such peptides contain the 6 amino acid sequence SYGEVG (PEP NO: and / or SEQ ID NO: 794). Such peptides form a group of peptides (“Group 107”). In some embodiments, the present invention provides a peptide comprising the amino acid sequence of any one of PEP NOs: and / or SEQ ID NOs: 1, 2, 3, 10, 11, 12, 13, 14, 15, 16, 18, 19, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 45, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 63, 64, 65, 66, 67, 68, 69, 70, 79, 80, 82, 83, 84, 86, 92, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 141, 143, 144, 146, 147, 148, 149, 152, 153, 154, 155, 156, 158, 159, 160, 161, 162, 165, 180, 186, 187, 188, 192, 211, 212, 213, 214, 217, 218, 219, 220, 221, 222, 226, 227, 228, 229, 230, 231, 291, 292, 293, 294, 295, 296, 297. Such peptides contain the 5 amino acid sequence SYGEV (PEP NO: and / or SEQ ID NO: 795). Such peptides form a group of peptides (“Group 108”). In some embodiments, the present invention provides a peptide comprising the amino acid sequence of any one of PEP NOs: and / or SEQ ID NOs: 1, 2, 3, 10, 11, 12, 13, 14, 15, 16, 18, 19, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 45, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 63, 64, 65, 66, 67, 68, 69, 70, 79, 80, 82, 83, 84, 86, 92, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 141, 143, 144, 146, 147, 148, 149, 151, 152, 153, 154, 155, 156, 158, 159, 160, 161, 162, 165, 180, 186, 187, 188, 192, 210, 211, 212, 213, 214, 217, 218, 219, 220, 221, 222, 225, 226, 227, 228, 229, 230, 231, 291, 292, 293, 294, 295, 296, 297. Such peptides contain the 4 amino acid sequence SYGE (PEP NO: and / or SEQ ID NO: 796). Such peptides form a group of peptides (“Group 109”). In some embodiments, the present invention provides a peptide comprising the amino acid sequence of any one of PEP NOs: and / or SEQ ID NOs: 1, 2, 3, 10, 11, 12, 13, 14, 15, 16, 18, 19, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 45, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 62, 63, 64, 65, 66, 67, 68, 69, 70, 79, 80, 82, 83, 84, 86, 92, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 158, 159, 160, 161, 162, 165, 180, 186, 187, 188, 192, 209, 210, 211, 212, 213, 214, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 291, 292, 293, 294, 295, 296, 297. Such peptides contain the 3 amino acid sequence SYG (PEP NO: 797). Such peptides form a group of peptides (“Group 110”). In some embodiments, the present invention provides a peptide comprising the amino acid sequence of any one of PEP NOs: and / or SEQ ID NOs: 2, 3, 10, 11, 12, 13, 14, 15, 16, 19, 43, 45, 46, 57, 58, 59, 70, 92, 139, 158, 159, 160, 161. Such peptides contain the 16 amino acid sequence YGEVGVRQAPFPSRAS (PEP NO: and / or SEQ ID NO: 798). Such peptides form a group of peptides (“Group 111”). In some embodiments, the present invention provides a peptide comprising the amino acid sequence of any one of PEP NOs: and / or SEQ ID NOs: 2, 3, 10, 11, 12, 13, 14, 15, 16, 19, 29, 43, 45, 46, 56, 57, 58, 59, 69, 70, 82, 92, 126, 139, 158, 159, 160, 161, 162, 180, 186. Such peptides contain the 15 amino acid sequence YGEVGVRQAPFPSRA (PEP NO: and / or SEQ ID NO: 799). Such peptides form a group of peptides (“Group 112”). In some embodiments, the present invention provides a peptide comprising the amino acid sequence of any one of PEP NOs: and / or SEQ ID NOs: 2, 3, 10, 11, 12, 13, 14, 15, 16, 19, 28, 29, 43, 45, 46, 55, 56, 57, 58, 59, 68, 69, 70, 82, 92, 125, 126, 131, 139, 158, 159, 160, 161, 162, 180, 186. Such peptides contain the 14 amino acid sequence YGEVGVRQAPFPSR (PEP NO: and / or SEQ ID NO: 800). Such peptides form a group of peptides (“Group 113”). In some embodiments, the present invention provides a peptide comprising the amino acid sequence of any one of PEP NOs: and / or SEQ ID NOs: 2, 3, 10, 11, 12, 13, 14, 15, 16, 19, 25, 26, 28, 29, 38, 39, 40, 43, 45, 46, 54, 55, 56, 57, 58, 59, 67, 68, 69, 70, 82, 86, 92, 124, 125, 126, 129, 130, 131, 135, 139, 158, 159, 160, 161, 162, 180, 186, 187, 188, 291, 292, 293, 294, 295, 296, 297. Such peptides contain the 13 amino acid sequence YGEVGVRQAPFPS (PEP NO: and / or SEQ ID NO: 801). Such peptides form a group of peptides (“Group 114”). In some embodiments, the present invention provides a peptide comprising the amino acid sequence of any one of PEP NOs: and / or SEQ ID NOs: 1, 2, 3, 10, 11, 12, 13, 14, 15, 16, 19, 25, 26, 27, 28, 29, 33, 34, 38, 39, 40, 43, 45, 46, 53, 54, 55, 56, 57, 58, 59, 66, 67, 68, 69, 70, 80, 82, 83, 86, 92, 123, 124, 125, 126, 129, 130, 131, 134, 135, 138, 139, 140, 158, 159, 160, 161, 162, 180, 186, 187, 188, 291, 292, 293, 294, 295, 296, 297. Such peptides contain the 12 amino acid sequence YGEVGVRQAPFP (PEP NO: and / or SEQ ID NO: 802). Such peptides form a group of peptides (“Group 115”). In some embodiments, the present invention provides a peptide comprising the amino acid sequence of any one of PEP NOs: and / or SEQ ID NOs: 1, 2, 3, 10, 11, 12, 13, 14, 15, 16, 18, 19, 25, 26, 27, 28, 29, 33, 34, 38, 39, 40, 41, 43, 45, 46, 52, 53, 54, 55, 56, 57, 58, 59, 65, 66, 67, 68, 69, 70, 80, 82, 83, 86, 92, 122, 123, 124, 125, 126, 128, 129, 130, 131, 133, 134, 135, 137, 138, 139, 140, 158, 159, 160, 161, 162, 165, 180, 186, 187, 188, 291, 292, 293, 294, 295, 296, 297. Such peptides contain the 11 amino acid sequence YGEVGVRQAPF (PEP NO: and / or SEQ ID NO: 803). Such peptides form a group of peptides (“Group 116”). In some embodiments, the present invention provides a peptide comprising the amino acid sequence of any one of PEP NOs: and / or SEQ ID NOs: 1, 2, 3, 10, 11, 12, 13, 14, 15, 16, 18, 19, 25, 26, 27, 28, 29, 33, 34, 38, 39, 40, 41, 43, 45, 46, 51, 52, 53, 54, 55, 56, 57, 58, 59, 64, 65, 66, 67, 68, 69, 70, 79, 80, 82, 83, 86, 92, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 144, 149, 156, 158, 159, 160, 161, 162, 165, 180, 186, 187, 188, 214, 221, 222, 231, 291, 292, 293, 294, 295, 296, 297. Such peptides contain the 10 amino acid sequence YGEVGVRQAP (PEP NO: and / or SEQ ID NO: 804). Such peptides form a group of peptides (“Group 117”). In some embodiments, the present invention provides a peptide comprising the amino acid sequence of any one of PEP NOs: and / or SEQ ID NOs: 1, 2, 3, 10, 11, 12, 13, 14, 15, 16, 18, 19, 25, 26, 27, 28, 29, 33, 34, 38, 39, 40, 41, 43, 45, 46, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 63, 64, 65, 66, 67, 68, 69, 70, 79, 80, 82, 83, 86, 92, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 144, 148, 149, 155, 156, 158, 159, 160, 161, 162, 165, 180, 186, 187, 188, 213, 214, 221, 222, 230, 231, 291, 292, 293, 294, 295, 296, 297. Such peptides contain the 9 amino acid sequence YGEVGVRQA (PEP NO: and / or SEQ ID NO: 805). Such peptides form a group of peptides (“Group 118”). In some embodiments, the present invention provides a peptide comprising the amino acid sequence of any one of PEP NOs: and / or SEQ ID NOs: 1, 2, 3, 10, 11, 12, 13, 14, 15, 16, 18, 19, 25, 26, 27, 28, 29, 32, 33, 34, 38, 39, 40, 41, 43, 45, 46, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 63, 64, 65, 66, 67, 68, 69, 70, 79, 80, 82, 83, 86, 92, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 144, 146, 148, 149, 154, 155, 156, 158, 159, 160, 161, 162, 165, 180, 186, 187, 188, 212, 213, 214, 220, 221, 222, 229, 230, 231, 291, 292, 293, 294, 295, 296, 297. Such peptides contain the 8 amino acid sequence YGEVGVRQ (PEP NO: and / or SEQ ID NO: 806). Such peptides form a group of peptides (“Group 119”). In some embodiments, the present invention provides a peptide comprising the amino acid sequence of any one of PEP NOs: and / or SEQ ID NOs: 1, 2, 3, 10, 11, 12, 13, 14, 15, 16, 18, 19, 25, 26, 27, 28, 29, 31, 32, 33, 34, 38, 39, 40, 41, 43, 45, 46, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 63, 64, 65, 66, 67, 68, 69, 70, 79, 80, 82, 83, 86, 92, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 144, 146, 148, 149, 153, 154, 155, 156, 158, 159, 160, 161, 162, 165, 180, 186, 187, 188, 212, 213, 214, 220, 221, 222, 229, 230, 231, 291, 292, 293, 294, 295, 296, 297. Such peptides contain the 7 amino acid sequence YGEVGVR (PEP NO: and / or SEQ ID NO: 807). Such peptides form a group of peptides (“Group 120”). In some embodiments, the present invention provides a peptide comprising the amino acid sequence of any one of PEP NOs: and / or SEQ ID NOs: 1, 2, 3, 10, 11, 12, 13, 14, 15, 16, 18, 19, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 43, 45, 46, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 63, 64, 65, 66, 67, 68, 69, 70, 79, 80, 82, 83, 84, 86, 92, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 144, 146, 147, 148, 149, 153, 154, 155, 156, 158, 159, 160, 161, 162, 165, 180, 186, 187, 188, 211, 212, 213, 214, 220, 221, 222, 228, 229, 230, 231, 291, 292, 293, 294, 295, 296, 297. Such peptides contain the 6 amino acid sequence YGEVGV (PEP NO: and / or SEQ ID NO: 808). Such peptides form a group of peptides (“Group 121”). In some embodiments, the present invention provides a peptide comprising the amino acid sequence of any one of PEP NOs: and / or SEQ ID NOs: 1, 2, 3, 10, 11, 12, 13, 14, 15, 16, 18, 19, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 63, 64, 65, 66, 67, 68, 69, 70, 79, 80, 82, 83, 84, 86, 92, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 143, 144, 146, 147, 148, 149, 152, 153, 154, 155, 156, 158, 159, 160, 161, 162, 165, 180, 186, 187, 188, 211, 212, 213, 214, 219, 220, 221, 222, 227, 228, 229, 230, 231, 291, 292, 293, 294, 295, 296, 297. Such peptides contain the 5 amino acid sequence YGEVG (PEP NO: and / or SEQ ID NO: 809). Such peptides form a group of peptides (“Group 122”). In some embodiments, the present invention provides a peptide comprising the amino acid sequence of any one of PEP NOs: and / or SEQ ID NOs: 1, 2, 3, 10, 11, 12, 13, 14, 15, 16, 18, 19, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 63, 64, 65, 66, 67, 68, 69, 70, 79, 80, 82, 83, 84, 86, 92, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 143, 144, 146, 147, 148, 149, 152, 153, 154, 155, 156, 158, 159, 160, 161, 162, 165, 180, 186, 187, 188, 192, 211, 212, 213, 214, 217, 218, 219, 220, 221, 222, 226, 227, 228, 229, 230, 231, 291, 292, 293, 294, 295, 296, 297. Such peptides contain the 4 amino acid sequence YGEV (PEP NO: and / or SEQ ID NO: 810). Such peptides form a group of peptides (“Group 123”). In some embodiments, the present invention provides a peptide comprising the amino acid sequence of any one of PEP NOs: and / or SEQ ID NOs: 1, 2, 3, 10, 11, 12, 13, 14, 15, 16, 18, 19, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 63, 64, 65, 66, 67, 68, 69, 70, 79, 80, 82, 83, 84, 86, 92, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 143, 144, 146, 147, 148, 149, 151, 152, 153, 154, 155, 156, 158, 159, 160, 161, 162, 165, 180, 186, 187, 188, 192, 210, 211, 212, 213, 214, 217, 218, 219, 220, 221, 222, 225, 226, 227, 228, 229, 230, 231, 291, 292, 293, 294, 295, 296, 297. Such peptides contain the 3 amino acid sequence YGE (PEP NO: 811). Such peptides form a group of peptides (“Group 124”). In some embodiments, the present invention provides a peptide comprising the amino acid sequence of any one of PEP NOs: and / or SEQ ID NOs: 2, 3, 6, 9, 10, 11, 12, 13, 14, 15, 16, 19, 43, 44, 45, 46, 47, 57, 58, 59, 60, 70, 85, 88, 89, 90, 91, 92, 139, 158, 159, 160, 161. Such peptides contain the 15 amino acid sequence GEVGVRQAPFPSRAS (PEP NO: and / or SEQ ID NO: 812). Such peptides form a group of peptides (“Group 125”). In some embodiments, the present invention provides a peptide comprising the amino acid sequence of any one of PEP NOs: and / or SEQ ID NOs: 2, 3, 6, 9, 10, 11, 12, 13, 14, 15, 16, 19, 29, 43, 44, 45, 46, 47, 56, 57, 58, 59, 60, 69, 70, 82, 85, 88, 89, 90, 91, 92, 126, 139, 158, 159, 160, 161, 162, 164, 180, 186. Such peptides contain the 14 amino acid sequence GEVGVRQAPFPSRA (PEP NO: and / or SEQ ID NO: 813). Such peptides form a group of peptides (“Group 126”). In some embodiments, the present invention provides a peptide comprising the amino acid sequence of any one of PEP NOs: and / or SEQ ID NOs: 2, 3, 6, 9, 10, 11, 12, 13, 14, 15, 16, 19, 28, 29, 43, 44, 45, 46, 47, 55, 56, 57, 58, 59, 60, 68, 69, 70, 82, 85, 88, 89, 90, 91, 92, 125, 126, 131, 139, 158, 159, 160, 161, 162, 164, 180, 186. Such peptides contain the 13 amino acid sequence GEVGVRQAPFPSR (PEP NO: and / or SEQ ID NO: 814). Such peptides form a group of peptides (“Group 127”). In some embodiments, the present invention provides a peptide comprising the amino acid sequence of any one of PEP NOs: and / or SEQ ID NOs: 2, 3, 6, 9, 10, 11, 12, 13, 14, 15, 16, 19, 25, 26, 28, 29, 38, 39, 40, 43, 44, 45, 46, 47, 54, 55, 56, 57, 58, 59, 60, 67, 68, 69, 70, 76, 82, 85, 86, 88, 89, 90, 91, 92, 124, 125, 126, 129, 130, 131, 135, 139, 158, 159, 160, 161, 162, 164, 166, 180, 185, 186, 187, 188, 291, 292, 293, 294, 295, 296, 297. Such peptides contain the 12 amino acid sequence GEVGVRQAPFPS (PEP NO: and / or SEQ ID NO: 815). Such peptides form a group of peptides (“Group 128”). In some embodiments, the present invention provides a peptide comprising the amino acid sequence of any one of PEP NOs: and / or SEQ ID NOs: 1, 2, 3, 4, 5, 6, 9, 10, 11, 12, 13, 14, 15, 16, 19, 25, 26, 27, 28, 29, 33, 34, 38, 39, 40, 43, 44, 45, 46, 47, 53, 54, 55, 56, 57, 58, 59, 60, 66, 67, 68, 69, 70, 71, 72, 76, 77, 78, 80, 81, 82, 83, 85, 86, 88, 89, 90, 91, 92, 123, 124, 125, 126, 129, 130, 131, 134, 135, 138, 139, 140, 158, 159, 160, 161, 162, 164, 166, 180, 185, 186, 187, 188, 291, 292, 293, 294, 295, 296, 297. Such peptides contain the 11 amino acid sequence GEVGVRQAPFP (PEP NO: and / or SEQ ID NO: 816). Such peptides form a group of peptides (“Group 129”). In some embodiments, the present invention provides a peptide comprising the amino acid sequence of any one of PEP NOs: and / or SEQ ID NOs: 1, 2, 3, 4, 5, 6, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 33, 34, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 52, 53, 54, 55, 56, 57, 58, 59, 60, 65, 66, 67, 68, 69, 70, 71, 72, 76, 77, 78, 80, 81, 82, 83, 85, 86, 87, 88, 89, 90, 91, 92, 122, 123, 124, 125, 126, 128, 129, 130, 131, 133, 134, 135, 137, 138, 139, 140, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 168, 180, 183, 184, 185, 186, 187, 188, 189, 291, 292, 293, 294, 295, 296, 297. Such peptides contain the 10 amino acid sequence GEVGVRQAPF (PEP NO: and / or SEQ ID NO: 817). Such peptides form a group of peptides (“Group 130”). In some embodiments, the present invention provides a peptide comprising the amino acid sequence of any one of PEP NOs: and / or SEQ ID NOs: 2, 3, 6, 9, 10, 11, 12, 13, 14, 15, 16, 19, 43, 44, 45, 46, 47, 57, 58, 59, 60, 61, 70, 85, 88, 89, 90, 91, 92, 93, 94, 95, 139, 158, 159, 160, 161, 208. Such peptides contain the 14 amino acid sequence EVGVRQAPFPSRAS (PEP NO: and / or SEQ ID NO: 818). Such peptides form a group of peptides (“Group 131”). In some embodiments, the present invention provides a peptide comprising the amino acid sequence of any one of PEP NOs: and / or SEQ ID NOs: 2, 3, 6, 9, 10, 11, 12, 13, 14, 15, 16, 19, 29, 43, 44, 45, 46, 47, 56, 57, 58, 59, 60, 61, 69, 70, 82, 85, 88, 89, 90, 91, 92, 93, 94, 95, 126, 139, 158, 159, 160, 161, 162, 164, 180, 186, 208. Such peptides contain the 13 amino acid sequence EVGVRQAPFPSRA (PEP NO: and / or SEQ ID NO: 819). Such peptides form a group of peptides (“Group 132”). In some embodiments, the present invention provides a peptide comprising the amino acid sequence of any one of PEP NOs: and / or SEQ ID NOs: 2, 3, 6, 9, 10, 11, 12, 13, 14, 15, 16, 19, 28, 29, 43, 44, 45, 46, 47, 55, 56, 57, 58, 59, 60, 61, 68, 69, 70, 82, 85, 88, 89, 90, 91, 92, 93, 94, 95, 125, 126, 131, 139, 158, 159, 160, 161, 162, 164, 180, 186, 208. Such peptides contain the 12 amino acid sequence EVGVRQAPFPSR (PEP NO: and / or SEQ ID NO: 820). Such peptides form a group of peptides (“Group 133”). In some embodiments, the present invention provides a peptide comprising the amino acid sequence of any one of PEP NOs: and / or SEQ ID NOs: 2, 3, 6, 9, 10, 11, 12, 13, 14, 15, 16, 19, 25, 26, 28, 29, 38, 39, 40, 43, 44, 45, 46, 47, 54, 55, 56, 57, 58, 59, 60, 61, 67, 68, 69, 70, 76, 82, 85, 86, 88, 89, 90, 91, 92, 93, 94, 95, 124, 125, 126, 129, 130, 131, 135, 139, 158, 159, 160, 161, 162, 164, 166, 180, 185, 186, 187, 188, 208, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304. Such peptides contain the 11 amino acid sequence EVGVRQAPFPS (PEP NO: and / or SEQ ID NO: 821). Such peptides form a group of peptides (“Group 134”). In some embodiments, the present invention provides a peptide comprising the amino acid sequence of any one of PEP NOs: and / or SEQ ID NOs: 1, 2, 3, 4, 5, 6, 9, 10, 11, 12, 13, 14, 15, 16, 19, 25, 26, 27, 28, 29, 33, 34, 38, 39, 40, 43, 44, 45, 46, 47, 53, 54, 55, 56, 57, 58, 59, 60, 61, 66, 67, 68, 69, 70, 71, 72, 76, 77, 78, 80, 81, 82, 83, 85, 86, 88, 89, 90, 91, 92, 93, 94, 95, 123, 124, 125, 126, 129, 130, 131, 134, 135, 138, 139, 140, 158, 159, 160, 161, 162, 164, 166, 180, 185, 186, 187, 188, 208, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304. Such peptides contain the 10 amino acid sequence EVGVRQAPFP (PEP NO: and / or SEQ ID NO: 822). Such peptides form a group of peptides (“Group 135”). In some embodiments, the present invention provides a peptide comprising the amino acid sequence of any one of PEP NOs: and / or SEQ ID NOs: 1, 2, 3, 4, 5, 6, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 33, 34, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 65, 66, 67, 68, 69, 70, 71, 72, 76, 77, 78, 80, 81, 82, 83, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 122, 123, 124, 125, 126, 128, 129, 130, 131, 133, 134, 135, 137, 138, 139, 140, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 168, 180, 183, 184, 185, 186, 187, 188, 189, 208, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304. Such peptides contain the 9 amino acid sequence EVGVRQAPF (PEP NO: and / or SEQ ID NO: 823). Such peptides form a group of peptides (“Group 136”). In some embodiments, the present invention provides a peptide comprising the amino acid sequence of any one of PEP NOs: and / or SEQ ID NOs: 2, 3, 6, 9, 10, 11, 12, 13, 14, 15, 16, 19, 43, 44, 45, 46, 47, 48, 57, 58, 59, 60, 61, 62, 70, 85, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 139, 142, 145, 150, 158, 159, 160, 161, 208, 209, 215. Such peptides contain the 13 amino acid sequence VGVRQAPFPSRAS (PEP NO: and / or SEQ ID NO: 824). Such peptides form a group of peptides (“Group 137”). In some embodiments, the present invention provides a peptide comprising the amino acid sequence of any one of PEP NOs: and / or SEQ ID NOs: 2, 3, 6, 9, 10, 11, 12, 13, 14, 15, 16, 19, 29, 43, 44, 45, 46, 47, 48, 56, 57, 58, 59, 60, 61, 62, 69, 70, 82, 85, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 126, 139, 142, 145, 150, 158, 159, 160, 161, 162, 164, 180, 186, 208, 209, 215. Such peptides contain the 12 amino acid sequence VGVRQAPFPSRA (PEP NO: and / or SEQ ID NO: 825). Such peptides form a group of peptides (“Group 138”). In some embodiments, the present invention provides a peptide comprising the amino acid sequence of any one of PEP NOs: and / or SEQ ID NOs: 2, 3, 6, 9, 10, 11, 12, 13, 14, 15, 16, 19, 28, 29, 43, 44, 45, 46, 47, 48, 55, 56, 57, 58, 59, 60, 61, 62, 68, 69, 70, 82, 85, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 125, 126, 131, 139, 142, 145, 150, 158, 159, 160, 161, 162, 164, 180, 186, 208, 209, 215. Such peptides contain the 11 amino acid sequence VGVRQAPFPSR (PEP NO: and / or SEQ ID NO: 826). Such peptides form a group of peptides (“Group 139”). In some embodiments, the present invention provides a peptide comprising the amino acid sequence of any one of PEP NOs: and / or SEQ ID NOs: 2, 3, 6, 9, 10, 11, 12, 13, 14, 15, 16, 19, 25, 26, 28, 29, 38, 39, 40, 43, 44, 45, 46, 47, 48, 54, 55, 56, 57, 58, 59, 60, 61, 62, 67, 68, 69, 70, 76, 82, 85, 86, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 124, 125, 126, 129, 130, 131, 135, 139, 142, 145, 150, 158, 159, 160, 161, 162, 164, 166, 180, 185, 186, 187, 188, 208, 209, 215, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304. Such peptides contain the 10 amino acid sequence VGVRQAPFPS (PEP NO: and / or SEQ ID NO: 827). Such peptides form a group of peptides (“Group 140”). In some embodiments, the present invention provides a peptide comprising the amino acid sequence of any one of PEP NOs: and / or SEQ ID NOs: 1, 2, 3, 4, 5, 6, 9, 10, 11, 12, 13, 14, 15, 16, 19, 25, 26, 27, 28, 29, 33, 34, 38, 39, 40, 43, 44, 45, 46, 47, 48, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 66, 67, 68, 69, 70, 71, 72, 76, 77, 78, 80, 81, 82, 83, 85, 86, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 123, 124, 125, 126, 129, 130, 131, 134, 135, 138, 139, 140, 142, 145, 150, 158, 159, 160, 161, 162, 164, 166, 180, 185, 186, 187, 188, 208, 209, 215, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304. Such peptides contain the 9 amino acid sequence VGVRQAPFP (PEP NO: and / or SEQ ID NO: 828). Such peptides form a group of peptides (“Group 141”). In some embodiments, the present invention provides a peptide comprising the amino acid sequence of any one of PEP NOs: and / or SEQ ID NOs: 1, 2, 3, 4, 5, 6, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 33, 34, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 65, 66, 67, 68, 69, 70, 71, 72, 76, 77, 78, 80, 81, 82, 83, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 122, 123, 124, 125, 126, 128, 129, 130, 131, 133, 134, 135, 137, 138, 139, 140, 142, 145, 150, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 168, 180, 183, 184, 185, 186, 187, 188, 189, 208, 209, 215, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304. Such peptides contain the 8 amino acid sequence VGVRQAPF (PEP NO: and / or SEQ ID NO: 829). Such peptides form a group of peptides (“Group 142”). In some embodiments, the present invention provides a peptide comprising the amino acid sequence of any one of PEP NOs: and / or SEQ ID NOs: 2, 3, 6, 9, 10, 11, 12, 13, 14, 15, 16, 19, 43, 44, 45, 46, 47, 48, 57, 58, 59, 60, 61, 62, 70, 85, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 139, 142, 145, 150, 151, 158, 159, 160, 161, 208, 209, 210, 215, 216, 223, 224. Such peptides contain the 12 amino acid sequence GVRQAPFPSRAS (PEP NO: and / or SEQ ID NO: 830). Such peptides form a group of peptides (“Group 143”). In some embodiments, the present invention provides a peptide comprising the amino acid sequence of any one of PEP NOs: and / or SEQ ID NOs: 2, 3, 6, 9, 10, 11, 12, 13, 14, 15, 16, 19, 29, 43, 44, 45, 46, 47, 48, 56, 57, 58, 59, 60, 61, 62, 69, 70, 82, 85, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 126, 139, 142, 145, 150, 151, 158, 159, 160, 161, 162, 164, 180, 186, 208, 209, 210, 215, 216, 223, 224. Such peptides contain the 11 amino acid sequence GVRQAPFPSRA (PEP NO: and / or SEQ ID NO: 831). Such peptides form a group of peptides (“Group 144”). In some embodiments, the present invention provides a peptide comprising the amino acid sequence of any one of PEP NOs: and / or SEQ ID NOs: 2, 3, 6, 9, 10, 11, 12, 13, 14, 15, 16, 19, 28, 29, 43, 44, 45, 46, 47, 48, 55, 56, 57, 58, 59, 60, 61, 62, 68, 69, 70, 82, 85, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 125, 126, 131, 139, 142, 145, 150, 151, 158, 159, 160, 161, 162, 164, 180, 186, 208, 209, 210, 215, 216, 223, 224. Such peptides contain the 10 amino acid sequence GVRQAPFPSR (PEP NO: and / or SEQ ID NO: 832). Such peptides form a group of peptides (“Group 145”). In some embodiments, the present invention provides a peptide comprising the amino acid sequence of any one of PEP NOs: and / or SEQ ID NOs: 2, 3, 6, 9, 10, 11, 12, 13, 14, 15, 16, 19, 25, 26, 28, 29, 38, 39, 40, 43, 44, 45, 46, 47, 48, 54, 55, 56, 57, 58, 59, 60, 61, 62, 67, 68, 69, 70, 76, 82, 85, 86, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 124, 125, 126, 129, 130, 131, 135, 139, 142, 145, 150, 151, 158, 159, 160, 161, 162, 164, 166, 180, 185, 186, 187, 188, 208, 209, 210, 215, 216, 223, 224, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304. Such peptides contain the 9 amino acid sequence GVRQAPFPS (PEP NO: and / or SEQ ID NO: 833). Such peptides form a group of peptides (“Group 146”). In some embodiments, the present invention provides a peptide comprising the amino acid sequence of any one of PEP NOs: and / or SEQ ID NOs: 1, 2, 3, 4, 5, 6, 9, 10, 11, 12, 13, 14, 15, 16, 19, 25, 26, 27, 28, 29, 33, 34, 38, 39, 40, 43, 44, 45, 46, 47, 48, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 66, 67, 68, 69, 70, 71, 72, 76, 77, 78, 80, 81, 82, 83, 85, 86, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 123, 124, 125, 126, 129, 130, 131, 134, 135, 138, 139, 140, 142, 145, 150, 151, 158, 159, 160, 161, 162, 164, 166, 180, 181, 185, 186, 187, 188, 208, 209, 210, 215, 216, 223, 224, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304. Such peptides contain the 8 amino acid sequence GVRQAPFP (PEP NO: and / or SEQ ID NO: 834). Such peptides form a group of peptides (“Group 147”). In some embodiments, the present invention provides a peptide comprising the amino acid sequence of any one of PEP NOs: and / or SEQ ID NOs: 1, 2, 3, 4, 5, 6, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 33, 34, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 65, 66, 67, 68, 69, 70, 71, 72, 76, 77, 78, 80, 81, 82, 83, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 122, 123, 124, 125, 126, 128, 129, 130, 131, 133, 134, 135, 137, 138, 139, 140, 142, 145, 150, 151, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 168, 180, 181, 183, 184, 185, 186, 187, 188, 189, 208, 209, 210, 215, 216, 223, 224, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304. Such peptides contain the 7 amino acid sequence GVRQAPF (PEP NO: and / or SEQ ID NO: 835). Such peptides form a group of peptides (“Group 148”). In some embodiments, the present invention provides a peptide comprising the amino acid sequence of any one of PEP NOs: and / or SEQ ID NOs: 2, 3, 6, 9, 10, 11, 12, 13, 14, 15, 16, 19, 43, 44, 45, 46, 47, 48, 57, 58, 59, 60, 61, 62, 70, 85, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 139, 142, 145, 150, 151, 158, 159, 160, 161, 208, 209, 210, 215, 216, 217, 218, 223, 224. Such peptides contain the 11 amino acid sequence VRQAPFPSRAS (PEP NO: and / or SEQ ID NO: 836). Such peptides form a group of peptides (“Group 149”). In some embodiments, the present invention provides a peptide comprising the amino acid sequence of any one of PEP NOs: and / or SEQ ID NOs: 2, 3, 6, 9, 10, 11, 12, 13, 14, 15, 16, 19, 29, 43, 44, 45, 46, 47, 48, 56, 57, 58, 59, 60, 61, 62, 69, 70, 82, 85, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 126, 139, 142, 145, 150, 151, 158, 159, 160, 161, 162, 164, 180, 186, 208, 209, 210, 215, 216, 217, 218, 223, 224. Such peptides contain the 10 amino acid sequence VRQAPFPSRA (PEP NO: and / or SEQ ID NO: 837). Such peptides form a group of peptides (“Group 150”). In some embodiments, the present invention provides a peptide comprising the amino acid sequence of any one of PEP NOs: and / or SEQ ID NOs: 2, 3, 6, 9, 10, 11, 12, 13, 14, 15, 16, 19, 28, 29, 43, 44, 45, 46, 47, 48, 55, 56, 57, 58, 59, 60, 61, 62, 68, 69, 70, 82, 85, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 125, 126, 131, 139, 142, 145, 150, 151, 158, 159, 160, 161, 162, 164, 180, 186, 208, 209, 210, 215, 216, 217, 218, 223, 224. Such peptides contain the 9 amino acid sequence VRQAPFPSR (PEP NO: and / or SEQ ID NO: 838). Such peptides form a group of peptides (“Group 151”). In some embodiments, the present invention provides a peptide comprising the amino acid sequence of any one of PEP NOs: and / or SEQ ID NOs: 2, 3, 6, 9, 10, 11, 12, 13, 14, 15, 16, 19, 25, 26, 28, 29, 38, 39, 40, 43, 44, 45, 46, 47, 48, 54, 55, 56, 57, 58, 59, 60, 61, 62, 67, 68, 69, 70, 76, 82, 85, 86, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 124, 125, 126, 129, 130, 131, 135, 139, 142, 145, 150, 151, 158, 159, 160, 161, 162, 164, 166, 180, 185, 186, 187, 188, 192, 208, 209, 210, 215, 216, 217, 218, 223, 224, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304. Such peptides contain the 8 amino acid sequence VRQAPFPS (PEP NO: and / or SEQ ID NO: 839). Such peptides form a group of peptides (“Group 152”). In some embodiments, the present invention provides a peptide comprising the amino acid sequence of any one of PEP NOs: and / or SEQ ID NOs: 1, 2, 3, 4, 5, 6, 9, 10, 11, 12, 13, 14, 15, 16, 19, 25, 26, 27, 28, 29, 33, 34, 38, 39, 40, 43, 44, 45, 46, 47, 48, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 66, 67, 68, 69, 70, 71, 72, 76, 77, 78, 80, 81, 82, 83, 85, 86, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 123, 124, 125, 126, 129, 130, 131, 134, 135, 138, 139, 140, 142, 145, 150, 151, 158, 159, 160, 161, 162, 164, 166, 180, 181, 185, 186, 187, 188, 192, 208, 209, 210, 215, 216, 217, 218, 223, 224, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304. Such peptides contain the 7 amino acid sequence VRQAPFP (PEP NO: and / or SEQ ID NO: 840). Such peptides form a group of peptides (“Group 153”). In some embodiments, the present invention provides a peptide comprising the amino acid sequence of any one of PEP NOs: and / or SEQ ID NOs: 1, 2, 3, 4, 5, 6, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 33, 34, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 65, 66, 67, 68, 69, 70, 71, 72, 76, 77, 78, 80, 81, 82, 83, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 122, 123, 124, 125, 126, 128, 129, 130, 131, 133, 134, 135, 137, 138, 139, 140, 142, 145, 150, 151, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 168, 180, 181, 183, 184, 185, 186, 187, 188, 189, 192, 208, 209, 210, 215, 216, 217, 218, 223, 224, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304. Such peptides contain the 6 amino acid sequence VRQAPF (PEP NO: and / or SEQ ID NO: 841). Such peptides form a group of peptides (“Group 154”). In some embodiments, the present invention provides a peptide comprising the amino acid sequence of any one of PEP NOs: and / or SEQ ID NOs: 2, 3, 6, 9, 10, 11, 12, 13, 14, 15, 16, 19, 43, 44, 45, 46, 47, 48, 49, 57, 58, 59, 60, 61, 62, 70, 84, 85, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 139, 142, 143, 145, 150, 151, 152, 158, 159, 160, 161, 208, 209, 210, 215, 216, 217, 218, 223, 224, 225. Such peptides contain the 10 amino acid sequence RQAPFPSRAS (PEP NO: and / or SEQ ID NO: 842). Such peptides form a group of peptides (“Group 155”). In some embodiments, the present invention provides a peptide comprising the amino acid sequence of any one of PEP NOs: and / or SEQ ID NOs: 2, 3, 6, 9, 10, 11, 12, 13, 14, 15, 16, 19, 29, 43, 44, 45, 46, 47, 48, 49, 56, 57, 58, 59, 60, 61, 62, 69, 70, 82, 84, 85, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 126, 139, 142, 143, 145, 150, 151, 152, 158, 159, 160, 161, 162, 164, 180, 186, 208, 209, 210, 215, 216, 217, 218, 223, 224, 225. Such peptides contain the 9 amino acid sequence RQAPFPSRA (PEP NO: and / or SEQ ID NO: 843). Such peptides form a group of peptides (“Group 156”). In some embodiments, the present invention provides a peptide comprising the amino acid sequence of any one of PEP NOs: and / or SEQ ID NOs: 2, 3, 6, 9, 10, 11, 12, 13, 14, 15, 16, 19, 28, 29, 43, 44, 45, 46, 47, 48, 49, 55, 56, 57, 58, 59, 60, 61, 62, 68, 69, 70, 82, 84, 85, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 125, 126, 131, 139, 142, 143, 145, 150, 151, 152, 158, 159, 160, 161, 162, 164, 180, 186, 208, 209, 210, 215, 216, 217, 218, 223, 224, 225. Such peptides contain the 8 amino acid sequence RQAPFPSR (PEP NO: and / or SEQ ID NO: 844). Such peptides form a group of peptides (“Group 157”). In some embodiments, the present invention provides a peptide comprising the amino acid sequence of any one of PEP NOs: and / or SEQ ID NOs: 2, 3, 6, 9, 10, 11, 12, 13, 14, 15, 16, 19, 25, 26, 28, 29, 38, 39, 40, 43, 44, 45, 46, 47, 48, 49, 54, 55, 56, 57, 58, 59, 60, 61, 62, 67, 68, 69, 70, 76, 82, 84, 85, 86, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 124, 125, 126, 129, 130, 131, 135, 139, 142, 143, 145, 150, 151, 152, 158, 159, 160, 161, 162, 164, 166, 180, 185, 186, 187, 188, 192, 208, 209, 210, 215, 216, 217, 218, 223, 224, 225, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304. Such peptides contain the 7 amino acid sequence RQAPFPS (PEP NO: and / or SEQ ID NO: 845). Such peptides form a group of peptides (“Group 158”). In some embodiments, the present invention provides a peptide comprising the amino acid sequence of any one of PEP NOs: and / or SEQ ID NOs: 1, 2, 3, 4, 5, 6, 9, 10, 11, 12, 13, 14, 15, 16, 19, 25, 26, 27, 28, 29, 33, 34, 38, 39, 40, 43, 44, 45, 46, 47, 48, 49, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 66, 67, 68, 69, 70, 71, 72, 74, 75, 76, 77, 78, 80, 81, 82, 83, 84, 85, 86, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 123, 124, 125, 126, 129, 130, 131, 134, 135, 138, 139, 140, 142, 143, 145, 150, 151, 152, 158, 159, 160, 161, 162, 164, 166, 180, 181, 185, 186, 187, 188, 192, 208, 209, 210, 215, 216, 217, 218, 223, 224, 225, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304. Such peptides contain the 6 amino acid sequence RQAPFP (PEP NO: and / or SEQ ID NO: 846). Such peptides form a group of peptides (“Group 159”). In some embodiments, the present invention provides a peptide comprising the amino acid sequence of any one of PEP NOs: and / or SEQ ID NOs: 1, 2, 3, 4, 5, 6, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 33, 34, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 65, 66, 67, 68, 69, 70, 71, 72, 74, 75, 76, 77, 78, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 122, 123, 124, 125, 126, 128, 129, 130, 131, 133, 134, 135, 137, 138, 139, 140, 142, 143, 145, 150, 151, 152, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 168, 180, 181, 183, 184, 185, 186, 187, 188, 189, 192, 208, 209, 210, 215, 216, 217, 218, 223, 224, 225, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304. Such peptides contain the 5 amino acid sequence RQAPF (PEP NO: and / or SEQ ID NO: 847). Such peptides form a group of peptides (“Group 160”). In some embodiments, the present invention provides a peptide comprising the amino acid sequence of any one of PEP NOs: and / or SEQ ID NOs: 2, 3, 6, 9, 10, 11, 12, 13, 14, 15, 16, 19, 30, 43, 44, 45, 46, 47, 48, 49, 57, 58, 59, 60, 61, 62, 70, 84, 85, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 139, 142, 143, 145, 147, 150, 151, 152, 158, 159, 160, 161, 208, 209, 210, 211, 215, 216, 217, 218, 219, 223, 224, 225, 226. Such peptides contain the 9 amino acid sequence QAPFPSRAS (PEP NO: and / or SEQ ID NO: 848). Such peptides form a group of peptides (“Group 161”). In some embodiments, the present invention provides a peptide comprising the amino acid sequence of any one of PEP NOs: and / or SEQ ID NOs: 2, 3, 6, 9, 10, 11, 12, 13, 14, 15, 16, 19, 29, 30, 43, 44, 45, 46, 47, 48, 49, 56, 57, 58, 59, 60, 61, 62, 69, 70, 82, 84, 85, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 126, 139, 142, 143, 145, 147, 150, 151, 152, 158, 159, 160, 161, 162, 164, 180, 186, 208, 209, 210, 211, 215, 216, 217, 218, 219, 223, 224, 225, 226. Such peptides contain the 8 amino acid sequence QAPFPSRA (PEP NO: and / or SEQ ID NO: 849). Such peptides form a group of peptides (“Group 162”). In some embodiments, the present invention provides a peptide comprising the amino acid sequence of any one of PEP NOs: and / or SEQ ID NOs: 2, 3, 6, 9, 10, 11, 12, 13, 14, 15, 16, 19, 28, 29, 30, 43, 44, 45, 46, 47, 48, 49, 55, 56, 57, 58, 59, 60, 61, 62, 68, 69, 70, 82, 84, 85, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 125, 126, 131, 139, 142, 143, 145, 147, 150, 151, 152, 158, 159, 160, 161, 162, 164, 180, 186, 208, 209, 210, 211, 215, 216, 217, 218, 219, 223, 224, 225, 226. Such peptides contain the 7 amino acid sequence QAPFPSR (PEP NO: and / or SEQ ID NO: 850). Such peptides form a group of peptides (“Group 163”). In some embodiments, the present invention provides a peptide comprising the amino acid sequence of any one of PEP NOs: and / or SEQ ID NOs: 2, 3, 6, 9, 10, 11, 12, 13, 14, 15, 16, 19, 25, 26, 28, 29, 30, 38, 39, 40, 43, 44, 45, 46, 47, 48, 49, 54, 55, 56, 57, 58, 59, 60, 61, 62, 67, 68, 69, 70, 76, 82, 84, 85, 86, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 124, 125, 126, 129, 130, 131, 135, 139, 142, 143, 145, 147, 150, 151, 152, 158, 159, 160, 161, 162, 164, 166, 180, 185, 186, 187, 188, 192, 208, 209, 210, 211, 215, 216, 217, 218, 219, 223, 224, 225, 226, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304. Such peptides contain the 6 amino acid sequence QAPFPS (PEP NO: and / or SEQ ID NO: 851). Such peptides form a group of peptides (“Group 164”). In some embodiments, the present invention provides a peptide comprising the amino acid sequence of any one of PEP NOs: and / or SEQ ID NOs: 1, 2, 3, 4, 5, 6, 9, 10, 11, 12, 13, 14, 15, 16, 19, 25, 26, 27, 28, 29, 30, 33, 34, 35, 36, 37, 38, 39, 40, 43, 44, 45, 46, 47, 48, 49, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 66, 67, 68, 69, 70, 71, 72, 74, 75, 76, 77, 78, 80, 81, 82, 83, 84, 85, 86, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 123, 124, 125, 126, 129, 130, 131, 134, 135, 138, 139, 140, 142, 143, 145, 147, 150, 151, 152, 158, 159, 160, 161, 162, 164, 166, 180, 181, 185, 186, 187, 188, 192, 208, 209, 210, 211, 215, 216, 217, 218, 219, 223, 224, 225, 226, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304. Such peptides contain the 5 amino acid sequence QAPFP (PEP NO: and / or SEQ ID NO: 852). Such peptides form a group of peptides (“Group 165”). In some embodiments, the present invention provides a peptide comprising the amino acid sequence of any one of PEP NOs: and / or SEQ ID NOs: 1, 2, 3, 4, 5, 6, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 65, 66, 67, 68, 69, 70, 71, 72, 74, 75, 76, 77, 78, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 122, 123, 124, 125, 126, 128, 129, 130, 131, 133, 134, 135, 137, 138, 139, 140, 142, 143, 145, 147, 150, 151, 152, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 168, 180, 181, 183, 184, 185, 186, 187, 188, 189, 192, 208, 209, 210, 211, 215, 216, 217, 218, 219, 223, 224, 225, 226, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304. Such peptides contain the 4 amino acid sequence QAPF (PEP NO: and / or SEQ ID NO: 853). Such peptides form a group of peptides (“Group 166”). In some embodiments, the present invention provides a peptide comprising the amino acid sequence of any one of PEP NOs: and / or SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 147, 149, 150, 151, 152, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 168, 180, 181, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 203, 205, 208, 209, 210, 211, 214, 215, 216, 217, 218, 219, 221, 222, 223, 224, 225, 226, 231, 234, 235, 252, 272, 273, 277, 278, 279, 280, 281, 282, 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304. Such peptides contain the 3 amino acid sequence QAP (PEP NO: 854). Such peptides form a group of peptides (“Group 167”). In some embodiments, the present invention provides a peptide comprising the amino acid sequence of any one of PEP NOs: and / or SEQ ID NOs: 2, 3, 6, 9, 10, 11, 12, 13, 14, 15, 16, 19, 30, 31, 43, 44, 45, 46, 47, 48, 49, 57, 58, 59, 60, 61, 62, 70, 84, 85, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 139, 142, 143, 145, 147, 150, 151, 152, 153, 158, 159, 160, 161, 208, 209, 210, 211, 215, 216, 217, 218, 219, 223, 224, 225, 226, 227. Such peptides contain the 8 amino acid sequence APFPSRAS (PEP NO: and / or SEQ ID NO: 855). Such peptides form a group of peptides (“Group 168”). In some embodiments, the present invention provides a peptide comprising the amino acid sequence of any one of PEP NOs: and / or SEQ ID NOs: 2, 3, 6, 9, 10, 11, 12, 13, 14, 15, 16, 19, 29, 30, 31, 43, 44, 45, 46, 47, 48, 49, 56, 57, 58, 59, 60, 61, 62, 69, 70, 82, 84, 85, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 126, 139, 142, 143, 145, 147, 150, 151, 152, 153, 158, 159, 160, 161, 162, 164, 180, 186, 208, 209, 210, 211, 215, 216, 217, 218, 219, 223, 224, 225, 226, 227. Such peptides contain the 7 amino acid sequence APFPSRA (PEP NO: and / or SEQ ID NO: 856). Such peptides form a group of peptides (“Group 169”). In some embodiments, the present invention provides a peptide comprising the amino acid sequence of any one of PEP NOs: and / or SEQ ID NOs: 2, 3, 6, 9, 10, 11, 12, 13, 14, 15, 16, 19, 28, 29, 30, 31, 43, 44, 45, 46, 47, 48, 49, 55, 56, 57, 58, 59, 60, 61, 62, 68, 69, 70, 82, 84, 85, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 125, 126, 131, 139, 142, 143, 145, 147, 150, 151, 152, 153, 158, 159, 160, 161, 162, 164, 180, 186, 208, 209, 210, 211, 215, 216, 217, 218, 219, 223, 224, 225, 226, 227. Such peptides contain the 6 amino acid sequence APFPSR (PEP NO: and / or SEQ ID NO: 857). Such peptides form a group of peptides (“Group 170”). In some embodiments, the present invention provides a peptide comprising the amino acid sequence of any one of PEP NOs: and / or SEQ ID NOs: 2, 3, 6, 9, 10, 11, 12, 13, 14, 15, 16, 19, 25, 26, 28, 29, 30, 31, 38, 39, 40, 43, 44, 45, 46, 47, 48, 49, 54, 55, 56, 57, 58, 59, 60, 61, 62, 67, 68, 69, 70, 76, 82, 84, 85, 86, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 124, 125, 126, 129, 130, 131, 135, 139, 142, 143, 145, 147, 150, 151, 152, 153, 158, 159, 160, 161, 162, 164, 166, 180, 185, 186, 187, 188, 192, 208, 209, 210, 211, 215, 216, 217, 218, 219, 223, 224, 225, 226, 227, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304. Such peptides contain the 5 amino acid sequence APFPS (PEP NO: and / or SEQ ID NO: 858). Such peptides form a group of peptides (“Group 171”). In some embodiments, the present invention provides a peptide comprising the amino acid sequence of any one of PEP NOs: and / or SEQ ID NOs: 1, 2, 3, 4, 5, 6, 9, 10, 11, 12, 13, 14, 15, 16, 19, 25, 26, 27, 28, 29, 30, 31, 33, 34, 35, 36, 37, 38, 39, 40, 43, 44, 45, 46, 47, 48, 49, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 66, 67, 68, 69, 70, 71, 72, 74, 75, 76, 77, 78, 80, 81, 82, 83, 84, 85, 86, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 123, 124, 125, 126, 129, 130, 131, 134, 135, 138, 139, 140, 142, 143, 145, 147, 150, 151, 152, 153, 158, 159, 160, 161, 162, 164, 166, 180, 181, 185, 186, 187, 188, 192, 208, 209, 210, 211, 215, 216, 217, 218, 219, 223, 224, 225, 226, 227, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304. Such peptides contain the 4 amino acid sequence APFP (PEP NO: and / or SEQ ID NO: 859). Such peptides form a group of peptides (“Group 172”). In some embodiments, the present invention provides a peptide comprising the amino acid sequence of any one of PEP NOs: and / or SEQ ID NOs: 1, 2, 3, 4, 5, 6, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 65, 66, 67, 68, 69, 70, 71, 72, 74, 75, 76, 77, 78, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 122, 123, 124, 125, 126, 128, 129, 130, 131, 133, 134, 135, 137, 138, 139, 140, 142, 143, 145, 147, 150, 151, 152, 153, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 168, 180, 181, 183, 184, 185, 186, 187, 188, 189, 192, 208, 209, 210, 211, 215, 216, 217, 218, 219, 223, 224, 225, 226, 227, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304. Such peptides contain the 3 amino acid sequence APF (PEP NO: 860). Such peptides form a group of peptides (“Group 173”). In some embodiments, the present invention provides a peptide comprising the amino acid sequence of any one of PEP NOs: and / or SEQ ID NOs: 2, 3, 6, 9, 10, 11, 12, 13, 14, 15, 16, 19, 30, 31, 32, 43, 44, 45, 46, 47, 48, 49, 57, 58, 59, 60, 61, 62, 70, 84, 85, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 139, 142, 143, 145, 146, 147, 150, 151, 152, 153, 154, 158, 159, 160, 161, 208, 209, 210, 211, 212, 215, 216, 217, 218, 219, 223, 224, 225, 226, 227, 228. Such peptides contain the 7 amino acid sequence PFPSRAS (PEP NO: and / or SEQ ID NO: 861). Such peptides form a group of peptides (“Group 174”). In some embodiments, the present invention provides a peptide comprising the amino acid sequence of any one of PEP NOs: and / or SEQ ID NOs: 2, 3, 6, 9, 10, 11, 12, 13, 14, 15, 16, 19, 29, 30, 31, 32, 43, 44, 45, 46, 47, 48, 49, 56, 57, 58, 59, 60, 61, 62, 69, 70, 82, 84, 85, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 126, 139, 142, 143, 145, 146, 147, 150, 151, 152, 153, 154, 158, 159, 160, 161, 162, 164, 180, 186, 208, 209, 210, 211, 212, 215, 216, 217, 218, 219, 223, 224, 225, 226, 227, 228. Such peptides contain the 6 amino acid sequence PFPSRA (PEP NO: and / or SEQ ID NO: 862). Such peptides form a group of peptides (“Group 175”). In some embodiments, the present invention provides a peptide comprising the amino acid sequence of any one of PEP NOs: and / or SEQ ID NOs: 2, 3, 6, 9, 10, 11, 12, 13, 14, 15, 16, 19, 28, 29, 30, 31, 32, 43, 44, 45, 46, 47, 48, 49, 55, 56, 57, 58, 59, 60, 61, 62, 68, 69, 70, 82, 84, 85, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 125, 126, 131, 139, 142, 143, 145, 146, 147, 150, 151, 152, 153, 154, 158, 159, 160, 161, 162, 164, 180, 186, 208, 209, 210, 211, 212, 215, 216, 217, 218, 219, 223, 224, 225, 226, 227, 228. Such peptides contain the 5 amino acid sequence PFPSR (PEP NO: and / or SEQ ID NO: 863). Such peptides form a group of peptides (“Group 176”). In some embodiments, the present invention provides a peptide comprising the amino acid sequence of any one of PEP NOs: and / or SEQ ID NOs: 2, 3, 6, 9, 10, 11, 12, 13, 14, 15, 16, 19, 25, 26, 28, 29, 30, 31, 32, 38, 39, 40, 43, 44, 45, 46, 47, 48, 49, 54, 55, 56, 57, 58, 59, 60, 61, 62, 67, 68, 69, 70, 76, 82, 84, 85, 86, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 124, 125, 126, 129, 130, 131, 135, 139, 142, 143, 145, 146, 147, 150, 151, 152, 153, 154, 158, 159, 160, 161, 162, 164, 166, 180, 185, 186, 187, 188, 192, 208, 209, 210, 211, 212, 215, 216, 217, 218, 219, 223, 224, 225, 226, 227, 228, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304. Such peptides contain the 4 amino acid sequence PFPS (PEP NO: and / or SEQ ID NO: 864). Such peptides form a group of peptides (“Group 177”). In some embodiments, the present invention provides a peptide comprising the amino acid sequence of any one of PEP NOs: and / or SEQ ID NOs: 1, 2, 3, 4, 5, 6, 9, 10, 11, 12, 13, 14, 15, 16, 19, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 43, 44, 45, 46, 47, 48, 49, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 66, 67, 68, 69, 70, 71, 72, 74, 75, 76, 77, 78, 80, 81, 82, 83, 84, 85, 86, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 123, 124, 125, 126, 129, 130, 131, 134, 135, 138, 139, 140, 142, 143, 145, 146, 147, 150, 151, 152, 153, 154, 158, 159, 160, 161, 162, 164, 166, 180, 181, 185, 186, 187, 188, 192, 208, 209, 210, 211, 212, 215, 216, 217, 218, 219, 223, 224, 225, 226, 227, 228, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304, 307, 308. Such peptides contain the 3 amino acid sequence PFP (PEP NO: 865). Such peptides form a group of peptides (“Group 178”). In some embodiments, the present invention provides a peptide comprising the amino acid sequence of any one of PEP NOs: and / or SEQ ID NOs: 2, 3, 6, 9, 10, 11, 12, 13, 14, 15, 16, 19, 30, 31, 32, 43, 44, 45, 46, 47, 48, 49, 50, 57, 58, 59, 60, 61, 62, 63, 70, 84, 85, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 139, 142, 143, 145, 146, 147, 148, 150, 151, 152, 153, 154, 155, 158, 159, 160, 161, 208, 209, 210, 211, 212, 213, 215, 216, 217, 218, 219, 220, 223, 224, 225, 226, 227, 228. Such peptides contain the 6 amino acid sequence FPSRAS (PEP NO: and / or SEQ ID NO: 866). Such peptides form a group of peptides (“Group 179”). In some embodiments, the present invention provides a peptide comprising the amino acid sequence of any one of PEP NOs: and / or SEQ ID NOs: 2, 3, 6, 9, 10, 11, 12, 13, 14, 15, 16, 19, 29, 30, 31, 32, 43, 44, 45, 46, 47, 48, 49, 50, 56, 57, 58, 59, 60, 61, 62, 63, 69, 70, 82, 84, 85, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 126, 139, 142, 143, 145, 146, 147, 148, 150, 151, 152, 153, 154, 155, 158, 159, 160, 161, 162, 164, 180, 186, 208, 209, 210, 211, 212, 213, 215, 216, 217, 218, 219, 220, 223, 224, 225, 226, 227, 228. Such peptides contain the 5 amino acid sequence FPSRA (PEP NO: and / or SEQ ID NO: 867). Such peptides form a group of peptides (“Group 180”). In some embodiments, the present invention provides a peptide comprising the amino acid sequence of any one of PEP NOs: and / or SEQ ID NOs: 2, 3, 6, 9, 10, 11, 12, 13, 14, 15, 16, 19, 28, 29, 30, 31, 32, 43, 44, 45, 46, 47, 48, 49, 50, 55, 56, 57, 58, 59, 60, 61, 62, 63, 68, 69, 70, 82, 84, 85, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 125, 126, 131, 139, 142, 143, 145, 146, 147, 148, 150, 151, 152, 153, 154, 155, 158, 159, 160, 161, 162, 164, 180, 186, 208, 209, 210, 211, 212, 213, 215, 216, 217, 218, 219, 220, 223, 224, 225, 226, 227, 228. Such peptides contain the 4 amino acid sequence FPSR (PEP NO: and / or SEQ ID NO: 868). Such peptides form a group of peptides (“Group 181”). In some embodiments, the present invention provides a peptide comprising the amino acid sequence of any one of PEP NOs: and / or SEQ ID NOs: 2, 3, 6, 9, 10, 11, 12, 13, 14, 15, 16, 19, 25, 26, 28, 29, 30, 31, 32, 38, 39, 40, 43, 44, 45, 46, 47, 48, 49, 50, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 67, 68, 69, 70, 76, 82, 84, 85, 86, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 124, 125, 126, 129, 130, 131, 135, 139, 142, 143, 145, 146, 147, 148, 150, 151, 152, 153, 154, 155, 158, 159, 160, 161, 162, 164, 166, 180, 185, 186, 187, 188, 192, 208, 209, 210, 211, 212, 213, 215, 216, 217, 218, 219, 220, 223, 224, 225, 226, 227, 228, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304. Such peptides contain the 3 amino acid sequence FPS (PEP NO: 869). Such peptides form a group of peptides (“Group 182”). In some embodiments, the present invention provides a peptide comprising the amino acid sequence of any one of PEP NOs: and / or SEQ ID NOs: 2, 3, 6, 7, 9, 10, 11, 12, 13, 14, 15, 16, 19, 30, 31, 32, 43, 44, 45, 46, 47, 48, 49, 50, 51, 57, 58, 59, 60, 61, 62, 63, 64, 70, 84, 85, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 139, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 158, 159, 160, 161, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229. Such peptides contain the 5 amino acid sequence PSRAS (PEP NO: and / or SEQ ID NO: 870). Such peptides form a group of peptides (“Group 183”). In some embodiments, the present invention provides a peptide comprising the amino acid sequence of any one of PEP NOs: and / or SEQ ID NOs: 2, 3, 6, 7, 9, 10, 11, 12, 13, 14, 15, 16, 19, 29, 30, 31, 32, 43, 44, 45, 46, 47, 48, 49, 50, 51, 56, 57, 58, 59, 60, 61, 62, 63, 64, 69, 70, 82, 84, 85, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 126, 139, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 158, 159, 160, 161, 162, 164, 180, 186, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229. Such peptides contain the 4 amino acid sequence PSRA (PEP NO: and / or SEQ ID NO: 871). Such peptides form a group of peptides (“Group 184”). In some embodiments, the present invention provides a peptide comprising the amino acid sequence of any one of PEP NOs: and / or SEQ ID NOs: 2, 3, 6, 7, 9, 10, 11, 12, 13, 14, 15, 16, 19, 28, 29, 30, 31, 32, 43, 44, 45, 46, 47, 48, 49, 50, 51, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 68, 69, 70, 82, 84, 85, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 125, 126, 131, 139, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 158, 159, 160, 161, 162, 164, 180, 186, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229. Such peptides contain the 3 amino acid sequence PSR (PEP NO: 872). Such peptides form a group of peptides (“Group 185”). In some embodiments, the present invention provides a peptide comprising the amino acid sequence of any one of PEP NOs: and / or SEQ ID NOs: 2, 3, 6, 7, 9, 10, 11, 12, 13, 14, 15, 16, 18, 19, 30, 31, 32, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 57, 58, 59, 60, 61, 62, 63, 64, 65, 70, 83, 84, 85, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 139, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 158, 159, 160, 161, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230. Such peptides contain the 4 amino acid sequence SRAS (PEP NO: and / or SEQ ID NO: 873). Such peptides form a group of peptides (“Group 186”). In some embodiments, the present invention provides a peptide comprising the amino acid sequence of any one of PEP NOs: and / or SEQ ID NOs: 2, 3, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 18, 19, 29, 30, 31, 32, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 69, 70, 82, 83, 84, 85, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 126, 139, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 158, 159, 160, 161, 162, 164, 180, 186, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230. Such peptides contain the 3 amino acid sequence SRA (PEP NO: 874). Such peptides form a group of peptides (“Group 187”). In some embodiments, the present invention provides a peptide comprising the amino acid sequence of any one of PEP NOs: and / or SEQ ID NOs: 2, 3, 6, 7, 9, 10, 11, 12, 13, 14, 15, 16, 18, 19, 27, 30, 31, 32, 35, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 70, 83, 84, 85, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 127, 139, 140, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 158, 159, 160, 161, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231. Such peptides contain the 3 amino acid sequence RAS (PEP NO: 875). Such peptides form a group of peptides (“Group 188”). In some embodiments, the present invention provides a peptide comprising the amino acid sequence of any of PEP NOs: and / or SEQ ID NOs: 774-875 wherein the peptide has delta opioid agonist activity. 2.7. Consensus Sequences Peptides comprising PEP NOs: and / or SEQ ID NOs: 1-304, or various structural and / or functional subgroupings of those peptides, can also be described using consensus amino acid sequences based on an alignment as in Fig.1A-F. For example, in some embodiments, the present invention provides a peptide comprising the amino acid sequence: X2X3X4X5X6X7X8X9X10X11X12X13X14X15X16X17X18X19(PEP NO: 316), wherein the numbers in subscript are the amino acid positions, numbered as in Fig.1A-F, and wherein, independently of each other: X2is D, K, or R; X3 is G, K, S, or W; X4 is A, D, F, G, K, W, or Y; X5is A, C, D, E, G, H, K, N, S, or Y; X6is A, D, E, G, I, K, L, Q, or V; X7 is A, E, G, I, L, M, V, or W; X8is A, D, G, S, or V; X9is A, C, F, H, I, K, L, P, Q, R, T, V, or W; X10 is A, C, D, E, G, H, K, P, Q, R, V, W, or Y; X11 is A, E, H, N, Q, or R; X12is A, G, L, P, Q, T, or V; X13 is A, K, P, or S; X14 is A, F, I, K, L, or Y; X15is K, L, P, or V; X16is A, K, L, P, or S; X17 is A, C, D, H, K, N, Q, R, S, or Y; X18is A, G, I, K, or V; and X19is A, D, F, K, or S. In some embodiments, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 316 wherein the peptide has delta opioid agonist activity. In some embodiments, the present invention provides peptides comprising the amino acid sequence: D2S3Y4G5E6V7G8V9R10Q11A12P13F14P15S16X17A18S19(PEP NO: and / or SEQ ID NO: 317) wherein the numbers in subscript are the amino acid positions, numbered as in Fig.1A-F, and wherein X17 is K, Q, R or S. In some embodiments, the present invention provides a peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 317 wherein the peptide has delta opioid agonist activity. In some embodiments, the present invention provides a peptide comprising the amino acid sequence: X₃X₄X₅X₆X₇X₈X₉X₁₀X₁₁X₁₂X₁₃X₁₄X₁₅X₁₆X₁₇X₁₈X₁₉ (PEP NO: 318), X₄X₅X₆X₇X₈X₉X₁₀X₁₁X₁₂X₁₃X₁₄X₁₅X₁₆X₁₇X₁₈X₁₉ (PEP NO: 319), X₅X₆X₇X₈X₉X₁₀X₁₁X₁₂X₁₃X₁₄X₁₅X₁₆X₁₇X₁₈X₁₉ (PEP NO: 320), X₆X₇X₈X₉X₁₀X₁₁X₁₂X₁₃X₁₄X₁₅X₁₆X₁₇X₁₈X₁₉ (PEP NO: 321), X₇X₈X₉X₁₀X₁₁X₁₂X₁₃X₁₄X₁₅X₁₆X₁₇X₁₈X₁₉ (PEP NO: 322), X₈X₉X₁₀X₁₁X₁₂X₁₃X₁₄X₁₅X₁₆X₁₇X₁₈X₁₉ (PEP NO: 323), X₉X₁₀X₁₁X₁₂X₁₃X₁₄X₁₅X₁₆X₁₇X₁₈X₁₉ (PEP NO: 324), X₁₀X₁₁X₁₂X₁₃X₁₄X₁₅X₁₆X₁₇X₁₈X₁₉ (PEP NO: 325), X₁₁X₁₂X₁₃X₁₄X₁₅X₁₆X₁₇X₁₈X₁₉ (PEP NO: 326), X₁₂X₁₃X₁₄X₁₅X₁₆X₁₇X₁₈X₁₉ (PEP NO: 327), X₁₃X₁₄X₁₅X₁₆X₁₇X₁₈X₁₉ (PEP NO: 328), X₁₄X₁₅X₁₆X₁₇X₁₈X₁₉ (PEP NO: 329), X₁₅X₁₆X₁₇X₁₈X₁₉ (PEP NO: 330), X₁₆X₁₇X₁₈X₁₉ (PEP NO: 331), X₁₇X₁₈X₁₉ (PEP NO: 332), X₃X₄X₅X₆X₇X₈X₉X₁₀X₁₁X₁₂X₁₃X₁₄X₁₅X₁₆X₁₇X₁₈ (PEP NO: 333), X₄X₅X₆X₇X₈X₉X₁₀X₁₁X₁₂X₁₃X₁₄X₁₅X₁₆X₁₇X₁₈ (PEP NO: 334), X₅X₆X₇X₈X₉X₁₀X₁₁X₁₂X₁₃X₁₄X₁₅X₁₆X₁₇X₁₈ (PEP NO: 335), X₆X₇X₈X₉X₁₀X₁₁X₁₂X₁₃X₁₄X₁₅X₁₆X₁₇X₁₈ (PEP NO: 336), X₇X₈X₉X₁₀X₁₁X₁₂X₁₃X₁₄X₁₅X₁₆X₁₇X₁₈ (PEP NO: 337), X₈X₉X₁₀X₁₁X₁₂X₁₃X₁₄X₁₅X₁₆X₁₇X₁₈ (PEP NO: 338), X₉X₁₀X₁₁X₁₂X₁₃X₁₄X₁₅X₁₆X₁₇X₁₈ (PEP NO: 339), X₁₀X₁₁X₁₂X₁₃X₁₄X₁₅X₁₆X₁₇X₁₈ (PEP NO: 340), X₁₁X₁₂X₁₃X₁₄X₁₅X₁₆X₁₇X₁₈ (PEP NO: 341), X₁₂X₁₃X₁₄X₁₅X₁₆X₁₇X₁₈ (PEP NO: 342), X₁₃X₁₄X₁₅X₁₆X₁₇X₁₈ (PEP NO: 343), X₁₄X₁₅X₁₆X₁₇X₁₈ (PEP NO: 344), X₁₅X₁₆X₁₇X₁₈ (PEP NO: 345), X₁₆X₁₇X₁₈ (PEP NO: 346), X₃X₄X₅X₆X₇X₈X₉X₁₀X₁₁X₁₂X₁₃X₁₄X₁₅X₁₆X₁₇ (PEP NO: 347), X₄X₅X₆X₇X₈X₉X₁₀X₁₁X₁₂X₁₃X₁₄X₁₅X₁₆X₁₇ (PEP NO: 348), X₅X₆X₇X₈X₉X₁₀X₁₁X₁₂X₁₃X₁₄X₁₅X₁₆X₁₇ (PEP NO: 349), X₆X₇X₈X₉X₁₀X₁₁X₁₂X₁₃X₁₄X₁₅X₁₆X₁₇ (PEP NO: 350), X₇X₈X₉X₁₀X₁₁X₁₂X₁₃X₁₄X₁₅X₁₆X₁₇ (PEP NO: 351), X₈X₉X₁₀X₁₁X₁₂X₁₃X₁₄X₁₅X₁₆X₁₇ (PEP NO: 352), X₉X₁₀X₁₁X₁₂X₁₃X₁₄X₁₅X₁₆X₁₇ (PEP NO: 353), X₁₀X₁₁X₁₂X₁₃X₁₄X₁₅X₁₆X₁₇ (PEP NO: 354), X₁₁X₁₂X₁₃X₁₄X₁₅X₁₆X₁₇ (PEP NO: 355), X₁₂X₁₃X₁₄X₁₅X₁₆X₁₇ (PEP NO: 356), X₁₃X₁₄X₁₅X₁₆X₁₇ (PEP NO: 357), X₁₄X₁₅X₁₆X₁₇ (PEP NO: 358), X₁₅X₁₆X₁₇ (PEP NO: 359), X₃X₄X₅X₆X₇X₈X₉X₁₀X₁₁X₁₂X₁₃X₁₄X₁₅X₁₆ (PEP NO: 360), X₄X₅X₆X₇X₈X₉X₁₀X₁₁X₁₂X₁₃X₁₄X₁₅X₁₆ (PEP NO: 361), X₅X₆X₇X₈X₉X₁₀X₁₁X₁₂X₁₃X₁₄X₁₅X₁₆ (PEP NO: 362), X₆X₇X₈X₉X₁₀X₁₁X₁₂X₁₃X₁₄X₁₅X₁₆ (PEP NO: 363), X₇X₈X₉X₁₀X₁₁X₁₂X₁₃X₁₄X₁₅X₁₆ (PEP NO: 364), X₈X₉X₁₀X₁₁X₁₂X₁₃X₁₄X₁₅X₁₆ (PEP NO: 365), X₉X₁₀X₁₁X₁₂X₁₃X₁₄X₁₅X₁₆ (PEP NO: 366), X₁₀X₁₁X₁₂X₁₃X₁₄X₁₅X₁₆ (PEP NO: 367), X₁₁X₁₂X₁₃X₁₄X₁₅X₁₆ (PEP NO: 368), X₁₂X₁₃X₁₄X₁₅X₁₆ (PEP NO: 369), X₁₃X₁₄X₁₅X₁₆ (PEP NO: 370), X₁₄X₁₅X₁₆ (PEP NO: 371), X₃X₄X₅X₆X₇X₈X₉X₁₀X₁₁X₁₂X₁₃X₁₄X₁₅ (PEP NO: 372), X₄X₅X₆X₇X₈X₉X₁₀X₁₁X₁₂X₁₃X₁₄X₁₅ (PEP NO: 373), X₅X₆X₇X₈X₉X₁₀X₁₁X₁₂X₁₃X₁₄X₁₅ (PEP NO: 374), X₆X₇X₈X₉X₁₀X₁₁X₁₂X₁₃X₁₄X₁₅ (PEP NO: 375), X₇X₈X₉X₁₀X₁₁X₁₂X₁₃X₁₄X₁₅ (PEP NO: 376), X₈X₉X₁₀X₁₁X₁₂X₁₃X₁₄X₁₅ (PEP NO: 377), X₉X₁₀X₁₁X₁₂X₁₃X₁₄X₁₅ (PEP NO: 378), X₁₀X₁₁X₁₂X₁₃X₁₄X₁₅ (PEP NO: 379), X₁₁X₁₂X₁₃X₁₄X₁₅ (PEP NO: 380), X₁₂X₁₃X₁₄X₁₅ (PEP NO: 381), X₁₃X₁₄X₁₅ (PEP NO: 382), X₃X₄X₅X₆X₇X₈X₉X₁₀X₁₁X₁₂X₁₃X₁₄ (PEP NO: 383), X₄X₅X₆X₇X₈X₉X₁₀X₁...

Claims

CLAIMS We claim:

1. An isolated delta opioid receptor agonist peptide, wherein the peptide comprises: (a) the amino acid sequence: X2X3X4X5X6X7X8X9X10X11X12X13X14X15X16X17X18X19, wherein, independently of each other: X2 is D, K, or R; X3is G, K, S, or W; X4is A, D, F, G, K, W, or Y; X5 is A, C, D, E, G, H, K, N, S, or Y; X6 is A, D, E, G, I, K, L, Q, or V; X7is A, E, G, I, L, M, V, or W; X8 is A, D, G, S, or V; X9 is A, C, F, H, I, K, L, P, Q, R, T, V, or W; X10is A, C, D, E, G, H, K, P, Q, R, V, W, or Y; X11is A, E, H, N, Q, or R; X12 is A, G, L, P, Q, T, or V; X13is A, K, P, or S; X14is A, F, I, K, L, or Y; X15 is K, L, P, or V; X16is A, K, L, P, or S; X17is A, C, D, H, K, N, Q, R, S, or Y X18 is A, G, I, K, or V; and X19 is A, D, F, K, or S, or (b) a fragment of the amino acid sequence of part (a), wherein the fragment is from 3-17 amino acids in length, or (c) a retro-inverso variant of the amino acid sequence of part (a) or part (b), or (d) a variant of the amino acid sequence of part (a), (b), or (c), wherein one or more amino acids is added, deleted, or substituted with a different amino acid, or (e) a variant of the amino acid sequence of part (a), (b), (c), or (d) wherein one or more of the amino acids is a modified amino acid.

2. An isolated delta opioid receptor agonist peptide according to claim 1, comprising: (a) the amino acid sequence of any one of PEP NO: and / or SEQ ID NO: 1-315, 438-752 or 747-875, or(b) a fragment of the amino acid sequence of part (a), wherein the fragment is from 3-17 amino acids in length, or (c) a retro-inverso variant of the amino acid sequence of part (a) or part (b), or (d) a variant of the amino acid sequence of part (a), (b), or (c), wherein one or more amino acids is added, deleted, or substituted with a different amino acid, or (e) a variant of the amino acid sequence of part (a), (b), (c), or (d) wherein one or more of the amino acids is a modified amino acid.

3. An isolated delta opioid receptor agonist peptide according to claim 1, comprising: (a) the amino acid sequence of any one of PEP NO: and / or SEQ ID NO: 1-315, or (b) a fragment of the amino acid sequence of part (a), wherein the fragment is from 3-17 amino acids in length, or (c) a retro-inverso variant of the amino acid sequence of part (a) or part (b), or (d) a variant of the amino acid sequence of part (a), (b), or (c), wherein one or more amino acids is added, deleted, or substituted with a different amino acid, or (e) a variant of the amino acid sequence of part (a), (b), (c), or (d) wherein one or more of the amino acids is a modified amino acid.

4. An isolated delta opioid receptor agonist peptide comprising the amino acid sequence of any one of PEP NO: and / or SEQ ID NO: 1-315, 438-752 or 747-875.

5. An isolated peptide comprising the amino acid sequence of any one of PEP NO: and / or SEQ ID NO: 1-315.

6. An isolated peptide comprising the amino acid sequence of any one of PEP NO: and / or SEQ ID NO: 16, 17, 24, 86, 87, 157, 162, 163, 164, 165, 166, 167, 170, 171, 173, 175, 177, 178, 179, 182, 183, 185, 186, or 187.

7. An isolated peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO:

16.

8. An isolated peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO:

17.

9. An isolated peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO:

24.

10. An isolated peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO:

86.

11. An isolated peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO:

87.

12. An isolated peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 157.

13. An isolated peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO:

162.

14. An isolated peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO:

163.

15. An isolated peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO:

164.

16. An isolated peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO:

165.

17. An isolated peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO:

166.

18. An isolated peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO:

167.

19. An isolated peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO:

170.

20. An isolated peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO:

171.

21. An isolated peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO:

173.

22. An isolated peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO:

175.

23. An isolated peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO:

177.

24. An isolated peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO:

178.

25. An isolated peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO:

179.

26. An isolated peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO:

182.

27. An isolated peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO:

183.

28. An isolated peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO:

185.

29. An isolated peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO: 186.

30. An isolated peptide comprising the amino acid sequence of PEP NO: and / or SEQ ID NO:

187.

31. A composition comprising a peptide according to any one of claims 1-30.

32. A composition comprising a peptide according to any one of claims 1-30, and at least one pharmaceutically acceptable carrier or excipient.

33. A composition comprising a salt of a peptide according to any one of claims 1-30.

34. A composition comprising a salt of a peptide according to any one of claims 1-30, and at least one pharmaceutically acceptable carrier or excipient.

35. A method of activating a delta opioid receptor, the method comprising contacting a delta opioid receptor, or a cell comprising a delta opioid receptor, in vitro or in vivo with a peptide according to any one of claims 1-30.

36. A method of activating a delta opioid receptor, the method comprising contacting a delta opioid receptor, or a cell comprising a delta opioid receptor, in vitro or in vivo with a composition according to claim 31.

37. A method of activating a delta opioid receptor, the method comprising contacting a delta opioid receptor, or a cell comprising a delta opioid receptor, in vitro or in vivo with a composition according to claim 32.

38. A method of activating a delta opioid receptor, the method comprising contacting a delta opioid receptor, or a cell comprising a delta opioid receptor, in vitro or in vivo with a composition according to claim 33.

39. A method of activating a delta opioid receptor, the method comprising contacting a delta opioid receptor, or a cell comprising a delta opioid receptor, in vitro or in vivo with a composition according to claim 34.

40. A method of activating a delta opioid receptor in a subject in need thereof, the method comprising administering to the subject a peptide according to any one of claims 1-30.

41. A method of activating a delta opioid receptor in a subject in need thereof, the method comprising administering to the subject a composition according to claim 31.

42. A method of activating a delta opioid receptor in a subject in need thereof, the method comprising administering to the subject a composition according to claim 32.

43. A method of activating a delta opioid receptor in a subject in need thereof, the method comprising administering to the subject a composition according to claim 33.

44. A method of activating a delta opioid receptor in a subject in need thereof, the method comprising administering to the subject a composition according to claim 34.

45. A method of treating pain in a subject in need thereof, the method comprising administering to the subject an effective amount of a peptide according to any one of claims 1-30.

46. A method of treating pain in a subject in need thereof, the method comprising administering to the subject an effective amount of a composition according to claim 31.

47. A method of treating pain in a subject in need thereof, the method comprising administering to the subject an effective amount of a composition according to claim 32.

48. A method of activating a delta opioid receptor in a subject in need thereof, the method comprising administering to the subject a composition according to claim 33.

49. A method of activating a delta opioid receptor in a subject in need thereof, the method comprising administering to the subject a composition according to claim 34.

50. A composition comprising: a means for activating a delta opioid receptor, and a pharmaceutically acceptable carrier or excipient.

51. A composition comprising: a means for inducing analgesia in a subject, and a pharmaceutically acceptable carrier or excipient.

52. A composition comprising: a means for activating a delta opioid receptor by oral administration to a subject, and a pharmaceutically acceptable carrier or excipient.

53. A composition comprising: a means for inducing analgesia by oral administration to a subject, and a pharmaceutically acceptable carrier or excipient.

54. A composition comprising: a means for activating a delta opioid receptor with an EC50 of at least 10 micromolar, and a pharmaceutically acceptable carrier or excipient.

55. A composition comprising: a means for inducing analgesia by activating a delta opioid receptor with an EC50 of at least 10 micromolar, and a pharmaceutically acceptable carrier or excipient.

56. A composition comprising: a means for selectively activating a delta opioid receptor in vitro or in vivo, and a pharmaceutically acceptable carrier or excipient.

57. A composition comprising: a means for inducing analgesia by selectively activating a delta opioid receptor in vivo, and a pharmaceutically acceptable carrier or excipient.

58. A composition comprising: a fatty-acid containing means for activating a delta opioid receptor, and a pharmaceutically acceptable carrier or excipient.

59. A composition comprising: a fatty-acid containing means for inducing analgesia in a subject, and a pharmaceutically acceptable carrier or excipient.

60. A composition comprising: a palmitic-acid containing means for activating a delta opioid receptor, and a pharmaceutically acceptable carrier or excipient.

61. A composition comprising: a palmitic-acid containing means for inducing analgesia in a subject, and a pharmaceutically acceptable carrier or excipient.

62. A composition comprising: a means for activating a delta opioid receptor in a mammalian subject, and a pharmaceutically acceptable carrier or excipient.

63. A composition comprising: a means for inducing analgesia in a mammalian subject, and a pharmaceutically acceptable carrier or excipient.

64. A composition comprising: a means for activating a delta opioid receptor in a rodent, and a pharmaceutically acceptable carrier or excipient.

65. A composition comprising: a means for inducing analgesia in a rodent, and a pharmaceutically acceptable carrier or excipient.

66. A composition comprising: a means for activating a delta opioid receptor in a non-human primate, and a pharmaceutically acceptable carrier or excipient.

67. A composition comprising: a means for inducing analgesia in a non-human primate, and a pharmaceutically acceptable carrier or excipient.

68. A composition comprising: a means for activating a delta opioid receptor in a human subject, and a pharmaceutically acceptable carrier or excipient.

69. A composition comprising: a means for inducing analgesia in human subject, and a pharmaceutically acceptable carrier or excipient.

70. A composition comprising: a means for activating a delta opioid receptor outside of the central nervous system (CNS), and a pharmaceutically acceptable carrier or excipient.

71. A composition comprising: a means for inducing analgesia by activating a delta opioid receptor outside of the central nervous system (CNS), and a pharmaceutically acceptable carrier or excipient.

72. A composition comprising: a means for safely activating a delta opioid receptor in a living subject, and a pharmaceutically acceptable carrier or excipient.

73. A composition comprising: a means for safely inducing analgesia in a living subject, and a pharmaceutically acceptable carrier or excipient.

74. A composition comprising: a 3-5 amino peptide means for activating a delta opioid receptor, and a pharmaceutically acceptable carrier or excipient.

75. A composition comprising: a 3-5 amino peptide means for inducing analgesia in a living subject, and a pharmaceutically acceptable carrier or excipient.

76. A composition comprising: a 5-10 amino peptide means for activating a delta opioid receptor, and a pharmaceutically acceptable carrier or excipient.

77. A composition comprising: a 5-10 amino peptide means for inducing analgesia in a living subject, and a pharmaceutically acceptable carrier or excipient.

78. A composition comprising: a 10-15 amino peptide means for activating a delta opioid receptor, and a pharmaceutically acceptable carrier or excipient.

79. A composition comprising: a 10-15 amino peptide means for inducing analgesia in a living subject, and a pharmaceutically acceptable carrier or excipient.

80. A composition comprising: a 15-20 amino peptide means for activating a delta opioid receptor, and a pharmaceutically acceptable carrier or excipient.

81. A composition comprising: a 15-20 amino peptide means for inducing analgesia in a living subject, and a pharmaceutically acceptable carrier or excipient.

82. A method of activating a delta opioid receptor, the method comprising contacting a delta opioid receptor, or a cell comprising a delta opioid receptor, with a composition according to any one of claims 50-81.

83. A method of activating a delta opioid receptor in a living subject in need thereof, the method comprising administering to the subject a composition according to any one of claims 50-81.

84. A method of inducing analgesia in a subject in need thereof, the method comprising administering to the subject an effective amount of a composition according to any one of claims 50-81.

Images